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Regenerative medicine is a branch of translational researchfocused on the discovery of new 
approaches for replacement of cells tissue and organs used to improve the recovery in 
neurodegenerative or traumatic disease.  
Spinal cord injury (SCI) is a debilitating clinical condition, characterized by a complex of 
neurological dysfunctions.). SCI disabilities range from cognitive impairment to loss of sensation 
and partial to complete paralysis. 
We have isolated a subclass of neural progenitors, kept from SVZ 6 hours after animal death 
capable of surviving a powerful ischemia insult. These cells were named Post Mortem Neural 
Precursors Cells (PM-NPCs). Differentiation yield mostly neurons (about 30-40%) compared to 
regular NPCs (about 10-12%).Also the cholinergic yields is higher. Their EPO-dependent 
differentiation abilities produce a significantly higher percentage of neurons than regular NSCs.  
The potential of PM-NPCs in terms of replacement therapy was investigated in a mouse model of 
contusive spinal cord injury lesioned at T9 level with intensity equal to 70 kDyne, by means of 
Infinity Horizon Impactor device. 1x 106 PM-NPCs, were administered intravenously within two 
hours after the traumatic injury of the cordthen the functional recovery and the fate of transplanted 
cells were studied.   
Animals transplanted with PM-NPCs showed a remarkable improved recovery of hind limb 
function evaluated by Basso Mouse Scale up to 90 days after lesion. This was accompanied by 
reduced myelin loss, counteraction of the invasion of the lesion site by the inflammatory cells, and 
an attenuation of secondary degeneration. PM-NPCs migrate mostly at the injury site, where they 
survive and differentiate predominantly into cholinergic neurons, reconstitute a rich axonal and 
dendritic network and favors preservation of myelin fibers and promotes tyrosine hydroxylase and 
serotonergic fiber formation at lesion site.  Moreover, the molecular analysis of the lesion site show 
that PM-NPCs induce a modulation of inflammatory response and release of neurotrophic factors. 
Pro-inflammatory cytokines (IL-6, MIP-2 and TNF-alpha) levels significantly decrease after 48 
hours from spinal cord injury and PM-NPCs transplantation. 
Moreover, our results show that transplantation of PM-NPCs facilitated significant axonal 
sparing/regeneration. This is associated with an increased amount of intact tissue at the lesion site. 
Anterograde tracing revealed statistically significant increased numbers for supraspinal tracts in 
PM-NPCs treated animals. Consequently, axons that regenerate across the lesion bridge and reach 
the caudal interface may mediate improvement in hindlimb movement 
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Cell therapies has been proposed as a regenerative approach to compensate the loss of specific cell 
populations in neurodegenerative disorders, where symptoms can be ascribed to the degeneration of 
a specific cell type. Parkinson’s disease (PD) is the second most common neurodegenerative 
disease, caused by midbrain dopaminergic neurons degeneration in the Substantia Nigra (SN). Stem 
cell transplantation has emerged as a promising therapeutic approach. The other aim of this work 
was to evaluate the curative effects of PM-NPCs in a mouse model of PD. The degeneration 
ofdopaminergic neurons was obtained with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
administration in C57BL/6 mice at the dosage of 36 mg/kg intraperiteoneally. Then the lesion was 
stabilized by a second injection (i.p.) of the drug at the dosage of 20 mg/kg. 1x 105 of PM-PCs-GFP 
were administered to C57/BL mice by stereotaxic injection unilaterally in the left striatum 3 days 
after the second MPTP administration. The effects of transplanted cells were determined by means 
of performance tests aimed at detecting behavioral improvements. Our results show that animals 
treated with GFP-PM-NPCs had a remarkable improvement of parameters measured by means of 
both horizontal, vertical grid and olfactory tests starting with the third day after transplantation. 
These improvements were very significant and the average values were close to control. This was 
maintained throughout two weeks of experimental observation. This was likely promoted by PM-
NPCs-derived erythropoietin (EPO), since the co-injection of cells with anti-EPO or anti-EPOR 
antibodies had completely neutralized the positive outcome. At the end of observational period, 
most of the transplanted PM-NPCs were vital, and were able to migrate ventrally and caudally from 
the injection site, reaching the ipsilateral and contralateral Substantia Nigra. Transplanted cells were 
differentiated into dopaminergic, cholinergic, and gabaergic neurons. 
In conclusion, we purified a new class of neural precursors able to survive after a powerful ischemic 
insult (PM-NPCs). We found that treatment with PM-NPCs can limit the effects of degeneration of 
the injury both in the spinal cord and in Parkinson’s disease. For these reasons these cells represent 
a liable source for cellular therapy in neurodegenerative disorders, especially on spinal cord injury 
and Parkinson’s disease. 
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1.1 Regenerative Medicine 
 
Regenerative medicine is a new branch of translational researchfocused on the discovery of new 
approaches towards repair, replacement and regeneration of cells, tissues and organs. It requires 
a combination of several technologies moving beyond the traditional transplantation and 
replacement therapies, including genetic engineering, soluble molecules and advanced cell 
therapy (Greenwood, 2006).The main goal of regenerative medicine is not just replacing what is 
not functioning in the body, but also inducing and improving the regeneration of intrinsic 
organism capacity. 
 
 
Table 1.1 Top Ten Regenerative Medicine Applications for Improving Health in Developing Countries (Greenwood et al, 2006) 
  
 
 
The United States National Academies of Science Report, Stem Cells and the Future of 
Regenerative Medicine, estimates that more than a hundred million of patients with conditions 
such as cardiovascular disease, autoimmune diseases, diabetes, cancer, neurodegenerative 
diseases, and burns would be consider potential patientsin the US for stem cell–based therapies 
(Petit-Zeman, 2001). 
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Stem cells are a key component of regenerative medicine, as they open the door to new clinical 
applications.For a successful application of stem cell-based approaches, it is necessary to define 
the scientific and clinical advances, as well as regulatory, ethical, and societal issuesin terms of 
safety and efficacy(Hyun, 2008). Considering the large number of improved protocols of cells 
differentiation and the increasing availability of human multipotent stem cells, the prospect of an 
access to unlimited numbers of specific cell types on demand could become a reality for several 
diseases. Up-to-date advances in stem cell field are suggesting that the direct use of cells could 
really be translate into effective therapies for currently unmanageable disorders (Kriks, 2011; 
Ma, 2012), although the road towards translation in humans is still full of new challenges (Tabar, 
2014). 
There are three currently used approach in the field of regenerative medicine (Figure 1.1): the 
stem cells implantation for new structures formation, the implantation of pre-primed cells 
already committed to a given direction, and the stimulation of endogenous cells to replace 
missing structures(Stocum, 2004). Each of the different aspects identified in the first two 
approaches, the generation of an appropriate cohort of regenerative cells, their regulated division 
and differentiation, and the restoration of the appropriate part of the structure, must be evoked by 
endogenous cells. 
 
 
 
Figure.1.1.Schematic of three approaches to regenerative medicine.  
 
(A) Implantation of stem cells (light green) from culture leads to the restoration of the structure. (B) Stem cellsprovided with a 
scaffold (triangle) in order to guide restoration. (C) The residual cells of the structure induced a regenerative response (Stocum, 
2004). 
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So far, stem cell therapy has only been established as a clinical standard of care for diseases of 
the blood system. However, there is an increasing number of clinics testing stem cell 
interventions, some of them offer stem cell treatments for a variety of conditions without clear 
evidence of safety or efficacy. For the successful application of novel stem cell-based 
approaches, it will be necessary to define the scientific and clinical advances, as well as the 
associated regulatory, ethical, and societal issues, that need to be addressed in order to deliver 
treatments safely, effectively, and fairly (Fig. 1.2) (Hyun, 2008). 
  
 
 
 
Figure.1.2.The scientific challenges of stem cells research in regenerative medicine 
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1.2 Spinal cord injury 
 
Spinal Cord Injury (SCI) is a traumatic condition correlated with significant sensory and 
functional deficits, together with emotional, social, and financial burdens (Venkatesh, 2014). SCI 
disabilities range from cognitive impairment to loss of sensation and partial to complete 
paralysis. There are different types of spinal cord injuries depending on the region of the spinal 
cord and spinal level involved, and the injury may be complete or incomplete. Current therapies 
for improving clinical outcome include limiting inflammation, preventing secondary cell death 
and enhancing the plasticity of spared circuits. 
 
1.2.1 Spinal cord injury types 
 
Spinal cord injuries can be classified into three medical cases: the first one Is bone marrow 
contusion, which recognizes a minimum anatomical alteration state, which can correspond to a 
complete alteration of bone marrow function, usually reversible. The trauma is more severe if an 
edema is present on the lesion site, or with the presence of hemorrhages spots, particularly in the 
region of the bone (central hemorrhagic lesion). In these conditions, the blood supply is terminal 
anddependsexclusivelyby thecentral groove arterial.Thisisthe caseof thespinal cordcontusion, in 
whichthespinal cord injuryis often incompleteand its evolutiondepends on thetreatmentoflesionin 
the first hoursafterthe trauma.In this case, there is noalterationof the bone structure. 
On the other hand, a medical case with the more severe prognosis is the spinal cord laceration, 
which is rarely complete and usually involves complications caused by hemorrhagic masses, 
lacerations and meningeal vascular lesions with secondary ischemia,  that make the lesionclearly 
distinguishable at the macroscopic level (Chirugiavol2, Chirurgiaspecialistica). Often, 
immediately after spinal cord injury occurs an event called spinal shock, characterized by the 
complete death of all functionalnerves below the injury. This condition can last for six weeks 
and is not only due to the bruise and edema formed on the spinal cord (caused by the 
compressionof the bonebetween the vertebrae), but also to the lackof oxygen(causedby the 
interruption of theblood dispensingto the tissue).It is aphysiologicalblock of nerve conduction, 
which is not necessary associated with aspinal cord organic damage. Initiallyoccursasa full spinal 
cord injury, but aftera variable intervalthere isafunctional recoverythatcan becomplete (Manuale 
di chirurgia Vol 1). 
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Anothernegative consequence oftraumais the syringomyelia: thisisa painful diseasethat can 
developedin the first periodafterspinal cord injury and is causedby the formation of a large space 
inside the spinal cord fluid full, named fistula 
Spinal cord injuries can be complete and incomplete. 
Complete. There is no sensitive and motor function in the region caudal to the lesion, in the 
acute phase the limbs areflaccid, theosteotendinous reflexesand the sphinctersmotility are absent. 
Incomplete. There are signals of spinal functions with a better prognosis. There are fourtypes of 
incomplete lesions: 
 Anterior spinal artery syndrome: is the primary blood supply to the anterior portion of the 
spinal cord. In this condition, there is the interruption in the anterior two-thirds of the spinal 
cord and medulla oblongata, causing ischemia or infarction of the spinal cord (Fig.1.3). It is 
characterized by loss of motor function below the level of injury (para- and tetra-paresis/ 
plegia), loss of sensations carried by the anterior columns of the spinal cord (pain and 
temperature) and preservation of sensations carried by the posterior columns (fine touch and 
proprioception). Anterior spinal artery syndromehaspoor prognosis and is the most common 
form of spinal cord infarction (Manuale di chirurgia Vol 1,Chirurgiasistemica, fisiopatologia, 
clinica, terapia Vol. 1,Scivoletto and Di Donna, 2009). 
 
 
Figure 1.3. Representation of Anterior Cord Syndrome 
 
 Posterior cord syndrome: is a very rare condition. It is caused by lesion of the posterior 
portion of the spinal cord, is characterized by pain and paresthesia of the limbs with modest 
sensitivity disorders (Manuale di chirurgia Vol 1,Chirurgia sistemica, fisiopatologia, clinica, 
terapia Vol. 1). 
 
 Brown-Séquard syndrome or Brown-Séquard's paralysis: is caused by hemisection of the 
spinal cordwith crusade interruption of the motor and sensorytract, resulting in paralysis and 
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loss of proprioception on the ipsilateral side ofthe injury. In the contralateral emisomathere 
are temperature sensation and pain sensitivity deficits, tactile discriminative conservation and 
dissociation of sensibility (Fig. 1.4) (Manuale di chirurgia Vol 1,Chirurgia sistemica, 
fisiopatologia, clinica, terapia Vol. 1, Scivoletto and Di Donna, 2009). 
 
 
 
 
Figure 1.4. Representation of Brown-Séquard syndrome 
 
 Central cord syndrome: is most common in the older persons because osteoarthritis in the 
neck region causes impairment of the vertebrae. The motility disorder is prevalent in the 
upper limbsthan in the lower limbs, with variable sensory loss (Fig. 1.5) (Manuale di 
chirurgia Vol 1,Chirurgia sistemica, fisiopatologia, clinica, terapia Vol. 1, Merriam, 1986, 
Newey, 2000). 
 
 
 
 
 
 
 
Figure 1.5. Representation of Central Corn Syndrome 
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A traumatic lesion is not the only cause of spinal cord injury because other factors could be 
implicated as infection, cysts and tumors.Complete spinal cord injuries result in complete 
paraplegia or complete tetraplegia. 
Complete paraplegiais a complete lesion of the spinal cord atthe thoracic or lumbar level and 
involves lower limbs paralysis and sphincter disorders. 
Complete tetraplegia is a complete lesion of spinal cordat cervical level, causing the paralysis of 
all the limbs and neuro-vegetative disorders. 
Para-paresis and tetra-paresisare characterized by incomplete paresis,respectively in the lower 
limbs, and the upper and lower limbs. 
 
1.2.2 Diagnosis 
 
The presence of a spinal injury requires a rapid and careful diagnosis to minimize to the patient 
possible posttraumatic complications and to decide the appropriate therapy to use,depending on 
the type and the degree of the lesion. 
The main diagnostic tools used with patients with spinal cord injury is a radiological and 
neurological diagnosis.  
As regards the radiological diagnosis, all patients with suspected spinal lesionsshould be 
subjected to radiography of the spinal cord in at least two positions (antero-posterior and lateral), 
with the inclusion of the first seven cervical and the first thoracic vertebrae. The axial computed 
tomography (TAC) should be performed in all cases of suspected or confirmed bone injury with 
simple radiography. The most important diagnostic technique for spinal cord injury is the 
magnetic resonance (RMN) because it allows the evaluation of the bone marrow structures, 
estimating possible involvements in the traumatic processes (Chirugiavol2, 
Chirurgiaspecialistica, Chirurgia sistemica, fisiopatologia, clinica, terapia Vol. 1, Fehlings, 
1999). Neurological evaluation of the patient with spinal cord injury must consider not only the 
presence and site of motility disorders, but also motility and sphincter functions. Neurological 
examination is very important from the beginning and aims to establish a neurological level, 
where there are obvious motor orsensitivity deficits. The neurological examination shouldbe 
conducted as early as possible and repeated frequently, especially in the first days after trauma 
for the high possibility of positive or negative changes (Chirugiavol 2, 
Chirurgiaspecialistica).Once the neurological level has been established, it is important to make 
an accurate description of the neurological deficits. In the past, there were scales 
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assessmentdefining the neurological condition of patients that were comparable between 
different therapy centers. The most widely used and accepted scale is currently the proposal from 
the American Spinal Injury Association (ASIA) (Fig. 1.6), which includes a standard 
neurological classification of spinal injury by motor score, based on the evaluation of some key 
muscle and one sensory groups. Based on the results of the neurological classification of 
patients, standardsarefurther classified using the ASIA impairment scales, definingtherefore the 
degree of deficiency of the patient (MSKTC, 2014). 
The examination must be conducted bilaterally as they can be major differences between the two 
sides of the body. 
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Figure 1.6. ASIA evaluation scale.  
 
1.2.3 Epidemiology 
 
Traumatic injury to the central nervous system (CNS) has devastating effects on the quality of 
life and representsan economic burdenfor the suffering patient (Abbaszadeh, 2015). Spinal cord 
injury (SCI), in particular, usually caused by a mechanical damage to the spinal cord andmay 
results in a complete or incomplete loss of neural functions. These two conditions can lead to the 
loss ofmotor and/orsensory functions (Li, 2013).The annual incidence of SCI in the US is 
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approximately 40 cases per million population, not including those who died during the accident. 
The number of people alive with SCI in the US in 2014 are approximately 276,000, with a range 
from 240,000 to 337,000 persons (MSKTC, 2014). The mean age of SCI patient has increased 
during the 70’sfrom 30 years to 42 years in2010 and it occursin approximately 70% among male. 
The most common causes of injury are high velocity/ high impact sports (Fig.1.7)(Li,2013; 
MSKTC,2014), such as motorcycle and diving, and young subjects usually undergoa worst 
damage, compared to older victims (Tator, 2000;Sekhon, 2001), because of their higher elasticity 
in the vertebral ligament and their underdeveloped spinal musculature. 
 
 
 
Figure 1.7. Diagram of the main causes of spinal cord injury. 
 
 
The most frequent neurologic conditionsof SCI areincomplete tetraplegia (45%) followed by 
incomplete paraplegia (21%), complete paraplegia (20%), and complete tetraplegia (14%) (Fig 
1.7).Every year in the US are registered 12,000 cases of paraplegia and tetraplegia, caused by 
spinal cord injury, of which 4000 die before reaching the hospital and 1000 die during their 
hospitalization.Deaths after admission for acute SCI range from 4,4% to 16,7% (Sekhon and 
Fehlings, 2001; Kraus, 1980). Considering the relative morbidity associated with acute SCI, this 
results to be high, with many survivors requiring prolonged or repeated admissions to hospital 
for complications after the injury (Sekhon, 2001; Heinemann, 1989). 
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Figure 1.8. Percentage of frequent neurologic conditions of SCI 
 
 
In Europe the most frequent cause of SCI are road traffic accidents, followed by falls (Werhagen, 
2012), with an annual incidence of about 17.5%patients per million, of which 80% are male as in 
the rest of the world. 
 
1.2.4Physiopathology of Spinal Cord Injury  
 
The pathophysiological processes underlyingSCI, comprise the primary, secondary and chronic 
phase of injury (Fig. 1.9). In the primaryphase, the spinal cord is lacerated by a sharp penetrating 
force, contused or compressed by a blunt force or infarcted by a vascular insult.The secondary 
damage is represented by a cascade of biological eventsthat begin from the first minutes after 
injury and that can lead to neurological damages during the weeks later(Silva, 2014; Li and 
Lepski,2011). During  the chronic phase, which begins several months from the injury and 
continues throghout the lifetime of the patient with SCI, there is a remarkable increasing of  
neurological impairments in both orthograde and retrograde directions (Yiu and He, 2006; 
Lorber, 2015). 
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Figure 1.9.Initialspinalcordinsulttosecondaryinjurywith subsequent glial scar formation. (Anton Y. Jorgensen, 
2015) 
 
 
1.2.4.1 Primary Injury Phase. 
 
This phase refers to themoment of the mechanical trauma the cord (Li and Lepski, 2013). The 
typical insult is represented by dislocation, burst fractures, missile injuries and acutely rupture 
discs (Sekhon and Fehlings, 2001) and the consequent disruption of axons, blood vessels and cell 
membranes. Axonsare commonly found to traverse the lesion site, often occupying a “subpial 
rim” of spared yet demyelinated or demyelinated long tract axons (Rowland, 2008).The spinal 
cord damage in this moment is made by a combination of the initial impact as well as subsequent 
persisting compression. At morphological level, spinal cord resident cells results destroyed and a 
further delayed damage can induce death to cells survived to the original trauma (Oyinbo, 2011). 
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1.2.4.2 Secondary Injury Phase. 
 
The secondary phase begins in minutes after injury and lasts for weeks, usuallyinducing a 
reduction of autonomic activity (instead of abolishment) and graduallyincreasingthe tone muscle 
leading to the onset of spasticity movements (Tanhoffer, 2007). The area of trauma distinctly 
enlarges; there is a prosecution of the events begun during the primary phase, as well as 
newones, as free radicals formation, delayed calcium influx, immune system response, 
inflammation and apoptotic cell death (Oyinbo, 2011). All theeventscharacterizing the secondary 
phase can be usefully divided in other four phases: immediate, acute, intermediate and chronic 
stages of SCI. 
 
1.2.4.3 Immediate phase.  
 
The immediate phase begins at the time of injury and is characterized bya traumatic axons 
severing, animmediate death of neurons and glia, all accompanied by theso called ‘spinal shock’, 
which is the results of aninstantaneous loss of function at the level below the injury.  The first 
detectable pathological change is a generalized swelling of the spinal cord, often 
accompaniedwith central gray matter hemorrhage. In this condition, mechanical disruption of 
cell membranes, or ischemia, resulting from vascular disruption, start to induce necrotic cell 
death and hemorrhage (largely petechial) in the surrounding white matter. Hemorrhage and 
swelling, combined, produce cord ischemia that may involve several spinal segments, both in the 
rostral and caudal direction from the injury (Fig. 1.10) (Rowland, 2008).  
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Fig 1.10.Scheme of the main mechanisms responsible for secondary damage after 
spinal trauma.Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms 
 
 
1.2.4.4 Acute phase.  
 
The acute phase is the period in which the secondary injury processes become dominant. It is 
divided in two phases: early acute and subacute phase.The early acute phase starts 2 hours post 
injury and lasts until 48 hours.  It is characterized by continuing hemorrhage, increasing edema 
and inflammation. In these moments there is also theonset of additional processes that contribute 
to further axonal injury and cell death, asfree radical production, ionic dysregulation, glutamate-
mediated excitotoxicity and immune-associated neurotoxicity. Vascular disruption, hemorrhage, 
and resulting ischemia are central constituents of this secondary injury cascade (Rowland, 2008). 
Ionic dysregulation.Disruption of cell membranes due to trauma, depolarization of calcium 
channels due to ischemia, and excitotoxin-mediated activation of calcium channels are 
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associated with an intracellular shift of calcium ions. Happel and colleagues(Happel, 1981) 
showed anincrease of total tissue calcium in contused spinal cord injury animal bytwo-fold at 2 
hours and five-fold after5 hours (Tator, 1991). Immediately afterSCI, aloss of ionic homeostasis 
and excitotoxicity occur, and there are evidence that these closely related processes significantly 
contribute to the propagation of cellular injury after SCI. 
Under pathophysiological conditions such as anoxia, ischemia, or trauma, intracellular Na+ 
concentration rises and membranes depolarize as a result of energy failure,leading to reverse 
Na+-Ca2+ exchange and causing Ca2+accumulation in the intracellular compartment (Li, 2000).  
Excitotoxicity. It is a pathological conditioncaused by an excessive or prolonged exposure to 
glutamate that often leads to neuronal and glia cell death in many forms of neurotrauma, 
including SCI (Park et al, 2004). Imbalanced and de-regulated overactivation of glutamate 
receptors in motor neurons leads  to the influx of Na+ and Ca2+ through theN-methyl-D-
aspartate (NMDA) and alpha-amino-3-hydroxy-5-metylisoxazoleproprionat/kainatoreceptors 
(AMPA/kainato), resulting in excitotoxicity (Gerardo-Nava, 2013). When an injury occurs, 
extracellular level of glutamate increasesand energy-dependent transporters fails, especiallythe 
Na+/K+ATPase, leading to theswelling of the cell and the loss of K+(Lipton and Rosenberg, 
1994). The result of all these processes isthe overproduction of proteolytic enzymes, induction of 
lipid peroxidation, ROS(Reactive Oxygen Species) and RNS(Reactive Nitrogen Species) 
formation, and in triggering apoptosis, which is one of the main mechanism of cell death in 
neurologic diseases (Emerit, 2004). 
Free radicals mediated injury. Free radicals are highly reactive molecules characterized by an 
extra electron in the outer orbit and that are produced when oxygen interacts with certain 
molecules. In central nervous system injury, there are evidence of their pathophysiologic 
importance and their early occurrence in triggering cell membrane lipid peroxidation 
(SekhonandFehlings, 2001). Several oxidants and derivatives are generatedafter a damage, 
including superoxide anions (O2), formed by incomplete electron transport in mitochondria, 
hydrogen peroxide (H2O2) and hydroxyl radicals (OH) (Cornelius, 2013). Hydroxyl radicals 
(OH) is inducedby lowered pH whereas H2O2 is produced in the presence of free iron such as the 
one released from hemoglobin, transferrin or ferritin. In lesionedregions, where pH is lower, 
conditions are favorable for the potential release of iron from storage proteins (Halliwell, 2009) 
and hemoglobin itself stimulates oxygen radical reaction (Cornelius, 2013). Activated microglia 
and infiltrating neutrophils and macrophages provide additional sources of O2 at later timepoints. 
Enhanced production of reactive oxygen/nitrogen species (ROS/RNS) cause 
oxidative/nitrosative stress (Juurlink and Paterson, 1998) leading to damage in lipids, proteins, 
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and nucleic acids (Povlishockand Kosov, 1992). These, if unchecked, can cause geometrically 
progressive lipid peroxidation, spreading over the cellular surface and causing impairment of 
phospholipid-dependent enzymes, disruption of ionic gradients and membrane lysis.The level of 
ROS starts to elevate12 hours afterinjury and remains highfor ~ 1 week, returning to basal level 
after 4–5 weeks(Rowland et al, 2008). 
Permeability ofblood brain barrier (BBB):In uninjured central nervous system (CNS), the BBB 
is a highly selective permeability barrier that separates the circulating blood from the brain 
extracellular fluid (BECF). The BBB acts like a filter, limiting the transport of molecules 
throughout the CNS parenchyma.The blood–brain barrier not only allows the passage of water, 
some gases and lipid-soluble molecules by passive diffusion, but also avoid the entry of 
lipophilic molecules and potential neurotoxins protecting the brain from bacterial infections 
(Rowland, 2008). When a neurological injury occurs, the BBBpermeabilityincreases because of 
themechanical disruptionand the numerousinflammatory mediatorsreleased by endothelial 
cells.Moreover, the breakdown of the BBB results in abnormal leakage of proteins leading to 
vasogenic edema formation and brain pathology. In addition,two inflammatory cytokines, TNF 
and IL-1β, are upregulated after SCI (Pineau, 2007)and their effects knownto increasevascular 
permeability. In rats with SCI induced by a contusion,the peak of vascular permeability 
disruption of the BBB is 24h afterthe lesion, restoring physiological values in two weeks (Noble, 
1989). In human, the maximum reduction of spinal cordblood flow (SCBF) is seen within 15 min 
in the traumatized region, in particular  in the caudal segment, suggesting that release of 
vasoactive substances following trauma influences localblood flow impairments (Sharma, 2005). 
Molecules released by glial and inflammatory cells at the injury, asROS, nitric oxide (ON), 
histamine, matrix metalloproteinases and elastase are believed to have a role in vascular 
permeability of the BBB(Donnelly and Popovich, 2008). The passage of water throughout the 
BBB consequently lead to the formation of edema, building up around the ependymal canal or at 
the level of the white matter, leading to nerve compression.  
Changes in spinal cord blood flow (SCBF) and the perturbation that follow are an important 
part of the alterations induced by acute SCI these events can be divided into systemic and local. 
Hemorrhage may promote ischemia, or thrombosis may occur via platelet aggregation.Finally, 
excitatory amino acids, particularly, glutamate, may be involved. Ischemia may play a role in the 
formation of local cord edema and it results in cytotoxic cell swelling that effects both neurons 
and glia. In the normal situation, gray matter to white matter blood ﬂow is maintained at a 3:1 
ratio. Whitematterperfusiontypicallydecreaseswithin5minutes of an acute SCI and begins to 
return to normal within15minutes. In central gray matter typically occur, as early as 5 minutes 
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after an acute SCI. Traumatized spinal cords show severe hemorrhages 
predominantlyingraymatter, and it maybe obstruction of these anterior sulcal arteries that leads to 
the hemorrhagicnecrosis and subsequent central myelomalacia seen at the site of injury. 
Endothelialdamage occurs early, with the formation of craters, adherence of non-cellular debris, 
over-riding of endothelial cell junctions, and microglobular formations occurring 1 to 2 hours 
after acute SCI. Acute SCI is one of the causes of neurogenic shock, typically being related to 
the magnitude and severity of the cord injury (Sekhon and Fehlings, 2001). Oxidative stress, 
caused by ischemia-reperfusion and inflammatory byproducts, contributes to cell death cascades 
after traumatic and ischemic CNS injury.  Neutrophils, microglia and macrophages produce 
superoxide anion and nitric oxide, which combine to form the highly reactive and toxic 
compound peroxynitrite (Xiong, 2007). Free radicals produced during these processes induced 
apoptosis in neurons and glia via the irreversible oxidation of proteins, lipids and nucleic acids 
(Donnely and Popovich, 2008). 
Cell death. In chronic neurodegenerative diseases,  such as Alzheimer’s disease, amyotrophic 
lateral sclerosis, Parkinson’s disease and Huntington’s diseaseand also Spinal Cord Injury, 
selective neural cell loss by apoptosis is  common(Choi, 2003). Numerous studieshave provided 
convincing evidence that apoptosis is presentin neurons, oligodendroglia and microglia after SCI 
(Yip and Malaspina, 2012).Apoptosis usually occurs through intrinsic and extrinsic apoptotic 
pathways (Rios, 2015).The Bcl-2 family of proteins regulates the intrinsic apoptotic pathway, 
starting withpathologicaloverload of calcium, opening of the mitochondrial permeability 
transition pore (mPTP)and activation ofcaspases-9 and caspase-3 (Precht, 2005). The extrinsic 
apoptotic pathway is mainlytriggered by ligation of death receptors, such as Fas and 
tumornecrosis factor (TNF) (Choi, 2015 / Rios, 2015). The cytokine tumor necrosis factor-α 
(TNF-α) is present in the CNS at low levels but it is upregulated more than 100 fold in the 
ischemic brain(Barone, 1997; Liu, 1994; Tarkowski, 1997; Wang, 2004), suggesting a role in 
modulating cellular damage.In particular, there are evidencethat the activation of apoptosis 
depends onTNF-a-induced activation of caspase-8 and-3, without affecting caspase-9 (Badiola, 
2009).  
Inflammation mediators and cellular immune response. The early acute phase after SCI 
involves infiltration ofinflammatorycells, activation of resident microglia and of numerous other 
cell populations, includingastrocytes, microglia, T cells, neutrophils, and invadingmonocytes. 
TNFα, interferons and interleukinsalso play importantroles. In particular, neutrophils and 
macrophages invade the damaged spinal cord with a maximum peak respectively at 12-24 hours 
and 5–7 days after SCI (Popovich, 199;Taoka, 1997). It has been reported that anti-inflammatory 
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treatments selectively interrupted the early, destructive, leukocyte-mediated actions in the 
injured cord, butleaving an opportunity for later regenerative interventions and wound-healing 
responses (Marfia, 2014). 
The subacute phase starts from 2 days post injury and lasts for 2 weeks. This is the mos 
important period to get better effects of cell therapy. At this stage, phagocytic response is 
maximal, helping to remove the cellular debris and growth-inhibiting components present on 
myelin debris in the lesioned area (Donnelly and Popovich, 2008).In subacute period, 
astrocytesproliferate and activate themselves increasing the expression of glial fibrillary acid 
protein (GFAP). The reactive astrocytes grow with large cytoplasmic processes that interweave 
to form the astrocytic scar, which unfortunately represents both a physical and chemical barrier 
to axonal regeneration (Rowland, 2008). Despite the scar formation, astrocytes also have a 
positive function SCI condition, as they re-establish ionic homeostasis and integrity of the BBB, 
which is very important to limit the reabsorption of edema and the infiltration of immune cells 
(Herrmann, 2008). 
 
1.2.4.5 Intermediate phase. 
 
The intermediate phase is characterizedby the evolution of the astrocytic scar, astrogliosis and 
regenerative axonal sprouting (Hill, 2001).Astrogliosis repairs the blood-brain barrier and 
protects neurons and oligodendrocytes, improving regeneration (Young, 2014). In a mouse 
model of SCI,axonalsprouting has been found in the corticospinal tract from 3 week to 3 months 
postinjury,whereas in the reticulospinal tractbetween3 weeksand8 months after lesion(Hill, 
2001). These regenerative attempts are insufficient to product a functional recovery in a severe 
SCI, but it is important to remember that regenerative potential does exist in the adult spinal 
cord. 
 
1.2.4.6 Chronic phase. 
 
The chronic phase begins about 6 months after the lesion and it is characterized by the 
stabilization of the lesion. During this phase,most rats develop expansions of the central canal, 
either proximal or distal to the contusion site, forming cysts that look very similar to 
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syringomyelic cysts observed in humans (Young and Keck, 2002). After 15 days post injury, 
macrophages have completed the removal of the myelin, although it is possible to observe 
macrophages containing myelin fragmentsalso after three months from the nerve section 
(Warden, 2001; Bierowski, 2005). In some cases of severely injured spinal cords, Schwann cells 
can be seen at the injury site, probably migrating from spinal roots. Schwanncellshave the ability 
to re-myelinate the damagedaxons at the level of nodes of Ranvier.Although there could be some 
improvement in neurological function after several years post injury (McDonald, 2002), it can be 
assumed that after 1-2 years from the trauma, the neurological deficit has stabilized. At this 
point, the lesion is physically characterized by a cystic cavity and myelomacia (pathological term 
referring to the softening of the spinal cord). These events represent the final stage of necrotic 
death after SCI.The lesionmay not remain a static condition, and syrinx formation in as many as 
30% of patients with SCI can cause delayed neurological dysfunction and neuropathic pain 
(Stoodley, 2000; Rowland, 2008). 
 
 
Table 1.2. Steps of spinal injury and pathological key events. (Rowland, 2008) 
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1.3 Spinal cord injury therapies 
 
Although the progress made in the field of spinal cord injury has improved the patients’ 
condition and life expectancy, to date there are no solutions that enable the healing of a spinal 
cord injury. However, in recent years research has reached encouraging results with regard to the 
modulation of the inflammatory process without being able to induce the regeneration of the lost 
as a result of the trauma. 
 
1.3.1 Pharmacologicaltherapies 
 
In the last years many different pharmacological treatment methodshavebeen studied based on 
the pathophysiological mechanisms of spinal cord injury. 
 
1.3.1.1 Methylprednisolone.  
 
To reduce spinal cord edema corticosteroids are the best choice because of their antinflammatory 
action. It has been supposed that the neuroprotective effect of corticosteroids includes 
themodulationofinflammatory and immune responses,throughinflammatorycytokines as TNF-α 
and NF-kB(nuclear factor kappa-light-chain-enhancer of activated B cells) (Xu, 1998), inhibition 
of lipid peroxidation,healing of vascular perfusion andprevention of calcium entering into the 
cell (Kokoszka, 2001). A synthetic glucocorticoid, Methylprednisolone (MPS), has been used to 
reduce SCI and brain edema for many years.It has been suggestedthat the inhibition of 
peroxidase is the most important mechanism in the SCI treatment and that MPS appear to act 
withmore efficiency than other glucocorticoid. The widespread use of MPS in patients with SCI 
is due to the results obtained from three clinical trials, the National Acute Spinal Cord Injury 
Studies (NASCIS) I, II and III. In NASCIS I it has been evaluated the effects of ten days doses of 
100 or 1000 mg of MPS administered 48 h after lesion (Bracken, 1984; Yilmaz, 2015): these two 
groups did not differ in motor and sensory recovery. In animal trials, the maintenance dosage of 
30-40 mg/Kg injected intravenouslyhas resulted to be appropriate to obtain effective 
neuroprotection (Young, 1988). In NASCIS II trials the dosage administered was 30 mg/kg MPS 
followed by a maintenance dose of 5.4 mg/Kg for 23 h. Patients with SCI were randomized into 
three groups, methylprednisolone, naloxone (an opioid receptor antagonist, caused functional 
and electrophysiological improvement and reverse the spinal shock (Winkler, 1994)) or placebo. 
The MPS injected 8 hoursafter the lesion has induced sensory and motor improvement in 
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patients with full and partial SCI. This is the firsttrial demonstrating the efficacy of 
pharmacological therapy in spinal cord injury. In NASCIS III, methylprednisolone effect has 
been compared with tirilazadmesylate (member of the family of 21-aminosteroid, lazaroid, that 
acts on lipidic peroxidase) considering different administrationtimes.In both treatments, the 
authors reported sensory and motor improvement within 3 h from the trauma(Bracken, 1990). 
The results suggest the usage of the drug between 3 and 8 hours, with an increased beneficial 
effect seen if the infusion is prolongeduntil 48 hours. However, they found very poor 
effectiveness in neurological healing when the application of 48 hoursaccompanied by increased 
wound infection rates, pulmonary embolismand sepsis, leading tosecondary deaths (Yilmaz, 
2015).The anti-inflammatory effects of high dose of MPS decrease the neuronal regeneration and 
axonal growth. This is a possible explanation for the ineffectiveness of the MPS given more than 
8 hours after injury (NASCIS II) (Baptiste and Fehling, 2006).  
 
1.3.1.2 Ganglioside GM-1.  
 
Other possible pharmacological therapyfor SCI is the use of Ganglioside, a glycosphingolipid of 
the lipid membranes of the nervous cells thatcontains sialic acid. Systemic administration of 
ganglioside GM-1 can induceneuroprotective effect, such as neurite outgrowth, and prevent 
apoptosis and inhibition of excitotoxicity in SCI. A double blind trial has been done to 
investigate the efficacy of GM-1 in patients with cervical and thoracic SCI (Geisler, 1991): 
administration of 100mg of GM-1 in 18-32 doses, starting with the first injection 72 h post 
trauma. The results of this study showed an increase in post-traumatic recovery only in the lower 
limb, suggesting that GM-1 promotes the regenerated axonal “crossing” of the lesion site, having 
no effect in the gray matter of the trauma epicenter (Gorio, 1986). The neuro protective effect of 
this drug is maintained after 48 h post injury.These positive results led to realize other 
randomized trial started in 2001. In this trial patients with SCI werefirst treated with the same 
protocol used for NASCIS II, and later were divided into three groups: placebo, GM-1 lower 
dose (300 mg to start and 100 mg/day for 56 days) and GM-1 high dose (600 mg to start and 200 
mg/day for 56 days). The recovery, evaluated with ASIA scalereported an improvement in motor 
recovery. After three months, patients treated with GM-1 showedcompleterecovery of 
motor/sensory and bladder function (Geisler, 2001). 
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1.3.1.3 Opioid receptor antagonist.  
 
After SCI, there is an increase of the circulatingDynorphin A, an endogenous opioid. Dynorphin 
A is neurotransmitters, modulator of pain response. In high dose, this peptide is neurotoxic and 
the activation of subtype K of the opioid receptor is correlated to the decrease of the blood flow 
in the spinal cord (Long, 1986). Naloxone is a non-specific opioid receptor antagonist, with the 
important roleof improving the blood flow in the spinal cord and reducingedema and allodynia in 
animal models. However in human (NASCIS II)(Bracken, 1990)this opioid antagonist has not 
shown any significant neuroprotective effect over placebo, but other studies have indicated that 
the administration of Naloxone within 8 h post SCI is correlated whit a motor recovery in lower 
limb (Bracken and Holford, 1993).   
 
1.3.1.4 Thyrotropin releasing hormone (TRH).  
 
Thyrotropin is a tripeptide that stimulate hypophysis and is able to antagonize the effect of 
endogenous opioids, and of all the targets correlated in the SCI secondary damage, such 
asplatelet-activating factor (PAF) andexcitatory aminoacids. In rats the subcutaneously 
administration of TRH once a day for 7 days, started 24h or 7 days post trauma, 
increasesneurological functions(Hashimot, 1991). Clinical trials using TRH with a started dose 
of 0.2 mg/Kg and a maintenance one of 0.2 mg/Kg/h for 6 h, demonstrate that after 4 months this 
drug improves the motor recovery in patients with partial SCI, but not in patients with full 
trauma (Pitts, 1995). 
 
1.3.1.5 Antagonists for glutamate receptor (GluR antagonists).  
 
This pharmacological class can easily pass through the ematospinal barrier (ESB) and are 
immediately available to decrease the secondary excitotoxicdamage. Nevertheless, the GluR 
antagonists are not used in clinical treatment of CNS pathology like SCI, because of the 
collateral effects induced by the high dosage required for their effectiveness. In a recent study, 
the injection at the lesion site of an AMPA/Kainate antagonist (NBQX) within 4 h from the 
lesion in a rat model of SCIhas shown decreased the neurotoxicity without collateral effects. 
(Gaviria, 2000). 
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1.3.1.6 Calcium channel inhibitors. 
 
Calcium is an important element in SCI secondary damage because it is responsible for the 
intracellular excitotoxicity and ischemic vasospasm. In a SCI animal model study, Nimodipina (a 
drug that blocks the calcium channel diidropiridinesensible (L channels)) therapy was used in 
combination with dextran, in order to investigate the effectson spinal cord injured blood flow and 
axonal functionality (Fehlings, 1989). The study demonstrates that Nimodipinaadministered with 
dextran improve the axonal function in the sensory and somatosensory tract of the spinal cord. 
Despite this, in a clinical trial the treatment with Nimodipina has not shown any significant 
benefit in patients with SCI (Petitjean, 1998). 
 
1.3.1.7 Inhibition of sodium channel.  
 
After spinal cord injury, sodium cell concentration increases(Stys, 2004). These pharmacological 
inhibitors (QUALI?) reduce the sodium accumulation, preserve the white matter in lesioned 
spinal cord and reduce the myelin damage (Rosenberg, 1999). The administration of the 
tetradotoxine (TTX), inhibitors of sodium channel, into the lesion site of the mouse, decrease the 
axonal degeneration but there is no positive effecton the survival of glial cells that are rich in 
sodium channels (Rosenberg, 1999). Other inhibitors of sodium channel,Riluzole, has a 
neuroprotective properties and promote the neurological recovery in rat SCI. Riluzole reduces 
degeneration into white and gray matter in the rostral part of the lesion(Schwartz, 2001). 
Howeverit inhibits the presynaptic glutamate release calciumchannels inducted (Wang, 2004).  
 
1.3.1.8 Caspasesinhibitors.  
 
Caspases activation have a central role in apoptotic cells death after SCI and many molecules 
interfere with this process. These inhibitors are tri-tetra peptides that mimic the catalytic site of 
caspases substrates, like z-VAD-fmk or z-YVAD-fmk.These peptides block or inhibits the 
programming cell death and reduce the functional cells loss. 
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1.3.1.9 Monoclonal antibody (MoAb).  
 
A most important target for pharmacological therapies for SCI is the inflammatory response.The 
clinical trials that use MoAbin SCI have shownpromising results. MoAbwere usedto inhibit the 
interaction between immune cells and endothelium, or to inhibit the integrin-leukotriene 
complexes. Taoka et al. use this antibody on P-selectin in an animal model, reducing neutrophils 
infiltration and improving the functional recovery of hind limb (Taoka, 1997). Gris et al. have 
demonstrated that selective MoAb on CD11d subunit of the CD11d/CD18 integrin’s complex 
reduceslipid peroxidation, improving neurological function and allodynia (Gris, 2004). 
 
1.3.1.10 Cyclosporine A (CsA). 
 
In addition to drugs that limit leukocyte infiltration to the injury site, agents that suppress the 
immune response are beneficial in the SCI treatment. Treatment with a low dose of CsA (2,5 
mg/Kg) administered within the first 6 h after injury, showed decreasedlipid peroxidation in rats 
(Diaz-Ruiz, 1999). Moreover, it was demonstrated that the CsA has the ability to inhibit the 
autoimmune cellular reaction, within the injured spinal cord, while promoting a decrease in 
demyelination and of neuronal death (Ibarra, 2003). Moreover, recently it has been found that 
subsequent intraperitoneal injections of CsA (2, 6 and 12 h post injury) inhibit the inducible 
nitric oxide synthaseactivity, presumably by inhibiting calcineurin CA2+- dependent(Diaz-Ruiz, 
2004). 
 
1.3.1.11 Minocycline. 
Minocycline is a semisynthetic and highly lipophilic derivativeof the tetracyclineable to pass the 
blood-brain barrier, where it exerts its anti-inflammatory properties. This antibiotic inhibits 
excitotoxicity, oxidative stress, neural death pathways, both caspase-dependent and caspase-
independent, and the pro-inflammatory mediatorrelease by activated microglia (Wells, 2003; 
Stirling, 2004). It has been reported that systemic administration of minocycline showed a 
significant neuroprotective activity, by decreasing apoptosis of oligodendrocytes and microglial 
activation, reducing the size of the lesion and improving the neurological deficits. The 
neuroprotective mechanism proposed for the minocycline can be attributed to its ability to 
increase the mRNA levels of the anti-inflammatory cytokine IL-10, with a consequent decrease 
in the levels of TNF-alpha (Stirling, 2004). After acute SCI, minocycline reduces the size of the 
lesion.  
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1.3.1.12 Erythropoietin. 
 
Erythropoietin (EPO) is an endogenous cytokine mediator of 34 kDaproduced by the kidney  
withthe main function to stimulate erythropoiesis. In addition to this effect, when binds its 
receptor EpoR, EPOactivates a protective response against hypoxia, increasing circulating 
erythropoietin andmaintaining an adequate tissue oxygenation. In addition to its tissue protective 
effect in the CNS (103), EPO also inhibits apoptosis, decreases inflammation and has an effect in 
the migration and proliferation of neural stem cells (Sakanka, 1998; Shingo, 
2001).Itsneuroprotective effects on spinal trauma can be attributed to a variety of mechanisms, 
including the ability to reduce lipid peroxidation, inflammation and apoptosis (Erbayraktar, 
2003). After ischemic or mechanical trauma, the human recombinant erythropoietin (rhEPO), 
administered systemically, passes the blood brain barrier and prevents cell damage and 
inflammation (Brines, 2000). In two studiesrealized using two different animal models, one of 
crushing trauma and the other of a contusion trauma, administration of rhEPO in the acute phase 
mitigates the effects on spinal cord injury and significantly increases the functional recovery. 
Although the experimental evidence support the neuroprotective role of EPO, recent animal 
studies have focused on the treatment of chronic spinal injury with this protein (Wiessner, 2001). 
There are studies currently in progressabout the synthesis of derivative of EPO without 
erythropoietic effect(Erbayraktar, 2003; Leist, 2004).Erbayraktar and colleagues have managed 
to create amolecule thathas been shown to be neuroprotective in animal models of stroke, 
peripheral neuropathy and SCI without effectsin red cell mass (Erbayraktar, 2003). Another 
derivative of EPO was created by carbamylation of EPO lysine residues (Leist, 2004). The 
resulting molecule, CEPO, lost all hematopoietic potentials butmaintains all its neuroprotective 
properties when use in anappropriate treatment of SCI. 
 
1.3.1.13 Estrogen. 
 
The female hormones may act in the neuroprotection hormone-dependent, increasing the 
expression of bcl2and through the activation of protein kinase pathways.  They inducea 
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reduction of secondary tissue damage, macrophage/microglia accumulation and apoptosis but no 
behavioral recovery (Yilmaz, 2015).  
 
1.3.1.14 Progesterone.  
 
The progesterone reduces the production of inflammatory cytokines, can reduce the production 
of oxidants and free radicals and provides stabilityof neurotrophine in SCI (Fu, 2005). This 
protein alter the traditionalneurotransmitters like inhibitory GABA (Thomas, 1999). Was 
reported that progesterone alter neurotransmitters, gene expression and cell morphology in the 
spinal cord injury. 
 
1.3.1.15 Cyclooxigenase inhibitors.  
 
Indomethacin and ibuprofen are inflammatory prostaglandins that reduce tissue damage and 
edema in SCI. Contusion SCI increases the concentration of Cox2 in rats.  Inhibiting Cox2 with 
Cyclooxygenase-2 inhibitor (SC-236) provided neuroprotection and an improvement in behavior 
deficitsin rabbit (Dumont, 2001).    
 
1.3.1.16 Antioxidant. 
 
In the animals with spinal cord injury there is an increasing of free radicals. To reduce the 
concentration of free radical. The antioxidant such as Melatonin (Kaptanogen, 2000), vitamin E 
and selenium (Anderson, 1992), lipopolysaccharide (Davis, 2005) have been shown beneficial 
for SCI and reduce the concentration of free radicals. 
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Table 1.3 .Pharmacotherapy of acute spinal cord injury and mechanisms of action 
Methylprednisolone 
Inhibition of lipid peroxidation/antioxidative/anti-inflammatory. Properties decrease ischemia, 
support energy metabolism, inhibit neurofilament degradation, decrease intracellular Ca, decrease 
PGF/TxA, increase spinal neuron excitability, decrease cord edema 
Ganglioside GM-1 
Stimulate neurite regrowth/regeneration 
Opioid receptor antagonists 
Antagonize the increase in endogenous opioid levels after SCI (opioid receptor activation can 
contribute to excitotoxicity 
TRH and its analogs 
Antagonize endogenous opioids, platelet-activating factor, peptide leukotrienes and excitatory 
amino acids 
Nimodipine 
Decreaseintracellular Ca2+ accumulation, attenuate vasospasm 
Gacyclidine (GK11) 
Antagonism of glutamate receptors 
Magnesium 
Replace Mg2+ depletion that is common after SCI, diminish intracellular Ca2+ accumulation, block 
N-methyl-D-aspartate receptor ion channel, modulate binding of endogenous opioids 
Hypothermia 
Reduce extracellular glutamate, vasogenic edema, apoptosis,neutrophil and macrophage invasion 
and activation, and oxidative stress 
Minocycline 
Inhibition of microglial activation, inhibition of cytochrome c release 
Erythropoietin 
Reduced apoptosis and lipid peroxidation 
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Estrogen 
Not clearly known 
Progesterone 
Reduce the production of inflammatory cytokines 
Cyclooxygenase inhibitors 
Prevents/antagonizes decreased blood flow/platelet aggregation fromproduction of arachidonic acid 
metabolites 
Riluzole 
Blockade of voltage-sensitive sodium channels and antagonism ofpresynaptic calcium-dependent 
glutamate release 
Atorvastatin 
Prevents neuronal and oligodendrocytic apoptosis 
Antioxidants 
Antagonize deleterious effects of free radicals (lipid peroxidation, reperfusion injury, etc.)  
 
 
 
1.3.2 Cell therapy 
 
A recent therapeutic approaches used in the spinal cord injury treatment is the cell 
transplantation, in particular the use of stem cells. Cell transplantation after SCI has several 
goals: preserve neural tissue in thelesioned spinal cord, create a favorable environment for axon 
growth and replace damaged tissue through the differentiation of the transplanted cells.In the last 
two decades the cell transplantation became more relevantas a treatment for SCI and has been 
the subject of many pre-clinical studies. Numerous cellular typeswere used in the spinal cord 
injury studies for their different characteristics and properties; such as the ability to produce 
myelin and promote axonal growth. Many cell types are able to secrete trophic factorsthat may 
have a neuroprotective effect and can promote plasticityin the spinal cord survivedtissue post 
lesion.The cell types more studied for the treatment of spinal cord injury are: i) Schwann cells; 
ii) olfactory cells; iii)embryonic stem cells;  iv) mesenchymal stem cells;v) neural stem / 
progenitor cells (adult and embryonic). 
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1.3.2.1 Schwann cells 
Schwann cells form myelinated sheet in the peripheral nervous system (PNS), but were they also 
can support CNS axon regeneration (Pego, 2012). It has been shown that they are not only able 
to re-myelinate axons after being transplanted in spinal cord injury, but also create a permissive 
substrate for the growth of the regenerating axons. They have been previously studied and have 
shown a proven therapeutic effect in the treatment of SCI (Duncan and Milward, 1995), after 
being isolated directly from the patient and then injected as autologous transplants. Although, 
several weeks are needed to expand SCs to obtain a sufficient number of cells for 
transplantation, thus limiting their use in acute treatments (McCreedy, 2012). After a contusion 
injury, transplanted Schwann cells can reduced the cavitation, and promote the spinal axons 
regrowth (Pego, 2012), by mechanisms involving the secretion of various trophic factors, such as 
NGF, fibroblast growth factor-2 (FGF-2), BDNF or NT-3 (Takami, 2002). In contrary, these 
cells cause and sharpastrocyte reaction and also require a co-adjuvant treatment to increase the 
effectiveness, which is a disadvantage of this approach (eg. matrigel; cAMP, neurotrophic 
factors) (Tetzlaff, 2011). 
 
1.3.2.2 Human Olfactory Ensheathing Stem Cells (hOESCs) 
Olfactory mucosa/epithelium is a specialized tissue inside the nasal cavity that is involved in 
olfactory perception. This tissue is characterized by lifelong regeneration of adulthood and 
multipotent stem cells, condition that offers the possibility to promote regeneration and 
reconstruct in regenerative medicine. These cells are easily accessible with minimal invasive 
techniques (Rawson, 2002; Raisman, 2001). Two types of cells are useful in reparing the nervous 
system: stem-like progenitors cells and Olfactory Ensheathing cells (OECs) (Bianco, 
2004).OECs are a specific glia cells class that are restricted to the PNS and alsoCNS, and share 
certain characteristics with astrocytes as well as Schwann cells (Ramon-Cueto, 1998). In a 
previous study, Murrell et al. showed that human olfactory lamina propria derived stem cells 
can be (1) grown in large numbers and (2) differentiated into neural and non-neural cell types in 
vitro and in vivo. For the peculiar properties and the plasticity the hOESCs are used spinal cord 
human clinical trials. The first pilot clinical study with transplantation of autologous hOESCs 
(Lima, 2006)has been done in 2006. This pattern of recovery suggested functional regeneration 
of both efferent and afferent long-distance nerve fibers, also confirmed by imaging and 
neurophysiological examinations. Based on their apparent ability to integrate into the glial scar 
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and enhance the growth permissiveness of the injured spinal cord we can say that the 
Olfactoryensheathing cells are also a promising candidate for combinatorial cell-based strategies. 
Notably, hOESCs can be used not only to treat SCI, but also other CNS diseases like Parkinson 
’s disease (Wang, 2012; Murrell, 2008) and hippocampal lesions (Nivet, 2011).Although, OECs 
represent one of the most promising alternative for transplant-mediated repair of CNS, 
mechanism, of their beneficial effects remain to be clarified. However, the use of these cells in 
more severe traumatic models does not seem to be soeffective (Tetzlaff, 2011). 
1.3.2.3 Embryonic stem cells (ESCs)  
ESCs are the target of regeneration research for their unique pluripotency, which cannot be seen 
in any other types of stem cells. They are isolated directly from blastocyst in the early stage of 
embryonic development by mechanical or laser dissection. Unlike adult stem cells, ESCs are 
able to self-renew for an unlimited number of times and can give rise to all three germ layers 
tissues and potentially differentiate into every kind of cells (Conley, 2004). ESCs were firstly 
extracted from murine blastocyst (Martin, 1981)and it took a decade or two to isolate human 
(Thomson, 1998) or rat ESCs (Buehr, 2008).Most often ESCs are used for SCI treatment in a 
state of in vitro pre-differentiation into defined cell lines that could promote axonal elongation, 
myelin formation and remyelination. Thus, neural or glial precursors and mature neurons 
differentiated from ESCs have been grafted into the spinal cord of different SCI models. Several 
cocktails of growth factors based on retinoic acid (RA) and Sonic hedgehog (Shh) have been 
used to promote differentiation of ESCs to motoneurons (Feravelli, 2014), which after their 
transplantation to the injured spinal cord of mice showed to induce functional recovery  
(McDonald, 1999). In vitro pre-differentiation of oligodendrocytes has also been performed in 
mice and rats. Grafted cells contributed to the remyelination of SC axons and participated in 
movement improvement after the lesion (Liu, 2000).So far the greatest achievement was 
recorded by transplantation of oligodendrocyte progenitors derived from hESCs (Keirstead et al., 
2005;Cloutier et al., 2006), which advanced into the clinical trials (Chapman, 2012). The safety 
study involving patients in the subacute phase of SCI, did not report any safety issues, neither 
any significant improvement of medical conditions after transplantation of oligodendrocyte 
progenitors (Lucovic, 2012). Clinical trials provided by Geron Corporation were shut down in 
2011 for the economical reasons. Despite the promising results obtained in mice and rats, 
currently the clinical use of hESCs for SCI treatment seems to have come to a standstill. 
However, the unquestionable potential of these cells is being further studied and applied for 
other therapies in regenerative medicine. 
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1.3.2.4 Mesenchymal Stem Cells  
 
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety 
of cell types(Nardi, 2006) such as osteoblasts, chondrocytes, myocytes and adipocytes. The 
MSCs are known to present low immunogenicity, have an anti-
inflammatory/immunosuppressant effect, do not form tumors, and have a pathotropic action. 
This differentiate capability has been documented in specific cells and tissues of living animals 
and their counterparts growing in tissue culture. They are two kinds of MSCs used in Spinal 
Cord Injury transplant: Bone-marrow-derived stromal cells (BMSCs) and Human Adipose 
Derived Stem Cells (hADSCs). 
 
1.3.2.5 Bone Marrow Derived Stromal Cells (MSCs) 
 
The BMSCs are essentially a set of stromal cells that support the growth of hematopoietic stem 
cells and mesenchymal stem cells. These cells are used very frequently in the treatment of SCI 
and other diseases of ischemic character (Parr, 2007). These cells are easily accessible with 
minimal invasive techniques and can be used in autologous transplants (both in animal models 
and in humans), have shownto have an effect on motor recovery in rodents and were usedin 
models of chronic SCI. The BMSCs also appear to have the ability to create a substrate that 
allows the invasion of endogenous Schwann cells. However, the integration of this cells is 
extremely limited and show the little tendency to differentiate into neural cells (Tetzlaff, 2011). 
 
1.3.2.6 Adipose Derived Stem Cells (hADSCs) 
 
Recent studies have shown that subcutaneous adipose tissue provides a clear advantage over the 
other MSCs sources due to the simple possibility to extract the adipose tissue and to isolate the 
stem cells (Zuk, 2001).Stem cells frequency is significantly higher in adipose tissue than in bone 
marrow (Musina, 2005). It has been shown that ADSCs are able to differentiate into the classical 
mesodermal tissues like bone, fat and cartilage (Zuk, 2001; Zuk, 2002), and it is claimed that 
they can be differentiate into nerve, cardiomyocytes, hepatocytes and pancreatic cells (Safford, 
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2005). They favor neuronal repair, osteogenesis and vasculogenesis however, the potential of in 
vivo application of these cells is still unclear. Recent biological studies performed on stem cells 
suggest the possibility to significantly improve the potentiality of tissue regeneration by using 
ADSCs. They represent a promising source for the cell therapy, due to the less invasive way of 
isolation compared to the extractions of bone marrow, possibility to obtain a bigger  quantities of 
tissue from lipoaspirate and their easy expansion in vitro-.. The effects and safety of the 
intrathecal transplantation of autologous ADSCs in patients with SCI were evaluated in the first 
clinical trial (Hur, 2015). Over the 8 months of follow-up, intrathecal transplantation of 
autologous ADSCs for SCI was free of serious adverse events, and several patients showed mild 
improvements in neurological function. Patient selection, dosage, and delivery method of 
ADMSCs should be investigated further. 
 
1.3.2.7 Neural stem cells (NSCs) 
 
Neural stem cells are defined as multipotent and self-renewing stem cellsfound in both 
embryonic and adult tissue. (Pego, 2012).They are usually obtained from the subventricular zone 
(SVZ) of the brain or the spinal cord, and are amplified in crops such as neurosphere which are 
formed not only by  NSCs but also by neural cells at different stage of maturation (Gritti,1996). 
When transplanted after SCI, these cells seem to be able to integrate well into the host spinal 
cord andthe numerous studies evaluating the neurological functional recovery showed an 
improved behavior.The functional improvement was observed in different experimental models, 
using different animal species. The limitations in the use of (NSCs / NPCs) are  mainlydue to  
their tendency to differentiate preferentially into astrocytes and only minimally in 
oligodendrocytes and in neurons (Horky, 2006). Moreover, they do not seem to be particularly 
effective in generating a substrate suitable for axonal regeneration in order to create a neural 
tissue bridge over the lesion (Tetzlaff, 2011). Recent data using human fetal NSCs shown that, 
these cells can survive inside the lesion, differentiate into motoneurons and improve motor as 
well as sensory function after transplantation into a SCI (Romanyuk, 2011). An additional study 
has shown that NSCs derived from human fetal spinal cord and grafted into a rat model of 
ischemic spastic paraplegia resulted in the progressive recovery of motor function with a 
concurrent improvement in motor evoked potentials (Cizkova, 2007). The functional recovery 
was associated with the long-term survival of the grafted neurons, neuronal differentiation and 
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the development of a GABAergic phenotype in a sub-population of grafted cells that most 
probably contributed to the suppression of spasticity. Therefore, in an attempt to reduce these 
pain behaviours following injury, the transplantation of pre-differentiated ESC cells, 
serotonergic or GABAergic neural precursor cells has been successfully used in various pre-
clinical animal studies (Mukhida, 2007). 
 
1.3.2.8 Post Mortem Neural Precursor Cells (PM-NPCs) 
 
Post Mortem -Neural Precursor Cells (PM-NPCs) present at several hours after mouse death 
(Marfia, 2011) are cells that have different properties from classic neural stem cell (NSCs), 
subjected to prolonged global ischemia. It would be of great utility to use for the SCI treatment 
of a type of neural stem cells that in addition to having the benefits and potential described in the 
previous paragraph, was also able to survive in the ischemic environment to the spinal cord 
injury (Molcanyi, 2007; Popovich, 2003). Indeed the microenvironment formed in a spinal cord 
injury is characterized by an important ischemic area, the cells used for the SCI therapy once 
arrived in the lesion must survive in a very bad environment, and with a very poor perfusion, at 
least in the early stages immediate harm. In our laboratory we have been isolated Neural stem 
cell from the SVZ of adult mice. 
PM-NPCs growthunder hypoxic microenvironment, in this condition HIF-1 α and β dimerize and 
migrate to the nucleus; this enhances the expression of several key target geneswhich acts as 
regulators of cellular proliferation and differentiation, such as erythropoietin (EPO), vascular 
endothelial growth factor (VEGF), tyrosine hydroxylase (TH) and OCT4, (Adelman and Simon, 
2002). These cells differentiate about 33% β tubulin III- and 36% of MAP2-positive compared to 
10–12% of NPCs. After differentiation PM-NPCs show HIF-1α activation, active voltage-
dependent Ca++ channels and express both EPO and EPO-R (Marfia, 2011). These cells may 
represent a more successful approach to the treatment of traumatic CNS injuriesand 
neurodegenerative disease such as Parkinson disease. 
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1.4 Parkinson Disease 
 
As previous reported cell therapies have long been considered a feasible regenerative approach 
to compensate the loss of specific cell populations in neurodegenerative disorders, where 
symptoms can be ascribed to the degeneration of a specific cell type, such as the loss of 
Substantia Nigra (SN) dopaminergic neurons in Parkinson’s disease (PD) (Barker, 2013 and 
2014). Parkinson's disease (PD), the second most common neurodegenerative disorder after 
Alzheimer's disease, was originally described in 1817 by James Parkinson in the classic "Essay 
on the Shaking Palsy". All the cardinal signs of PD relate to motor dysfunction and include 
resting tremor, bradykinesia, rigidity and postural reflex impairment. Other manifestations 
include psychiatric symptoms such as anxiety and depression and dysautonomic symptoms such 
as hypotension and constipation, paresthesias, cramps, olfactory dysfunction, and seborrheic 
dermatitis. As the disease progresses, decreased cognitive ability may appear (Marsden et al., 
Oxford textbook of medicine. Vol 3). The main pathological finding associated with the motor 
deficits of PD is degeneration of the dopaminergic neurons of the pars compacta of the substantia 
nigra leading to loss of dopamine in the striatum. Symptoms do not develop until about 50-60% 
of the nigral neurons are lost and about 80-85% of the dopamine content of the striatum is 
depleted (Marsden et al., Oxford textbook of medicine. Vol 3).  
Dopamine neurons have been successfully derived from human embryonic stem cells, and their 
transplantation in rat PD models showed positive behavioral outcome (Bjorklund, 2002, Kim, 
2002; Kriks, 2011; Yang, 2008; Martínez-Cerdeño, 2010). Previously, also allografts of ventral 
mesencephalon tissue had been used as implants that survived for a long time, and received and 
made synapses within the host brain. Their use promote recovery from behavioral deficits in 6-
OHDA exposed rats (Lindvall, 1990; Schultzberg, 1984; Haque, 1997; Takahashi, 2007). 
Following those experiences, clinical observations were made in human patients with the 
transplantation of cells obtained from human fetal mesencephalon (Barker, 2013). It resulted that 
transplanted dopaminergic neurons could re-innervate the striatum, restore dopamine release 
and, at least in some cases, support clinical amelioration of the patient condition. Unfortunately, 
these positive effects were associated often to disabling side effects such as dyskinesias of 
orofacial muscles, and upper and lower extremities (Barker, 2013, Hallett, 2014; Kefalopoulou, 
2014; Hallett, 2015; Tsui, 2011). Such use of human embryonic or fetal central nervous system 
tissue gave rise to numerous ethical concerns (Barker, 2014, Barker, 2013). The association of 
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actual issues and severe side effects enhanced the efforts to adopt other sources, and 
dopaminergic neurons obtained from induced pluripotent stem cells through somatic cell 
reprogramming, gave positive results in rodents or non-human primate models of PD (; Werning, 
2008; Sundberg, 2013; Doi, 2014; Yu, 2007). Recently, we reported the existence of a subclass 
of SVZ-derived neural progenitors surviving after donor death (Marfia, 2011). Such post mortem 
neural precursors (PM-NPCs) show a higher neural–like differentiation, and the process is likely 
dependent on autocrine erythropoietin (EPO) release, since it is prevented by the exposure to 
anti-EPO and -EPOR antibodies (Marfia, 2011). When PM-NPCs were administered after 
traumatic spinal cord injury in the mouse, secondary degeneration and neuroinflammation were 
greatly attenuated, and the recovery of hind limb function was markedly improved (Carelli, 2014 
and 2015). In order to determine the therapeutic potential of PM-NPCs in a pre-clinical 
experimental model of PD, here we transplanted PM-NPCs, unilaterally into the striatum of 
symptomatic, and dopamine-depleted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- 
exposed C57/bl mice. We found that PM-NPCs treated animals had had a rapid behavioral 
improvement within the third day after cells transplantation. The behavioral recovery was likely 
mediated by PM-NPCs-derived EPO, as the co-injection of anti-EPO or anti-EPO-R antibodies 
totally abolished the favorable outcome. The majority of transplanted PM-NPCs were vital and 
capable of migrating ventrally and caudally throughout the striatum from the injection site, and 
could reach the ipsilateral SN pars compacta (SNpc). This study confirm the therapeutic 
potential of PM-NPCs in neurodegenerative conditions. 
 
1.4.1Synthesis and Metabolism of Dopamine 
 
 
Figure 1.11. Structure of Dopamine, the principal neurotransmitter involved in Parkinson’s disease. 
 
The amino acids phenylalanine and tyrosine are the precursors of dopamine (DA) (Fig 1.11). For 
the most part, mammals convert dietary phenylalanine to tyrosine by phenylalanine hydroxylase 
(predominantly located in the liver). Tyrosine crosses readily into the brain through uptake; 
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however, unlike tryptophan, normal brain levels of tyrosine are typically saturating. Conversion 
of tyrosine to L-DOPA (3,4-dihydroxyphenylalanine) by the enzyme tyrosine hydroxylase is the 
rate-limiting step in the synthesis of DA. Tyrosine hydroxylase is a mixed-function enzyme that 
requires iron and a biopterin co-factor; enzyme activity is regulated by phosphorylation and by 
end-product inhibition. Four alternatively spliced isoforms of tyrosine hydroxylase have been 
identified in humans, which is in contrast to many non-human primates (two isoforms) and rat 
(one isoform). At present, it is unclear if these various isoforms play different roles. Once 
generated, L-DOPA is rapidly converted to DA by L-aminoacid aromatic decarboxylase 
(AADC), the same enzyme that generates serotonin (5-HT) from L-5-hydroxytryptophan. In the 
central nervous system (CNS) and periphery, AADC activity is very high, and basal levels of L-
DOPA cannot be readily measured. 
Metabolism of DA occurs primarily by the cellular L-monoamino oxidase (MAO) enzymes 
localized on both pre- and post-synaptic elements. MAO acts on DA to generate an inactive 
aldehyde derivative by oxidative deamination (Fig 1.12), which is subsequently metabolized by 
aldehyde dehydrogenase to form 3,4-dihydroxyphenylacetic acid (DOPAC). 
DOPAC can be further metabolized by catechol-O-methyltransferase (COMT) to form 
homovanillic acid (HVA). Both DOPAC and HVA, as well as DA, are excreted in the urine. 
Levels of DOPAC and HVA are reliable indicators of DA turnover; ratios of these metabolites to 
DA in cerebral spinal fluid serve as accurate representations of brain dopaminergic activity. In 
addition to metabolizing DOPAC, COMT also utilizes DA as a substrate to generate 3-
methoxytyramine, which is subsequently converted to HVA by MAO (Fig 1.12) (Goodman & 
Gilman’s Ed. 12).  
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Figure 1.12. Schematic of Dopamine Synthesis and Metabolism (Source Goodman &Gilmans). 
 
1.4.2Dopamine neurotransmission 
 
The neurochemical events that underlie DA neurotransmission are summarized in Figure 1.13. In 
dopaminergic neurons, synthesized DA is packaged into secretory vesicles (or into granules 
within adrenal chromaffin cells) by the vesicular monoamine transporter, VMAT2. This 
packaging allows DA to be stored in readily releasable aliquots and protects the transmitter from 
further anabolism or catabolism. Synaptically released DA is subject to both transporter 
clearance and metabolism. The DA transporter (DAT) is not selective for DA; moreover, DA can 
also be cleared from the synapse by the norepinephrine (NE) transporter, NET. Reuptake of DA 
by DAT is the primary mechanism for termination of DA action, and allows for either vesicular 
repackaging of transmitter or metabolism. DAT activity is regulated by phosphorylation, offering 
the potential for DA to regulate its own uptake. 
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Figure 1.13. Dopaminergic nerve terminal. Dopamine (DA) is synthesized from tyrosine in the nerve terminal by the sequential 
actions of tyrosine hydrolase (TH) and aromatic amino acid decarboxylase (AADC). DA is sequestered by VMAT2 in storage 
granules and released by exocytosis. Synaptic DA activates presynaptic autoreceptors and postsynaptic D1 and D2 receptors. 
Synaptic DA may be taken up into the neuron via the DA and NE transporters (DAT, NET), or removed by postsynaptic uptake 
via OCT3 transporters. Cytosolic DA is subject to degradation by monoamine oxidase (MAO) and aldehyde dehydrogenase 
(ALDH) in the neuron, and by catechol-O-methyl tranferase (COMT) and MAO/ALDH in non-neuronal cells; the final metabolic 
product is homovanillic acid (HVA). 
 
1.4.3 Animal models of Parkinson’s disease: classical toxin-induced rodent models 
 
Over the last two decades, significant strides has been made toward acquiring a better knowledge 
of both the etiology and pathogenesis of PD. Experimental models are of paramount importance 
to obtain greater insights into the pathogenesis of the disease.  
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Table 1.3. Characteristics of Animal Models for Parkinson’s disease 
 
Thus far, neurotoxin-based animal models have been the most popular tool employed to produce 
selective neuronal death in both in vitro and in vivo systems. These models have been commonly 
referred to as the pathogenic models. 
The two most widely used rodent models of PD are the classical 6-OHDA-treated rat and the 
MPTP-treated mouse.  
 
 
Figure 1.14. Chemical structure of 6-OHDA and MPTP 
 
 
 
1.4.3.1 6-Hydroxydopamine (6-OHDA) 
The 6-OHDA model has been extensively used as a test bed for novel symptomatic agents as 
well as providing a means for assessing neuroprotective and neurorepair strategies. Although  
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unlikely to be the first model of choice for testing symptomatic agents, since its behavioural 
phenotype is less robust than the 6-OHDA rat, the MPTP-treated mouse provides a useful 
secondary screening model and has the added advantage of being relatively easy to construct 
compared with the 6-OHDA rat. The characterization of the hydroxylated analogue of dopamine, 
6-OHDA, as a toxin-inducing degeneration of dopaminergic neurons in the nigro-striatal tract 
(Ungerstedt, 1968) has led to it being a widely used tool to induce Parkinsonism in rodents. 
Unlike MPTP, 6-OHDA does not efficiently cross the blood–brain barrier and so requires direct 
injection into the brain. 6-OHDA is injected into the nigro-striatal tract at one of three locations: 
into the substantia nigra pars compacta (SNpc) where the A9 dopaminergic cell bodies are 
located; into the median forebrain bundle (mfb), through which the dopaminergic nigro-striatal 
tract ascends; or into the terminal region, the striatum. Following its injection, 6-OHDA is taken 
up into the dopaminergic neurons via the dopamine transporter, DAT. Given that 6-OHDA also 
shows high affinity for the noradrenaline transporter, NET (Luthman, 1989). Although the exact 
mechanism underlying 6-OHDA toxicity is still under investigation, current understanding is 
that, once inside dopaminergic neurons, 6-OHDA initiates degeneration through a combination 
of oxidative stress and mitochondrial respiratory dysfunction. Certainly, 6-OHDA readily 
oxidizes to form reactive oxygen species (ROS) such as H2O2 (Mazzio, 2004), to reduce striatal 
levels of antioxidant enzymes [total glutathione (GSH) or superoxide dismutase] (Perumal, 1992; 
Kunikowska and Jenner, 2001), to elevate levels of iron in the SN (Oestreicher, 1994) and to 
interact directly with complexes I and IV of the mitochondrial respiratory chain, leading to 
subsequent respiratory inhibition and further oxidative stress (Glinka, 1997). Many of these 
effects are thought to mirror events occurring in PD brain (Jenner, 1989), thereby supporting a 
high degree of construct validity for the 6-OHDA model. The 6-OHDA model also mimics many 
of the biochemical features of PD, including reduced levels of striatal dopamine and tyrosine 
hydroxylase (TH; rate-limiting step of DA biosynthesis). The 6-OHDA model shares a common 
failing with many other animal models of PD as it does not lead to the formation of the 
pathological hallmark of PD, the Lewy body. Lewy bodies are eosinophilic inclusions that 
contain ubiquitinated proteins such as α-synuclein (Spillantini, 1997 and 1998) and are 
associated with lipofuscin-containing lysosomes that have also been shown to accumulate α-
synuclein in PD brain stem (Braak, 2001). The exact role of Lewy bodies remains to be 
established, but drugs to reduce aggregate formation are considered a potential future strategy for 
treating PD. A recent report of parkin-containing aggregate formation in 6-OHDA-lesioned rat 
(Um, 2010) is therefore an exciting advance but requires confirmation. The one pathological 
feature of PD robustly displayed by the 6-OHDA model is degeneration of the nigro-striatal 
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tract. The extent of degeneration can be established post-mortem by assessing the reduction in 
various parameters in the lesion (ipsilateral) hemisphere, compared with the intact (contralateral) 
hemisphere including number of nissl-stained cells or TH-positive neurons in the SNpc; levels of 
TH or DAT immunoreactivity in the striatum and levels of [3H] mazindol binding to DAT in the 
striatum. Behavioural indices can also be taken as a potential pre-screen for predicted lesion size.  
 
1.4.3.2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
 
MPTP is a commonly used toxin for inducing both rodent and primate models of PD based on its 
ability to induce persistent parkinsonism in man (Davis, 1979; Langston, 1983). Subsequent 
investigations in non-human primates identified that selective destruction of dopaminergic 
neurons of the nigro-striatal tract was the pathological basis behind the motor deficits observed 
(Burns, 1983; Jenner, 1984; Langston, 1983), and out of this came the most relevant animal 
model of PD that persists today. The impact of the MPTP-treated primate model in the PD field 
is second to none, but first we will focus attention on the use of MPTP in non-primate species. 
Many species, including rats, are insensitive to the toxic effects of MPTP, possibly due to the 
relatively rapid clearance of 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of 
MPTP (Johannessen, 1985). However, specific strains of mice, notably black C57, and Swiss 
Webster are sensitive to MPTP (Sonsalla and Heikkila, 1988) and have enabled development of 
the MPTP mouse model of PD. The mechanism underlying the neurotoxic action of MPTP has 
been the subject of intense investigation and is relatively well understood. MPTP is a lipophilic 
pro-toxin that, following systemic injection (usually i.p. or s.c.), rapidly crosses the blood–brain 
barrier (Riachi, 1989). Once inside the brain, MPTP is converted by MAO-B (principally in glia 
and serotonergic neurons) into the intermediary, 1-methyl-4-phenyl-2,3,dihydropyridinium 
(MPDP+) before its rapid and spontaneous oxidation to the toxic moiety MPP+ (Chiba, 1984). 
Following its release into the extracellular space, MPP+ is taken up via DAT into dopaminergic 
neurons where cytoplasmic MPP+ can trigger the production of ROS, which may contribute to 
its overall neurotoxicity (Javitch et al., 1985). However, the majority of MPP+ is eventually 
accumulated within mitochondria where the key toxic mechanism occurs. Once inside 
mitochondria, MPP+ impairs mitochondrial respiration via inhibition of complex I of the 
electron transport chain. This action impairs the flow of electrons along the respiratory chain, 
leading to reduced ATP production and the generation of ROS, such as superoxide radicals. The  
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combined effects of lowered cellular ATP and elevated ROS production are most likely 
responsible for initiation of cell death-related signalling pathways such as p38 mitogen-activated 
kinase (Karunakaran, 2008), c-jun N-terminal kinase (JNK) (Saporito, 2000) and bax (Hassouna, 
1996; Vila, 2001), all of which have been demonstrated in vivo following MPTP treatment and 
may contribute to apoptotic cell death (Jackson-Lewis and Przedborski, 2007) (Figure 1.14). The 
MPTP-treated mouse has some clear advantages over the 6-OHDA lesion model, not least of all 
economic benefits in terms of the cheaper costs associated with purchasing and housing mice. 
Being systemically active, MPTP administration does not require the type of skilled stereotaxic 
surgery that production of a 6-OHDA lesion requires. The systemic injection also produces a 
bilateral degeneration of the nigrostriatal tract, more reflective of that seen in PD. The MPTP 
model also mimics many of the known biochemical features of PD. For example, in addition to 
the well-known reductions in striatal DA and tyrosine hydroxylase (TH), there are also elevated 
levels of both striatal preproenkephalin-A (PPE-A) (Gudehithlu, 1991) and ACh 
(Hadjiconstantinou, 1985). Further downstream in the basal ganglia, extracellular glutamate 
levels have been shown to be elevated in the SN of MPTP-treated mice, a rise associated with 
the induction of programmed cell death (Meredith, 2009), also glutathione (GSH) levels are 
significantly reduced  as in PD itself. Finally, in further support of the face validity of this model, 
inflammatory markers are elevated in the striatum and SN of MPTP-treated mice (Kurkowska-
Jastrzebska, 1999; Hebert, 2003), which occurs as a result of reactive microgliosis in PD. The 
MPTP model does, however, have some clear disadvantages over the 6-OHDA model, 
particularly in terms of reproducibility and the range of behavioural readouts that can be 
obtained. Mice are far less sensitive to MPTP than primates, and the higher doses required can 
be acutely lethal as a result of the peripheral neuro- or cardiotoxicity induced (Jackson-Lewis 
and Przedborski, 2007). Given that the risk of mortality usually occurs within 24 h of the first 
dose of MPTP and is dose-dependent, the high rates (up to 50%) seen following acute bolus 
dosing in the earlier studies can be reduced to acceptable levels (<20%) with reductions in the 
dose administered and can be almost completely avoided using alternative protocols in which the 
same or even higher total dose is given in multiple doses (Gibrat, 2009). The various dosing 
regimens used to generate the MPTP mouse model have been extensively reviewed in Jackson-
Lewis and Przedborski, 2007. In many cases, MPTP is given with probenecid (250 mg·kg-1), a 
uricosuric agent that reduces the renal clearance of MPTP, thereby prolonging its action. The 
most common protocols and the degree of nigrostriatal tract denervation produced by these can 
be summarized as follows: acute bolus, 1x30–40 mg·kg-1 giving 80–90% striatal DA depletion; 
acute multiple, 2x40 mg·kg-1 or 4x12.5–25 mg·kg-1 given at 2 h intervals producing variable 
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60–90% striatal DA loss; sub-acute, 25-40 mg·kg-1/day for 5 days + probenecid giving 76% loss 
striatal DA and 60% SNpc cell loss; chronic intermittent, 25 mg·kg-1 twice weekly for 5 weeks 
+ probenecid, giving 95% loss around 1 week, but reducing to a stable 70–80% loss by 12 weeks 
post treatment (Pothakos, 2009). Chronic infusion can be performed by administration of 20–40 
mg·kg-1/day for up to 28 days given via osmotic minipumps, giving most variable degree of cell 
loss so far ranging from 25% to 80% loss of cells in the SNpc and 28–90% loss of striatal 
dopamine (Fornai, 2005; Alvarez-Fischer, 2008). The pattern of cell death produced is similar to 
that seen in humans, with the SNpc affected more than the VTA and chronic infusion may also 
induce loss of noradrenergic cells in the locus coeruleus, further resembling the clinical picture 
(Fornai, 2005). However, in all cases, the cell death is rapid in onset, with first signs appearing 
within 12–72 h, and is maintained for up to 28 days (Novikova, 2006), although striatal 
dopamine depletion may show signs of recovery when using acute or sub-acute MPTP dosing 
paradigms (Lau and Meredith, 2003). As noted for the 6-OHDA model, this rapidity of cell death 
is not reflective of the disease itself and is an obvious weakness of this model. 
 
 
Figure 1.14. The mechanisms by which neurotoxins kill dopamine neurons involve mitochondrial dysfunction and oxidative 
damage. 6-hydroxydopamine (6-OHDA) is taken up by the dopamine transporter and it then generates free radicals. 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) is converted by monoamine oxidase B (MAOB) to 1-methyl-4-phenylpyridinium 
(MPP+). MPP+ is taken up by the dopamine transporter and can then be accumulated by mitochondria, leading to complex I 
inhibition and the generation of free radicals, or by the vesicular monoamine transporter, thus reducing toxicity. Rotenone is a 
direct inhibitor of complex I, which also leads to free-radical generation. MPTP and rotenone treatment increase the expression 
of alpha-synuclein and, in the latter case, this leads to the formation of Lewy bodies. 
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2. Aim of the study 
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In attempt to cure the serious consequences of spinal cord traumatic injury and Parkinson’s disease 
were developed pharmacological treatments that have disregarded the hopes. These procedures are 
not decisive for the spinal cord injury cure. 
Equally most of the experimental therapies of new generation, pharmacological and not, have the 
purpose of decrease the damage but little benefit accruing to the motor recovery and the neural 
regeneration. 
The stem cell therapy approach is considered a promising tool for CNS regeneration,it seems to be 
just one of many clinical applications of stem cells. In recent years, the transplantation of 
embryonic cells represented a major therapeutic hope, however, the difficulty of finding the 
biological materialand the ethical issues, have slowed their use. For this reasonsthe research is 
concentrate in the direction of stem cells obtained from other source, such as bone marrow, dermis 
andadult nervous tissue. 
The principal aims of this thesis work was to test the potential role of post mortem neural 
precursors cells (PM-NPCs) in terms to replacement therapy in a mouse model of contusive 
spinal cord injury and Parkinson’s disease. PM-NPCs are a subclass of Sub Ventricular Zone 
(SVZ)-derived neural progenitors, capable of surviving many hours after donor death (Marfia, 
2011). The in vitrodifferentiation of these cells yields more neurons (about 30-40%) compared to 
neural precursors cells isolated immediately after the animal sacrifice (Gritti, . With the aim to 
improve the monitoring of cells after transplantation, PM-NPCs will be isolated from the SVZ of 
mice constitutively expressing the green fluorescent protein GFP. 
Detailed aims of the study: 
 Isolation and characterization of GFP PM-NPSCs 
Post-Mortem Neural Precursor Cells will be isolated from a transgenic mouse strain 
expressing green fluorescent protein (GFP) under the promoter C of the ubiquitin gene 
[C57BL/6-Tg(UBC-GFP)30Scha/J]. In particular, cells will be obtained from the SVZ at 6 
hours after the mouse death. These cells will be characterized for their growth features, 
expression of stem markers, spheroids formation capability and in vitro neural 
differentiation potential. 
 Stem cells transplantation  
As experimental animal models will be used: 1) CD1 mice in which we induced contusive 
Spinal Cord injury at the T9 level of intensity equal to 70 kDyne, by means of Infinity 
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Horizon Impactor device;2) C57BL/J mice in which the Parkinsonism will be induced by the 
administration of MPTP following a specific paradigm (see Materials and Methods).  
 In vivo evaluation of stem cells effects  
The effect of PM-NPCs transplantation, on motor behaviour will be evaluated by specific 
animal tests, such asBMS for contusive trauma, horizontal grid, vertical grid and olfactory 
tests for PD.  
 Ex vivo evaluation of survival, homing and fate of transplanted stem cells 
At the end of the observational period (30 days for SCI and two weeks for PD) the animals 
will be sacrificed and perfused, spinal cord and brains will be removed from the different 
animals, fixed and processed for the immunohistochemical analysis.  
By immunofluorescence will be studied the survival, migration and differentiation 
capabilities of the grafted cells 
 Neurochemical changes in Parkinson disease  
 
Animals’ brain will be removed and dissected in specific areas (striatum, midbrain and 
cortex) for evaluate the levels of catecholamines and their metabolites by HPLC analysis. 
 
 Investigate a possible protective mechanism of grafted cells 
 
We will determine the mRNA levels of inflammatory and anti-inflammatory cytokines and 
neurotrophic factors. 
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3. Materials and Methods 
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3.1 Animals 
 
Post-mortem neural precursors were obtained from 2-months old CD1 mice (Charles River, 
Calco, Italy). The animals were kept in standard conditions for at least 3 days before the 
experiments (22 ± 2° C, 65% humidity, and artificial light between 8:00 a.m. to 8:00 p.m.). 
Post-mortem neural precursors constitutively expressing green fluorescent protein (GFP) were 
obtained from 2-months old C57 black mice carrying the transgene for GFP under the control of 
ubiquitin promoter C (C57BL/6-Tg (UBC-GFP) 30Scha/J; The Jackson Laboratories, Bar 
Harbor, Maine, USA). 
 
3.2 Post Mortem Neural Precursor cells isolation 
 
Adult CD-1 albino mice and (C57BL/6-Tg (UBC-GFP) 30Scha/J, weighing 25-30 g (Charles 
River), were anesthetized by intraperitoneal (i.p.) injection of 4% chloral hydrate (0.1 mL/10 g 
body weight) and  sacrificed by cervical dislocation. The cadavers were maintained at room 
temperature (25°C) for 6 hours. Their brains were removed after the indicated periods and the 
area encompassing the SVZ and surrounding the lateral wall of the forebrain ventricle was 
dissected using fine scissors. Primary cultures of NPCs, their maintenance and immunostaining 
were performed as previously described (Bottai et al 2008; Gritti et al 1999). 
Tissues derived from a single mouse were used to generate each culture using the following 
protocol: 
1. Transfer the dissected tissue to a phosphate buffer solution containing penicillin and 
streptomycin 100 U/mL each (Invitrogen, San Diego, CA, USA) and glucose (0.6%) at 4°C 
until the end of the dissection. 
2. To perform the enzymatic dissociation, transfer the tissue to an Earl’s balanced salt solution 
(EBSS) (Sigma-Aldrich, St. Louis, MO, USA) containing 1 mg/mL papain (27 U/mg; 
Worthington DBA, Lakewood, NJ, USA), 0.2 mg/mL cysteine (Sigma-Aldrich), and 0.2 
mg/mL EDTA (Sigma-Aldrich). 
3. Incubate for 45 min at 37°C on a rocking platform. 
4. Centrifuge tissues at 123g and discard the supernatant.  
5. Re-suspend the pellet in 1 mL of EBSS and mechanically dissociate it using an aerosol 
resistant tip (1000 μL Gilson Pipette). Cells were re-suspended in 10 mL EBSS. 
6. Centrifuge at 123g for 10 min, discard the supernatant and re-suspend the pellet in 200 μL of 
EBSS.  
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7. Re-suspend the pellet in 1 mL of EBSS and mechanically dissociate it using an aerosol 
resistant tip (200 μL Gilson Pipette). Cells were re-suspended in 10 mL EBSS. 
8. Centrifuge at 123g for 10 min, discard the supernatant and re-suspend the pellet in 
Neurobasal® Medium (GIBCO®, Life Technologies Italia, Monza, Italy) containing B-27® 
supplement, 2% L-Glutamine (Euroclone, Pero, MI, Italy), bFGF (human recombinant, 20 
ng/mL; Peprotech, Rocky Hill, NJ, USA, or Upstate Biotechnology, Lake Placid, NY, USA) 
and EGF (human recombinant, 20 ng/mL; Peprotech). 
9. Plate the cells at 3500 cells/cm2 in the appropriate volume of medium in a 25cm2 flask, at 
37°C in a humidified 5% CO2 atmosphere. 
 
3.2.1 Neural precursors in culture 
 
 
PM-NPCs were plated in growth medium containing bFGF and EGF, after at least 2 weeks in 
culturegave rise to neurospheres, in absence of serum (Gritti et al 1996; 1999). The total number 
of viable cells was assessed by trypan blue exclusion. The spheres formed were harvested, 
collected by centrifugation (10 min at 123g), mechanically dissociated by pipetting to a single-
cell suspension and re-plated in medium at the density of 10.000 cells/cm2. This procedure was 
repeated every 4-5 days for up to 6 months. 
 
3.2.2 Spheroids immunofluorescence 
 
 
1. Transfer 1 mL of culture medium containing the spheroids in an eppendorf. 
2. Add 100 µL of 37% PFA for 15’ at RT. 
3. Centrifuge for 5’ at 920 g. 
4. Discard the supernatant and add 1mL of Permebilization solution (300 mM sucrose; 0,2% 
Triton X-100; PBS) for 15’ at RT. 
5. Centrifuge for 5’ at 920 g. 
6. Discard the supernatant and add 1mL of Block Solution (2% BSA; PBS) for 15’ RT on a 
rocking platform. 
7. Centrifuge for 5’ at 920 g. 
8. Discard the supernatant. 
9. Add 100 µL of Binding Buffer (0,2% BSA; PBS) containing the Primary Antibody for 1h on 
a rocking platform. 
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10. Centrifuge for 5’ at 920 g. 
11. Discard the supernatant.  
12. Add 100 µL of Binding Buffer containing the Secondary Antibody for 45’ on a rocking 
platform. 
13. Centrifuge for 5’ at 920 g. 
14. Discard the supernatant and wash 2 times with Binding Buffer. 
15. Centrifuge for 5’ at 920 g. 
16. Discard the supernatant and re-suspend the pellet in a solution containing 90% glycerol, 5% 
PBS 1X, 5% DAPI. 
17. Mount: 
a. Place a drop of the solution with the spheroids on the microscope slide 
b. Let fall gently the coverslip on the slide 
18. Dry overnight at 4°C. 
19. Seal the coverslip edges with varnish.  
Images were taken using Leica SP2 confocal microscope with He/Kr and Ar lasers (Heidelberg, 
Germany). In negative control experiments, primary antibodies were replaced with equivalent 
concentrations of unrelated IgG of the same subclass. 
The following primary antibodies were used: 
 Anti-Nestin (monocl.1:100; Millipore).  
 Anti-microtubuleassociationprotein 2  (MAP2; 1:200; Chemicon). 
The following secondary antibodies were used: 
 Alexa fluor 543 goat-anti-rabbit IgG (1:1000; Invitrogen, Life Technologies Italia, Monza, 
Italy). 
 Alexa fluor 543 goat-anti-mouse IgG (1:1000; Invitrogen, Life Technologies Italia, Monza, 
Italy). 
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3.2.3 Neuronal differentiation of PM-NPCs 
 
In order to verify the multipotency of neural stem cells, the PM-NPCs were subjected to tests in 
vitro differentiation. Neurosphereswere mechanically dissociated and cells (1,5x104 cells/cm2) 
were seeded into Matrigel®-coated glass coverslips (12 mm diameter) in the presence of bFGF 
(10ng/ml). After 48 hours, cells were shifted into the differentiation medium in which bFGF 
were substituted with FBS (1% vol/vol) for 5 days. PM-NPCs attached to the dish and 
differentiated into the three cell types present in the adult CNS: neurons, astrocytes, and 
oligodendrocytes in a typical cell lineage ratio (Marfia et al 2011). 
 
3.2.4 Fixing of differentiated cells 
After seven days of differentiation,the cells  were  fixed and characterized by 
immunocytochemical staining. 
The fixing procedureincludes: 
1. Wash with PBS 0.01 M (a phosphate buffer saline containig: 1.5 MNaCl, 20 
mMKH2PO4andNa2HPO480mM) for 5 min. 
2. Add 4% Paraformaldehyde(Sigma) for 10’ to fix aldehyde groups in the cell proteins 
3. Wash with PBS1X two times for 10 min. 
4. The cells can be stored at 4 °C. 
 
3.2.5 Cells Immunofluorescence 
 
1. Wash with PBS (3 times; 5 min each, room temperature). 
2. Incubate the coverslips for 90 min at 37°C (or overnight at 4 °C) in PBS containing 10% 
normal goat serum (NGS), 0.2% Triton X-100. 
3. Wash with PBS. 
4. Incubate the coverslips overnight at 4 °C in PBS containing 5% normal goat serum (NGS), 
0.1% Triton X-100and the appropriate primary antibodies or antisera. 
5.  Wash with PBS. 
6. Incubate for 45’ (room temperature) with thesecondary antibody. 
7. Incubate cells with the DNA-binding dye 4'-6'-diamidino-2-phenylindole (DAPI) (2μg/ml in 
PBS) for 10’ at room temperature. 
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8. Wash 2 times in PBS. 
9. Mount using Fluorsave Reagent (Calbiochem, Merck Chemical, Darmstadt, Germany): 
a. Place a drop of Fluorsave on the microscope slide. 
b. Let gently fall the glass coverslip with the cells on the slide. 
c. Keep attention to not make bubbles. 
10. Dry overnight at room temperature. 
 
Cells were analyzed by a fluorescence microscope (Leica, Wetzlar, Germany). Acquisition of the 
stained cells was performed using the image-analysis software (Leica, Wetzlar, Germany) or by 
confocal microscope Leica SP2 microscope with He/Kr and Ar lasers (Leica, Wetzlar, 
Germany). Images were taken with a 40X objective lens and 1X zoom (Leica). In control 
experiments, primary antibodies were either omitted or replaced with equivalent concentrations 
of unrelated Ig of the same subclass. Moreover, in double labelling experiments, sections 
incubated with one primary antibody and two secondary anti-sera revealed no appreciable cross-
reaction.  
Neural differentiation was assessed by immunocytochemistry with antibodies against:  
 Anti-NG2 (1:200; Millipore) 
 microtubule-associated protein 2 (MAP2; monocl. 1:200; Sigma) 
 Glial fibrillary acidic protein (GFAP; monocl. 1:400; Roche, Basel, CH) 
The following secondary antibodies were used: 
 Alexa fluor 543 goat-anti-rabbit IgG (1:1000; Invitrogen, Life Technologies Italia, Monza, 
Italy). 
 
3.2.6 Cell count 
 
The quantification of positive cells to neural markers was performed, by confocal microscopy, 
after specific immunocytochemical staining following 7 days differentiation in culture. Cell 
counts were performed on a minimum of 9 independent fields (3 fields/3 coverslips/treatment) of 
photomicrographs captured with 40X objective. Total counts of each neural markers 
immunoreactive cells were performed and the number of positive cells per culture was expressed 
as the percentage to the total cells. DAPI supplied the total number of cells being a nuclear 
staining. 
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3.2.7 Cell freezing 
 
When the neurospheres amount to the size of approximately 200 µm they are harvested and 
centrifuged at 700 rpm for 10 min, at this point is drew all the supernatant and the pellet is 
resuspended in 1.5 ml of colture medium containing dimethyl sulfoxide (DMSO) (Sigma) to a 
final concentration of 10%. The neurospheresare suspended with a pipette P1000 without being 
dissociated and transferred criovials (Nalgene). The step of freezing takes place in two stages; 
initially criovials containing cells are placed in a plastic container that allow a gradual lowering 
of the temperature of 1 ° C per minute and storedin-80° C freezer. 
 
3.2.8 Cell defrosting 
 
The neurospherespreserved,can be put back into culture after defrosting. The criovial containing 
the cells of interest is placed in a thermostated bath at the temperature of 37 °C until defrosting 
occurred that must be as rapid as possible because the DMSO although acting as protection for 
cells at a low temperature is found to have toxic effects at room temperature. After defrosting the 
cell suspension is moved in 15 ml tube. Add culture medium previously heated at the 
temperature of 37 °C until volume of 10 ml and centrifuge at 700 rpm for 10 min. In this passage 
are washed DMSO residues toxic for the cells. Pellet is resuspended in 1 ml of culture medium 
by P1000 and placed with adequate medium volume in a T25 flask. After 24 hours the defrosted 
neurospheres can be dissociated, counted and replated as described before. 
 
3.2.9 PKH26 cells labelling 
 
PKH26 cell linker Kits provide fluorescent labelling of live cells over an extended period, with 
no apparent toxic effects. Fluorescent linker kits are effective for a variety of cell types and 
exhibit no significant leaking, or transfer from cell to cell. They provide stable, clear, intense, 
accurate and reproducible fluorescent labeling of cells (Fig. 3.1).  
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Figure 3.1 Typical wavelength emission of PKH26 
 
 
For these transplantation experiments, 1 x 106cells in 150 μLwere injected in each animal. 
Before transplantation, PM-NPCs were labelled with PKH26 and the staining was performed 
according to the protocol of the manufacturer (Sigma–Aldrich). 
The following procedure uses a 2 mL final staining volume containing final concentrations of 
2x10-6 M of PKH26 and 1x107 cells/mL: 
1. Resuspend cells to a concentration of 1x106cells/150 μl (transplant 1x106cellsper 
mouse).Prepare at least 1.2 x 106 cells per mouse because an excess of cells is required for 
syringe loading purposes. 
2. Wash cells 3 times using neural stem cell medium 13in a 10ml conical vial. In each washing 
step, precipitate cells by centrifugation (500 x g for 5 min, room temperature). 
3. Count the cells before the final spin. 
4. Centrifuge the cells (500 x g for 5 min), and then aspirate the supernatant, being careful not to 
remove any cells butleaving no more than 25μlof supernatant. 
5. Prepare a 2X cell suspension by adding 1mlof Diluent C to the cell pellet and resuspend with 
gentle pipetting. 
6. Immediately before staining, prepare a 2X Dye Solution (4x10–6 M) in Diluent C by adding 
4mlof the PKH26 ethanol dye solution to 1mlof Diluent C in a tube and mix well to disperse. 
7. Rapidly add the 1ml of 2X cell suspension to 1 mlof 2X Dye Solution and immediatelymix 
the sample by pipetting (final cell density will be 1.2x107cells/ml and 2x10–6M PKH26).  
8. Incubate the cell/dye suspension for 1- 5 min. 
9. Stop the staining by adding an equal volume (2ml) of serum and incubate for 1 min. 
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10. Centrifuge cells (500 x g for 10 min) and carefully remove the supernatant.  
11. Resuspend cell pellet in 10ml of complete medium and centrifuge (500 x g for 5 min). 
12. Wash the cell pellet 2 more times with 10ml of complete medium to ensure removal 
ofunbound dye. 
13. Resuspend the cell pellet in 10ml of complete medium for assessment of cell recovery, cell 
viability and fluorescence intensity. If cells areneeded for transplantation, wash and resuspend 
them in a sterile physiological solution at a concentration of 3.3x105 cells/50μl. 
 
3.2.10 Hoechst cells labelling 
 
Hoeschstis a fluorescence DNA binding molecule suitable for the fluorescent microscopy and 
FACS. This molecule is used for bothdisplay themitochondria, and identifyingthe nuclei, 
similarly tothe DAPI staining. 
For these transplantation experiments, 1 x 106cells in 150 μLwere injected to each animal. 
Before transplantation, PM-NPCs were labelled with Hoechst33342 (Sigma) and the staining 
was performed according to the following protocol: 
1. Resuspend cells to a concentration of 1x106cells/150 μl (transplant 1x106 cells per 
mouse).Prepare at least 1.2 x 106 cells per mouse because an excess of cells is required for 
syringe loading purposes. 
2. Adda concentration of 1μl/ml of Hoechst to the cell solution used for injected animals. 
3. Incubate the cell/dye suspension for 1 hour at 37 °C. 
4. Wash and resuspend them in a sterile physiological solution at a concentration of 3.3x105 
cells/50μl. 
 
3.3 Animal treatment for Spinal Cord Injury 
 
The CD1 mice were surged for creating the contusion model of injury, which is analogous to the 
one of clinical patients and we use Infinity Horizon Impactor device 
The procedure consist in following steps. 
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3.3.1 Preparation of mice for surgery and transplantation 
 
1. Keep the male adult CD1 mice (25–30 g) for at least 3 days before the experiments in 
standard conditions (22 ± 2 °C, 65% humidity, and artificial light between 08:00 a.m. to 08:00 
p.m.). 
2. To identify the animal, mark the tail by means of water resistant colored ink. 
3. Use an electric clipper to cut the dorsal hair of the mouse from the neck, about at T2 level, to 
the lumbar area.  
4. Sterilize the prepared area with an iodide solution and ethanol (70% in sterile water). 
5. Treat the animal with a sub cutaneous (s.c.) injection of 200 μl gentamycin (1 mg/ml in sterile 
saline solution). 
6. Apply ophthalmic lubricant to both animal eyes to prevent desiccation and inject 
buprenorphine (subcutaneously, 0.03 mg/kg) to alleviate pain. 
 
3.3.2 Preparation for surgery 
 
1. Clean and sterilize surgery equipment. 
2. Prepare the surgery area by wiping with an aseptic agent. Set up the IH Impactor device.  
3. Prepare the anesthesia equipment: the Active Gas Scavenger with VetScav Filter Weighing 
Device, continuous flow Induction Chamber, Oxygen Generator, Low Flow O2 Meter for 
Mice. Clean the induction chamber and the mask used during surgery.  
4. Anesthetize animals with 2.5% (v/v) isoflurane in oxygen (1 L/min), and wait 5 min after the 
flow induction for the drug to take effect. Check if the whiskers are twitching or if there is 
slow hind limb withdrawal in response to pinching the footpad. During the surgery, reduce the 
isoflurane concentration to 2.0% (v/v) isoflurane in oxygen (1 L/min).  
 
3.3.3 Laminectomy 
 
1. Place the mouse on a slide warmer to avoid the problem of hypothermia during the surgery. 
Position the animal with the dorsal side up. 
2. Make a vertical incision with a scalpel over the region of interest from T7 to T12. 
3. Hold the skin and superficial fat pad by using standard forceps (usually found in the space 
between the 5th and 6th thoracic dorsal processes).  
4. Count the process under the vessel as T6 then move to T7. 
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5. Place a little bearing under the ventral side of the mouse to increase the curvature of the 
spine. Immobilize the spinal cord by blocking it with the Graefe forceps. 
6. Cut the paravertebral muscles bilaterally from T7 and T10 vertebral level by using the 
scalpel until the dorsal surface of the lamina contacts the scalpel tip. 
7. Use the scalpel to tick off the junction from T7 until T10. Stop in the space between T8 and 
T9 spiny protrusions. Cut the tissues between T8-T9 and T9-T10 with the micro scissors.  
8. Use the Rongeur to remove the T9 process. Expose the junction by carefully scraping away 
the muscle layer with the micro scissors. Continue until bone is exposed. 
9. Use the forceps to remove muscles from the lamina and open a small space between the 
vertebrae. Gently insert the micro scissors under the bone, cut the lamina on both sides and 
remove this part with forceps. 
10. Remove the lamina with the forceps to expose the cord. Be sure not to leave any free or 
jagged bone fragments behind; remove them with the Rongeur. 
11. Use the small tip forceps to remove the periosteum as well as any bone fragments or 
muscles that may be near the incision. 
12. Remove the top half of the T9 dorsal process and proceed to the IH Impactor device 
protocol. 
 
3.3.4 IH Impactordeviceprotocol (Contusion) 
 
1. Place the mouse in the middle of the stabilization platform of the IH Impactor device (Fig. 
3.2). 
2. Block the animal with the two teeth forceps connected with the stabilization platform by two 
joint positioning arms (left arm for the thoracic vertebra, right arm for cervical vertebra). 
3. Use the rostral arm to grasp the lateral edge of the rostral vertebral body (T8).  
4. Manipulate the caudal arm in the same manner to grasp the T10 vertebral body. 
5. Place the stabilization platform in the device and lower the tip (diameter 0.75 mm) as close 
to the cord as possible without touching it. 
6. Lift the tip three complete turns before initiating the impact.  
7. Perform the contusion with the impactor set to deliver a force of 70 kdyn at 100 mm/s. 
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Figure 3.2 Infinite Horizon Impactor Device 
 
 
3.3.5 Sutures and post-care 
 
1. Suture the incision with a 4/0 absorbable suture thread. Cover the exposed spinal cord at the 
site of removed lamina; suture the tissue at the extremities of the cut by means of a small 
needle. Put the two stitches immediately above and under the site of spinal cord exposure. 
2. Close the skin using two or three Reflex clips without pinching off the underlying muscles. 
3. Hydrate the mouse post-surgery with 2 ml of saline solution subcutaneously injected in the 
lower back.  
4. Place the mouse back in a pre-warmed cage to avoid hypothermia during surgical recovery. 
Place cages on heating pads. 
5. Monitor the mice during the acute phase post-injury by checking the size bladder, the suture 
and the animal weight twice a day. Gently squeeze bladder (twice a day for 7 days) to avoid 
urinary tract’s infections (urine could be cloudy, bloody or containing any precipitates). 
6. Treat mice once a day with a saline solution injection (2 ml for two days post-surgery s.c. 
injection) and antibiotic (gentamycin 0.2 ml; s.c. injection) for five days post injury. 
7. Treat mice for post-operative analgesia with buprenorphine (0.1 mg/kg; twice a day) for 3 
days post injury. 
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3.4 Tail vein Injection of cells 
 
In the following step the procedure for injecting the cells into the tail vein is demonstrated. Cells 
could be also administered with an intraspinal transplant by using a stereotaxic frame (Bottai, 
2010; Basso, 2006)or into the cisterna magna (Janowwski, 2008). It is important to consider that 
other cell types could be transplanted with this method, such as mesenchymal stromal cells (e.g., 
bone marrow mesenchymal stem cells, adipose derived stem cells, amniotic fluid cells). 
Furthermore, other treatment options such as nanoparticles can be injected via the tail vein after 
the spinal cord injury. 
 
1. Use 70% ethanol and PBS to clean the needle before use. Handle the needle and the syringe 
only with sterile gloves. 
2. Resuspend the cells in the test tube and load 75 μl of cells into a 0.3 ml syringe (29 gauge 
needle and 0.33 cc syringe).  
3. Make sure that no bubbles are present within the cell suspension. Keep the syringe in a 
horizontal position to avoid cell sedimentation. 
4. Place the mouse cage underneath the heat lamp to dilate the tail veins. 
5. Grab the mouse and gently pull it into the mouse restrainer to visualize the lateral tail vein as 
a narrow blue line. 
6. Clean the tail with an alcohol swab. Once the vein is visualized, grab the tail vein between 
the middle finger and thumb of the left hand. 
7. Bring the needle to the surface at a 15° angle from the horizon and make sure the bevel is 
up. 
8. Inject 50 μl of cells at a rate of 33  μl/s. After the injection, delay the retraction of the needle 
by 10 s. Retract the needle slowly and pay attention to the possible efflux of cell suspension. 
9. Clean the syringe as in step 7.1 between loads. 
 
3.5 Behavioural Tests and hind limb function 
 
Neurological function must be testedperiodically, from day 3 after injury for 4 weeks. To 
evaluate locomotor function and hind limb recovery after contusion according to the Basso 
mouse scale (BMS) (Basso, 2006). During this test the mouse was placed in the open field and 
two people observe the test. One person records all the data on the score sheet and the other 
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keeps the animal moving in the open field. Both people watch the animal and call out the 
movement each sees. One animal is put in the open field at a time and its tested for 4 minute. 
After each test assigned numerical values from 0 to 9 corresponding to the different behavioral 
recovery, 9 correspond to the healthy animal. 
 
SCORE 
0 No ankle movement 
1 Slight ankle movement 
2 Extensive ankle movement 
3 Plantar placing of the paw with or without weight support or Occasional, frequent or 
consistent dorsal stepping but no plantar stepping 
4 Occasional plantar stepping 
5 Frequent or consistent plantar stepping, no coordination or Frequent or consistent 
plantar stepping, some coordination, paws rotated at initial contact and lift off (R/R) 
6 Frequent or consistent plantar stepping, some coordination, paws parallel at initial 
contact (P/R, P/P) or Frequent or consistent plantar stepping, mostly coordinated, 
paws rotated at initial contact and lift off (R/R) 
7 Frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial 
contact and rotated at lift off (P/R) or Frequent or consistent plantar stepping, mostly 
coordinated, paws parallel at initial contact and lift off (P/P), and severe trunk 
instability 
 
8 Frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial 
contact and lift off (P/P), and mild trunk instability or Frequent or consistent plantar 
stepping, mostly coordinated, paws parallel at initial contact and lift off (P/P), and 
normal trunk stability and tail down or up & down 
9 Frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial 
contact and lift off (P/P), and normal trunk stability and tail always up. 
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3.6 Animal treatments for Parkinson’s Disease 
Parkinsonism was induced by the intraperitoneal (i.p.) administration of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) in C57/bl mice following the acute paradigm with a small 
modification. Figure 11 explain the activity of neurotoxin MPTP.   
 
Figure 3.3. Mechanism of neurotoxin MPTP 
 
Briefly, animals were administered of a double dose of MPTP hydrochloride: a first 
intraperitoneal (i.p.) injection of MPTP (36mg/kg) and a second i.p. injection of MPTP 
(20mg/kg) after seven days. In order to investigate the stability of the lesion a group of animals 
were sacrificed 3 days  after the second toxin administration (CTRL n=8; MPTP n=8). Animals 
were transplanted with 5x104 cells/µl (5 µl) GFP PM-NPCs (n=24) or PBS (n=6), according to 
the following stereotaxic coordinates in relation to bregma: 0.1 mm posterior, 2.4 mm 
mediolateral and 3.6 mm dorsal at the level of left striatum (Cui, 2011). Fourteen days after 
transplant, thirteen animals per group were sacrificed by cervical dislocation, and their brains 
were removed and dissected (Fig 3.4).  
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Figure 3.4. Experimental design 
 
Immediately after dissection, the whole striatum, frontal cortex and midbrain were frozen on dry 
ice until they were assayed. The dissected brain areas of eight mice were used for the 
neurotransmitters determination (see later). Remaining brains areas (n=5 mice) were used for 
cytokines and neurotrophic factors gene expression analysis (see later). Ten animals per group 
were anesthetized by an intraperitoneal injection of sodium pentobarbital (65 mg/kg), perfused 
through the left ventricle with 50 mL of saline solution and fixed with 200 mL of 4% 
paraformaldehyde in 0.1 mol/L phosphate-buffered saline (PBS). Brains were subsequently 
removed from the skulls and then cryoprotected at 4°C in sucrose 300 g/L in 0.1 mol/L PBS 
solution for further sectioning.  
 
3.7 Behavioral tests for Parkinson’s disease 
 
The recovery of motor dysfunction, before and after cell transplantation, was investigated by 
means of Horizontal grid test (Tillerson and Miller, 2003), Vertical grid test (Kim, 2010), and 
olfactory test (Schintu, 2009). 
Horizontal grid test. The grid apparatus was constructed according to Tillerson and co-workers 
2003 (Tillerson and Miller, 2003). The animal was videotaped for 30 s and the videos were 
replayed for percentage forepaw fault analysis using a recorder with slow motion option. The 
number of unsuccessful forepaw steps divided by the total number of attempted forepaw steps 
was evaluated (Tillerson and miller, 2003). Before MPTP administration, the mice were 
acclimated to the grid twice a day for 1 week. 
Vertical grid test. The vertical grid apparatus was constructed according to Kim and co-workers 
(Kim, 2010). For this test, the mouse was placed 3 cm from the top of the apparatus, facing 
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upward, and was videotaped while it turned around and climbed down. The score reported was 
the time required by the mouse to make a turn, climb down and reach the bottom of the grid with 
its forepaw within 180s (Kim, 2010). Before MPTP administration, the mice were acclimated to 
the grid twice a day for 1 week. 
Olfactory test. Mice were deprived of food for 20 hours before test. A corn chip was buried 
under the bedding (1 cm) in a cage corner. Each mouse was positioned in the center of the testing 
cage and the time to retrieve and bite the corn chip was measured (Schintu, 2009). 
 
3.8 MR in vivo 
 
All animals were viewed using a tool 7T MRI System (Pharmascan, Bruker Biospin).The 
animals were anesthetized with isoflurane, positioned supine on the pad and placed in the radio 
frequency coil (38 mm diameter) inside the magnet. Images were acquired transverse control to 
confirm correct positioning the region of interest. 
Different sequences of magnetic resonance have been used: 
 
• Sequence Spin Echo (MSME), (256x128 matrix; TR / TE: 1200/12 ms; 2 medium; acquisition 
time: 5 '7' '; with suppression of lipid) 
• Sequencegradient echo sequence (FLASH), (256x128 matrix; TR / TE: 1200/10 ms; 2 medium; 
acquisition time: 5 '7' ') 
• Sequence Fast Spin Echo (RARE) (256x128 matrix; TR / TE: 2000/56 ms; 2 medium; 
acquisition time: 4'16 '') 
All animals were acquired in order to obtain sagittal, coronal (5 slices with a thickness of 0.7 
mm; field of view (Field of View FOV) 4x4 cm and a spatial resolution of 156 x 312 uM) and 
axial (12 slices with a thickness of 0.7 mm; FOV 3x3 cm and spatial resolution of 117 x 234 m). 
 
3.9 Perfusion 
 
1. At the end of the experimental period, anesthetize animals by an intraperitoneal injection of 
sodium pentobarbital (65 mg/kg). Use toe pinches to evaluate the anaesthesia level and 
proceed only after mouse is unresponsive to the noxious stimuli. 
2. Restrain the animal in a supine position on a surgery plane. 
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3. Cut through the integument and abdominal wall just beneath the rib cage. Separate the 
diaphragm from the liver. 
4. Use the scissors to cut the diaphragm to expose the pleural cavity. 
5. Cut the sides of the rib cage until the collar bones.  
6. Use the hemostats to clamp the xiphoid cartilage and place the hemostat over the head. 
7. Hold the bottom third of the heart on a transversal plane with the forceps. Insert the needle 
into the left ventricle. 
8. Use a hemostat to clamp the heart. This secures the needle and prevents leakage.  
9. Use the scissors to cut the right atrium. 
10. Allow the PBS to pump (18 ml/min) through the animal. Maintain this pressure throughout 
the buffer infusion period (3-4 min; corresponding to about 70 ml PBS). Continue until the 
heart is clean. 
11. Switch the stopcock to allow the fixative (4% Paraformaldehyde in distilled water, 4%PFA) 
through the pump. Allow the 4% PFA to pump through the animal for approximately 8-10 
minutes (300 ml). Gradually increase the pressure to reach a maximum of 30 ml/min. A 
hardened liver is the best indication of a successful perfusion. 
 
3.10 Tissue collection and processing  
 
1. Dissect spinal cords from T5 to L1. Then post-fix the tissue in 6 ml in 4% PFA (overnight at 
4 °C). 
2. Put the same tissue in a solution with 30% sucrose for 72 h at 4 °C in order to cryoprotect it 
and to prevent the formation of crystals during freezing. 
3. Quick freeze the cord using dry ice cryprotect with OCT and store it at -80 °C. 
4. Section by means of a cryostat with 15 micron thickness and collect sections onto glass 
slides and continue for Cresyl violet and immunocytochemistry.  
 
 
3.10.1 Cresyl-violet staining 
 
Cresyl-violet staining is a type of labelling that highlights the cellular architecture of the cut 
sections in order to seethe conformation of white and gray matter after injury. 
The staining was performed following this protocol: 
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1. Wash in PBS 1X pH 7.4 for 5 min. 
2. Incubate with a solution of Cresyl –violet for 10 min at 56°C. 
3. Refrige for 10 min at room temperature. 
4. Wash in EtOH 95%. 
5. Wash in Isopropilicalcool for 4 min. 
6. Clarify in Xilene for a time to wash the excess of staining. 
7. Mounted with Permount and analyze by optical microscope.  
 
3.10.2 Immunoistochemistry 
 
To evaluate the inflammation after the injury in saline and cells injected mice, number of 
macrophages were estimated in the lesion site,as well as at the rostral and caudal level. The 
animals were sacrificed after 7 days post injury, the spinal cord was extracted and placed into 
OCT.  The samples were cut with cryostat for 10 µm transversal sections. The procedure of the 
staining includes following steps: 
 
1. Wash in PBS 1X pH 7.4 three times for 5 min for each 
2. Incubate in a solution of Na4Cl 0.05 M in PBS 1X for 30 min 
3. Wash in PBS 1X pH 7.4 three times for 5 min for each 
4. Wash with 1% H2O2 to block the endogenous peroxidise for 5 min 
5. Wash in PBS 1X pH 7.4 three times for 5 min for each 
6. Permeabilize each slide with 5% NGS and 0.2% Triton X-100 in PBS 90 min at room 
temperature. 
7. Incubate each slide of primary antibodies (Anti-EB-1, 1:200. SIGMA; Anti TH, 1:800. 
Millipore) overnight at 4 °C (dilute antibody in 5% NGS; 0.2% Triton X-100 in PBS) 
8. Wash in PBS 1X pH 7.4 three times for 5 min for each 
9. Incubate with appropriate secondary antibodies (Anti-Rat biotinylated, 1:1000. Sigma;  
Anti-Rabbit biotinylated, 1:1000. Sigma)  for 2 hours at room temperature 
10. Incubate with ABcomplex for 45 min at room temperature (prepare the avidinbiotine 
solution 30 min before use) 
11. Wash in PBS 1X pH 7.4 three times for 5 min for each 
12. Incubate with 3% DAB diluited in Tris 0.1M pH 7.4 until time to stain the sections. 
13. Wash in PBS 1X pH 7.4 
14. Dehydrate the section  in alcohol scale (5’ in ethanol 75%, 5’ in ethanol 
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15. 100%). 
16. Clarify in xylene for 3 min. 
17. Mount with Permount and analyze by optical microscope 
 
3.10.3 Immunofluorescence 
 
The in vivo immunofluorescence staining was carried out on the slides containing cryosectionsof 
the mice tissue perfused in 4% Paraformaldehyde and inserted into OCT. The stainingmethod 
consisted of the following steps: 
 
1. Rinse sections with 200 μl of PBS for each slide  
2. Permeabilize each slide with 200 μl of 10% NGS and 0.2% Triton X-100 in PBS for 1 hour 
at room temperature. 
3. Rinse sections with 200 μl of PBS for each slide (3 times; 5 min each, room temperature). 
4. Block non-specific sites with 200 μl of blocking solution for slide (5% NGS; 0.1% Triton X-
100 in PBS) for 30 min (room temperature). 
5. Incubate each slide with 200 μl of primary antibodies overnight at 4 °C (dilute antibody in 
5% NGS; 0.1% Triton X-100 in PBS). 
6. Wash sections with 200 μl of PBS for each slide (3 times; 5 min. each; room temperature). 
7. Incubate with appropriate secondary antibodies for 2 hours at room temperature.  
8. Wash sections with 200 μl of PBS for each slide (3 times; 5 min. each; room temperature). 
9. Stain nuclei with 200 μl of 4',6-diamidin-2-phenilindole (DAPI) (1 µg/ml final 
concentration, 10 min at room temperature). 
10. Mount by using the FluorSave Reagent and analyse by confocal microscopy.  
 
In control determinations, primary antibodies must be omitted and replaced with equivalent 
concentrations of unrelated IgG of the same subclass.  
Neural differentiation was assessed by immunohistochemistry using theantibodies against:  
 
 Anti-Anti-beta III Tubulin (β Tub; monoclon. 1:500; Sigma)  
 
 Anti-Anti-Choline Acetyltransferase (ChAT; monoclon. 1:100; Sigma) 
 
 Anti-Tyrosine Hydroxylase (TH; monoclon. 1:500; Sigma) 
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 Anti-Serotonin (5-HT; monoclon. 1:200; Sigma) 
 
 Anti- Microtubule-Associated Protein 2 (MAP2; monocl. 1:200; Sigma) 
 
 Anti-Glial Fibrillary Acidic Protein (GFAP; monocl. 1:400; Roche, Basel, CH) 
 
 Anti-Growth Associated Protein-43 (GAP-43; monoclon. 1:200; Sigma) 
 
 Anti Neuronal Nuclei (NeuN: monoclonal. 1:100; Millipore) 
 
 Anti Macrophages/Monocyte (MOMA; monoclonal. 1:100; Chemicon) 
 
 Anti Chondroitin Sulfate Proteoglycan (NG2; monoclonal. 1:200; Millipore) 
 
 Anti Nestin (Nestin; monoclonal. 1:200; Millipore) 
 
The following secondary antibodies were used: 
 
 Alexa fluor 543 and 488 goat-anti-rabbit IgG (1:200; Invitrogen, Life Technologies Italia, 
Monza, Italy). 
 
 Alexa fluor 488 and 594 goat-anti-mouse IgG (1:200; Invitrogen, Life Technologies Italia, 
Monza, Italy). 
 
 Alexa fluor 647 and 488 goat-anti-rat IgG (1:200; Invitrogen, Life Technologies Italia, 
Monza, Italy). 
 
 Alexa fluor 546 and 488 donkey-anti- goat IgG (1:200; Invitrogen, Life Technologies Italia, 
Monza, Italy). 
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3.10.4 Assessement of Myelin preservation 
 
The FluoroMyelin™ Green fluorescent myelin stain is capable of a selective and rapid labelingof 
myelin present in the nervous tissue section. By binding to the lipids of axonal sheatvia the 
Lipophilic associations. It is often usedfor visualizationofthemyelin distribution and itsco-
localization with other markers. The procedure of the staining includes following steps: 
 
1. Incubate the cryosections with fluoromyelindiluted 1:300 in PBS for 20 minutes;  
2. Wash three times for 10 minutes each with PBS 
3. Counted with FluorSave (Merck, Darmstadt, Germany). 
 
Qualitatively and quantitatively analysed by confocal microscopy (Leica TSC2; Leica 
Microsystems, Heidelberg, Germany) 
 
3.10.5 Fluroruby staining 
 
Fluororuby is a fluorescent rhodamine-conjugated dextran, which has been used to study in vivo 
axonal transport within the central nervous system. A 10% solution of Fluororubyprepared by 
dissolving 10 mg of dry powder in 100 µL of PBS, was delivered via intraspinal injection at 
T6/T7 using a 5uL Hamilton microsyringe. Injection volumes typically ranged from 0.5-1 µL 
and were gradually injected over a 10-15 minute interval (Schofield et al., 2007).  
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3.10.6 Confocal microscopy 
 
 
Figure 3.3 Scheme of confocal microscopy 
 
Confocal microscopy offers several advantages over conventional optical microscopy, including 
controllable depth of field, the elimination of image degrading out-of-focus information, and the 
ability to collect serial optical sections from thick specimens. The key to the confocal approach 
is the use of spatial filtering to eliminate out-of-focus light or flare in specimens that are thicker 
than the plane of focus. In recent years, there has been a tremendous explosion in the popularity 
of confocal microscopy, due in part to the relative ease with which extremely high-quality 
images can be obtained from specimens prepared for conventional optical microscopy. In a 
conventional wide field microscope, the entire specimen is bathed in light from a mercury or 
xenon source, and the image can be viewed directly by eye or projected onto an image capture 
device or photographic film. In contrast, the method of image formation in a confocal 
microscope is fundamentally different. Illumination is achieved by scanning one or more focused 
beams of light, usually from a laser or arc-discharge source, across the specimen. This point of 
illumination is brought to focus in the specimen by the objective lens, and laterally scanned 
using some form of scanning device under computer control. The sequences of points of light 
from the specimen are detected by a photomultiplier tube (PMT) through a pinhole (or in some 
cases, a slit), and the output from the PMT is built into an image and displayed by the computer. 
Although unstained specimens can be viewed using light reflected back from the specimen, they 
usually are labelled with one or more fluorescent probes. 
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3.10.6.1 Specimen Preparation and Imaging 
 
The procedures for preparing and imaging specimens in the confocal microscope are largely 
derived from those that have been developed over many years for use with the conventional wide 
field microscope. In the biomedical sciences, a major application of confocal microscopy 
involves imaging either fixed or living cells and tissues that have usually been labelled with one 
or more fluorescent probes. A large number of fluorescent probes are available that, when 
incorporated in relatively simple protocols, specifically stain certain cellular organelles and 
structures. Among the plethora of available probes are dyes that label nuclei, the Golgi 
apparatus, the endoplasmic reticulum, and mitochondria, and also dyes such as fluorescently 
labelled phalloidins that target polymerized actin in cells. Regardless of the specimen preparation 
protocol employed, a primary benefit of the way in which confocal microscopy is carried out is 
the flexibility in image display and analysis that results from the simultaneous collection of 
multiple images, in digital form, into a computer. 
 
3.10.6.2 Critical aspects of confocal microscopy 
 
Quantitative three-dimensional imaging in fluorescence microscopy is often complicated by 
artefacts due to specimen preparation (e.g.autofluorescence problems, retractile structures 
presence, presence or absence of highly stained structures, immersion oil, coverslip thickness 
etc.), controllable and uncontrollable experimental variables or configuration problems with the 
microscope (e.g. optical component alignment, objective magnification, bleaching artefacts, 
aberrations, quantum efficiency, and the specimen embedding medium). 
In our experimental conditions, the immunofluorescence experiments were assessed by confocal 
microscopy TSC SP2 Leica. 
 
3.11 Inflammation 
Inflammation is part of the complex biological response to the tissuedamage or harmful stimuli, 
such as spinal cord injury. Involves immune cells, blood vessels, and molecular mediators the 
inflammatory reaction protects the remaining tissue, in order to eliminate the initial cause of cell 
injury, clear out necrotic cells and tissues damaged from the original insult and the 
inflammatory process, and to initiate tissue repair. 
 
Toniella Giallongo Matr. R10212 
80 
 
3.11.1 Neutrophils quantification 
 
After 24 hours post injury, the animals were sacrificed, the spinal cord was placed intoOCT and 
cut transversely into 10 μmthick sections. We proceed toneutrophils quantification not only at 
the level of trauma, but also rostrally andcaudally, to determinate the different levels of the  
inflammationin the mice treated with stem cells and placebo mice.  
Consequently we prepared twosolutions: the first one containing naphthol (Sigma) (14mg in 1 
ml) dissolved in DMSO (Sigma) and Triton X-100 in 9: 1 ratio, andthe second one, known as 
esaziotideparaseabilin, consisting of pararosalina 4% in 2M HCl and NaNO2 in H2O 2% mixed 
1: 1. The second solution is diluted 1: 200 in 1X PBS for the negative control and in the 
concentration of 1: 100 in1X PBS and Naphthol for the staining. The stained sections bone 
marrow were washed 2 times with 1X PBS for 5 'and subsequently were incubated with 
appropriate solutions for 1 h at RT. Then the tissue was washed with tap water for 10 'and with 
distilled water for another 10 '. Nuclei were stained with hematoxylin (Sigma-Aldrich) 
incubating the sections for 5'. The washing in the tap water was repeated for 15 ' more and the 
slide coverslip weremounted with 50% glycerol in PBS 1X. Neutrophils were counted in both 
groups of samples in the dorsal caudal and rostral level of the lesion, using light microscope 
with40X magnification. 
 
3.11.2 RNA extraction 
 
 3.11.2.1 Real-time RT-PCR analysis  
 
For these experiments, cells were grown and differentiated in 25cm2 Petri dishes as described 
before. Total RNA was isolated by using TRI Reagent® (SIGMA) in accordance with the 
manufacturer’s instructions. In briefly, the procedure used was the following:  
• Add 1 ml of TRI Reagent directly on the culture dish. After addition of the reagent, the cell 
lysate should be passed several times through a pipette to form a homogenous lysate. 
• Phase Separation: To ensure complete dissociation of nucleoprotein complexes, allow samples 
to stand for 5 minutes at room temperature. Add 0.2 ml of chloroform per ml of TRI Reagent 
used. Cover the sample tightly, shake vigorously for 15 seconds, and allow to stand for 15 min at 
room temperature. Centrifuge the resulting mixture at 12,000 x g for 15 minutes at 4°C.  
Centrifugation separates the mixture into 3 phases: a red organic phase (containing protein), an 
interphase (containing DNA), and a colourless upper aqueous phase (containing RNA). 
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• Transfer the aqueous phase to a fresh tube and add 0.5 ml of isopropanol per ml of TRI 
Reagent used in Sample Preparation and mix. Allow the sample to stand for 10 min at room 
temperature. Centrifuge at 12,000 x g for 10 min at 4°C. The RNA precipitate will form a 
pellet on the side and bottom of the tube.  
• Remove the supernatant and wash the RNA pellet by adding 1 ml of 75% ethanol per 1 ml of 
TRI Reagent used in Sample Preparation. Vortex the sample and then centrifuge at 7,500 x g 
for 5 min at 4°C.  
• Briefly dry the RNA pellet for 5–10 minutes by air-drying. Do not let the RNA pellet dry 
completely, as this will greatly decrease its solubility. Add an appropriate volume of 0.5% 
SDS water, or to the RNA pellet. To facilitate dissolution, mix by repeated pipetting with a 
micropipette at 55–60 °C for 10 min.  
The RNA quality was verify by running it onto 1% agarose gel and the amount of RNA in the 
sample was quantified spectrophotometrically. The ratio between A260/A280 was calculated to 
verify RNA purity. 100 ng/sample was used for cDNA synthesis.  
 
3.11.2.2 Degradation of genomic DNA and reverse transcription-PCR (RT-PCR)  
 
The degradation of contaminating genomic DNA from RNA samples was performed with DNase 
I (RNase-free) (New England BioLabs) according to manufacturer’s instructions. In briefly, the 
procedure used was the following: 
• Resuspend1 µg RNA in 1X DNase I Reaction Buffer to a final volume of 10 µ. 
• Add 1 unit of DNase I, mix thoroughly and incubate at 37°C for 10 min. 
• Add 0.5 M EDTA to a final concentration of 5 mM. EDTA should be added to a final 
concentration of 5 mM to protect RNA from being degraded during enzyme inactivation.  
• Heat inactivate at 75° C for 10 min. The synthesis of single-strand cDNA was carried out on 
1μg of RNA template, using iScript™ Reverse Transcription Supermix for RT-qPCR (BIO-
RAD) following the manufacturer’s instructions. 
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Component  Volume per 
reaction 
5X iScript reverse transcription 
supermix 
4 µl 
RNA template (1 µg total RNA) 11 µl 
Nuclease-free water 5 µl 
Total volume 20 µl 
 
Reaction protocol: 
 
Priming 5 min at 25°C 
Reverse transcription 30 min at 42°C 
RT inactivation 5 min at 85°C 
 
Retrotrascription samples are stored at -20°C, until their use for real time RT-PCR. 
 
 
3.11.2.3 Real Time RT-PCR  
 
Real-time RT-PCR quantities the initial amount of the template most specifically, sensitively and 
reproducibly, and is a preferable alternative to other forms of quantitative RT-PCR that detect 
the amount of final amplified product at the end-point (Freeman WM et al., 1999). Real-time 
PCR monitors the fluorescence emitted during the reaction as an indicator of amplicon 
production during each PCR cycle as opposed to the endpoint detection (Higuchi R et al., 1993), 
eliminating post-PCR processing of PCR products. This helps to increase throughput and to 
reduce the chances of carryover contamination. In comparison to conventional RT-PCR, real-
time PCR also offers a much wider dynamic range of up to 107 -fold (compared to 1000-fold in 
conventional RT-PCR). The real-time PCR system is based on the detection and quantitation of a 
fluorescent report (Livak KJ et al., 1995). This signal increases in direct proportion to the 
amount of PCR product in a reaction. By recording the amount of fluorescence emission at each  
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cycle, it is possible to monitor the PCR reaction during exponential phase where the first 
significant increase in the amount of PCR product correlates to the initial amount of target 
template. The higher the starting copy number of the nucleic acid target, the sooner a significant 
increase in fluorescence is observed. Currently four different chemistries, TaqMan®, Molecular 
Beacons, Scorpions® and SYBR® Green (BIO-RAD), are available for real-time PCR. All of 
these chemistries allow detection of PCR products via the generation of a fluorescent signal. 
 
 
Fig.3.4 Real time PCR curves and Ct value 
 
 
TaqMan probes, Molecular Beacons and Scorpions depend on Förster Resonance Energy 
Transfer (FRET) to generate the fluorescence signal via the coupling of a fluorogenic dye 
molecule and a quencher moiety to the same or different oligonucleotide substrates. SYBR 
Green is a fluorogenic dye that exhibits little fluorescence when in solution, but emits a strong 
fluorescent signal upon binding to double-stranded DNA. The threshold cycle or Ct value (Fig. 
3.4) is the point when the system begins to detect the increase in the signalassociated with an 
exponential growth of PCR product during the log-linear phase. This phase provides the most 
useful information about the reaction and the slope of the log-linear phase is a reflection of the 
amplification efficiency. The efficiency (Eff) of the reaction can be calculated by the formula: 
Eff=10(-1/slope) –1. The efficiency of the PCR should be 90 - 100% (–3.6 > slope > –3.1). A 
number of variables can affect the efficiency of the PCR. These include length of the amplicon, 
secondary structure and primer quality. The Ct is an important parameter for quantitation. The 
higher the initial amount of genomic DNA, the sooner accumulated product is detected in the 
PCR process, and the lower is the Ct value. The threshold should be placed above any baseline 
activity and within the exponential increase phase. Some software allows determination of the 
cycle threshold (Ct) by a mathematical analysis of the growth curve. This provides better runt- 
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run reproducibility. Two strategies are commonly employed to quantify the real-time RT-PCR 
data: the standard curve method (absolute quantification) and the comparative Ct method 
(relative quantification). In the standard curve method, a standard curve is first constructed 
from an RNA of known concentration. This curve is then used as a reference standard for 
extrapolating quantitative information for mRNA targets of unknown concentrations, thus 
generating absolute copy number data. In addition to RNA, other nucleic acid samples can be 
used to construct the standard curve, including purified plasmid dsDNA, in vitro generated 
ssDNA or any cDNA sample expressing the target gene. Spectrophotometric measurements at 
260 nm can be used to assess the concentration of these DNAs, which can then be converted to a 
copy number value based on the molecular weight of the sample used. However, cDNA plasmids 
are the preferred standards for standard curve quantitation. The comparative Ct method 
involves comparing the Ct values of the samples of interest with a control or calibrator such as a 
non-treated sample or RNA from normal tissue. The Ct values of both the calibrator and the 
samples of interest are normalized to an appropriate endogenous housekeeping gene. The 
comparative Ct method is also known as the 2–ΔΔCt method (Livak KJ et al., 2001), whereΔΔCt = 
ΔCt,sample - ΔCt,reference. ΔCt,sampleis the Ct value for any sample normalized to the endogenous 
housekeeping gene and ΔCt, reference is the Ct value for the calibrator also normalized to the 
endogenous housekeeping gene. For the ΔΔCt calculation to be valid, the amplification 
efficiencies of the target and the endogenous reference must be approximately equal. This can be 
established by looking at how ΔCt varies with template dilution. If the plot of cDNA dilution 
versus delta Ct is close to zero, it implies that the efficiencies of the target and housekeeping 
genes are very similar. This quantification method is described in the Applied Biosystems User 
Bulletins #2 and #5. Relative gene expression comparisons work best when the expression of the 
chosen internal control is abundant and remains constant among the samples. By using an 
invariant endogenous control as an active reference, quantitation of an mRNA target can be 
normalised for differences in the amount of total RNA added to each reaction. For this purpose, 
the most common choices are 18S RNA, GAPDH (glyceraldehyde-3- phosphate dehydrogenase) 
and β-actin. Real-time PCR requires an instrumentation platform that consists of a thermal 
cycler, a computer, optics for fluorescence excitation and emission collection, data acquisition, 
and analysis software. These machines, available from several manufacturers, differ in sample 
capacity (some are 96-well standard format, others process fewer samples or require specialized 
glass capillary tubes), method of excitation (some use lasers, others broad spectrum light sources 
with tuneable filters), and overall sensitivity. In our experimental conditions, Real-time PCR was 
performed in an MJ Opticon 2 using iQ™ SYBR Green supermix (BIO-RAD) following the 
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manufacturer’s instructions. 18S rRNAwas used as reference housekeeping gene for 
normalization. We performed an analysis using the ΔΔCt, this procedure can be used since we 
have determined previously that the replication efficiencies (slopes of the calibration or standard 
curves) for the genes of interest and housekeeping gene are very close. All the amplification 
reactions were performed in duplicate. The primers were designed using Oligo Perfect® 
Designer Software (INVITROGEN).  
 
The nucleotide sequences of the primers for spinal cord injury were: 
Gene Name Forwardprimer Reverceprimer 
GAPDH CGACTTCAACAGCAACTCCCACTCTCC TGGGTGGTCCAGGGTTTCTTACTCCTT 
BDNF CATTACCTTCCTGCATCTGTTGG CGTGGACGTTTACTTCTTTCATGG 
IL-6 GACAACCACGGCCTTCCCTAC CGTTGTTCATACAATCAGAATTGCC 
NGF TGGGCCCAATAAAGGTTTTGCC TGGGCTTCAGGGACAGAGTCTCC 
TNFα TCTATGGCCCAGACCCTCACAC CAGCCACTCCAGCTGCTCCTC 
MIP2 ACGCCCCCAGGACCCCACTG GGACAGCAGCCCAGGCTCCTCC 
LIF AACGTGGAAAAGCTATGTGCG GCGACCATCCGATACAGCTC 
 
 
The nucleotide sequences of the primers for Parkinson disease were: 
Gene Name Forwardprimer Reverceprimer 
18S TTTCGGAACTGAGGCCATGATTAAG AGTTTCAGCTTTGCAACCATACTCC 
IL15 CCATCTCGTGCTACTTGTGTTTCCTTCTAA GAAAGCAGTTCATTGCAGTAACTTTGCAAC 
IL-6 TCCAGTTGCCTTCTTGGGACTGATGCTGGT AGTTTCAGATTGTTTTCTGCAAGTGCATCA 
IL1α ATGGCCAAAGTTCCTGACTTGTTTGAAGAC GTTGCTTGACGTTGCTGATACTGTCACCCG 
TNF-α GACGTGGAACTGGCAGAAGAGGCACTCCC GAGGCCATTTGGGAACTTCTCATCCCTTTG 
NGF CTCAGCAGGAAGGCTACAAGA TACAGGCTGAGGTAGGGAGG 
BDNF ACTACCAAAGCCACAAGGCA GCTGATCCTCATGCCAGTCA 
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3.11.2.4 Real Time RT-PCR conditions 
 
Amplification reactions were performed in 96-well standard plate. Each sample wasanalysed in 
duplicate. Reaction mix for all primers was prepared adding 2 µl of cDNA sample (dilution 1:10) 
to the following mix: 
• 1.2 μl of primer forward (10 µM) 
• 1.2 μl of primer reverse (10 µM) 
• 10.6 μl of Dnase and Rnase free water 
• 15 μl of 2X iQ™ SYBR Green supermix 
 
Amplification conditions were: 
 
 
 
 
 
 
3.12 Statistical Analysis 
 
Data are expressed as means ± SEM. The two-way analysis of variance (Anova) and 
Bonferroni’s post-test were applied using Prism 5 software (GraphPad Software Inc, La Jolla, 
USA) assuming a p value less than 0.05 as the limit of significance. 
 
3.13 Determination of dopamine and metabolites in Parkinson’s disease 
For dopamine and its metabolites analysis it has been followed the protocol described by Vaglini 
and co-workers (28). Briefly, the striatal tissue samples were homogenized in 600 µL ice-cold 
0.1 N perchloric acid containing 10 pg/lLdihydroxybenzylamine (DBA) as the internal standard; 
an aliquot of homogenate was assayed for protein. The homogenates were centrifuged and the 
levels of monoamines and their metabolites in the supernatant were determined by reverse-phase 
HPLC coupled to an electrochemical detector. One liter of mobile phase contained 10.35 g (75 
mM) sodium dihydrogen orthophosphate, 0,505 g (2,5 mM) heptan sulfonic acid, 25 mM EDTA, 
• 95°C for 10 min      40 cycles 
• 95°C for 15 sec 
• 60°C for 30 sec1 cycle 
• 75°C for 30 sec 
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100 µL triethylamine and 200 mL acetonitrile, adjusted to a final pH of 3,00 with phosphoric 
acid. A C18 inertsil ODS-3, 4.6 · 250 mm, 5-µm, reverse-phase column was used (Beckman, 
San Ramon, CA, USA). The mobile phase (filtered and degassed) was delivered at a flow rate of 
1.2 mL/min; the applied potential was set to – 0.10 V (detector 1) and + 0.30 V (detector 2). For 
catecholamine assays, a standard curve was prepared using known amounts of DA and 
metabolites dissolved in 0.1 N perchloric acid containing a constant amount (10 pg/mL) of the 
internal standard (DBA) used for tissue samples. The standard curve for each compound (DA or 
its metabolite) was calculated using regression analysis of the ratios of the peak areas (compound 
area/DBA area) for various concentrations of each compound recorded at the reducing electrode. 
An analogous regression analysis was performed for the oxidizing electrode. For DA and its 
metabolites, results are expressed as the mean ± SD of at least 5 animals per group. 
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4. Results 
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4.1 Derivation of GFP positive Post-Mortem Neural Precursor Cells and 
Characterization of their Self-Renewal capability 
 
Adult C57BL/6-Tg (UBC-GFP) 30Scha/J or CD1 mice were softly anesthetized and killed by 
cervical dislocation. The cadavers were maintained at room temperature (25°C) for 6 hours, 
and after this period the animals were decapitated and their brains were removed, the neural 
precursors were extracted (see Materiali and Methods) from the area including the SVZ 
surrounding the lateral wall of the forebrain ventricle. PM-NPCs expressing green fluorescent 
protein (GFP PM-NPCs) ( Fig. 4.1A) proliferate in response to the exposure to hFGF and 
bEGF, and formed typical neurospheres similar to those formed  by NPCs amd PM-NPCs 
obtained from CD1 mice (Marfia, 2011) (Fig. 4.1B). 
                              A 
B
 
Figure 4.1. GFP positive PM-NPCs are able to form neurospheres. 
Undifferentiated post mortem neural precursors cells isolated from the Sub Ventricular Zone (SVZ) of adult mice that 
constitutively expresses the green fluorescent protein (GFP) proliferate in response to growth factors (EGF and FGF-2) and 
form neurospheres. (A) Pictures were taken 48 after cells isolation. Scale bars 200 µm. (B) Picture were taken 5 days post in 
culture Scale bars 100 µm. 
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To assess for self-renewal, individual primary spheres were mechanically dissociated, and 
cells were plated in growth medium at the density of 3000 cells/cm2 in 500 μl. The number of 
neurosphers formed by GFP-positive PM-NPCs was 169 ± 7,63/well and was similar to the 
number of spheres formed by both classical neural stem cells (NPCs) and post mortem neural 
precursors cells from CD1 mice (Marfia, 2011)(Fig. 4.2).  This assay was performed at 
passage 7, 15 and 30 without observing any significant difference.  
 
 
 
Figure 4.2. Neurosphere assay. 
PM-NPCs population analysis was performed by counting the number of neurospheres generated after 10 days of culture. 
Classical neural stem cells from SVZ of adult CD1 mouse (NPCs; Gritti, 1996), post mortem neural precursors cells from 
SVZ of adult CD1 mouse (PM-NPCs, Marfia, 2011) and post mortem neural precursors cells from Adult C57BL/6-Tg(UBC-
GFP)30Scha/J  mouse (GFP+ PM-NPCs) were cultured in the presence of bEGF, and hFGF. The number of spheres formed 
in each well was counted after 7–12 days.  It is represented the number of neurospheres generated by 3000 cells plated in a 
single well. The experiment was performed three times in triplicate for each cell sources and was repeated at passage 7, 15 
and 30 without observing significant differences. Data are expressed as the mean of three independent experiments with 
similar results ± standard error. 
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4.2 Differentiation features of GFP positive PM-NPCs 
 
GFP PM-NPCs were differentiated to asses for multipotency. Neutrospheres were 
mechanically dissociated and cells to the concentration of 1x 104 cells/cm2 were seeded onto 
Matrigel®-coated glass coverslips (12 mm diameter) in a medium with bFGF and without 
hEGF. After 48 h cultures were shifted to a differentiation medium containing 1% (FBS) 
(Invitrogen). PM-NPCs attach to the dish and begin the differentiation process into neurons, 
astrocytes, and oligodendrocytes, after removal of growth factors and addition of serum and 
adhesion molecules. 7 and 15 days after differentiation induction the extent of the 
differentiation was evaluated by monitoring the number of cells expressing MAP-2, GFAP, 
and NG2 antigens (Fig. 4.3A and C). The quantification of neuronal-like differentiation after 
7 days is shown in panel B of the same figure. MAP-2 positive neurons were 39,3 ± 0,77 %; 
GFAP (astrocytes) and NG2 (oligodendrocyte precursors) -positive cells were 60,9 ± 2,81and 
12,86 ± 0,48 respectively. The extent of the GFP PM-NPCs differentiation confirmed that 
these precursors cells have similar features of that previously obtained (Marfia, 2011). 
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Figure 4.3. Neural marker expression after differentiation. After removal of growth factors, PM-NPCs neurospheres 
readly differentiates into MAP2 positive neurons, NG2 labelled oligodendrocytes precursors and astrocytes (GFAP). Staining 
with specific markers is showed in red. Nuclei are stained in blue with DAPI. Bars are 100 μm(A).A magnified is represented 
on the right of the figure (C) Quantification was performed by counting the number of cells positive for the staining. 
Positivity was expressed as a percent of the total cells.  The quantification indicates that about 40 % of  PM-NPCs 
differentiates into neurons. Data are expressed as the mean of three independent experiments with similar results± SEM(B).  
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4.3 GFP PM-NPCs neurospheres features before transplantation.   
 
As control, before transplantation was investigated the expression of Microtubule-Associated 
Protein 2 (MAP2) by immunocytochemistry assay in GFP PM-NPCs neurospheres MAP2 is 
important to determinate and stabilize dendritic shape during neuron development.  
As showed in figure 4.4 by immunocytochemistry the GFP PM-NPCs neurospheres before 
transplantation do not express Map2 (Fig. 4.4A) but, as expected, are positive to the staining 
with Nestin (stem cell marker) (Fig. 4.4B) 
 
A                                                             B 
 
Figure 4.4. PM-NPCs do not express MAP2. 
 PM-NPCs endogenously express green fluorescent protein and for that reason are showed in green. The labelling for nestin 
(A) and microtubule association protein 2 (MAP2;B) are showed in red. Nuclei were stained with DAPI and are showed in 
blue. The experiment was performed in duplicate with similar results and the picture showed here are representative. Scale 
bars are 100 microns. 
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4.4 PM-NPCs transplanted in Spinal Cord Injury 
4.4.1 PM-NPCs Improve Recovery of Hind Limb Function 
 
PBS-treated mice have a transient loss of ability in hind limb function caused by the 70 
Kdyne traumatic impact to the mice cord. This initial loss of hind limb movement followed by 
a progressive gradual recovery reaching the maximum in 2-3 weeks (3.20 ± 0.08 points of the 
BMS scale; n = 15) (Fig. 4.5). After these weeks animals reach a recovery corresponding to 
plantar placing of the paw with or without weight support or occasional, frequent, or 
consistent dorsal stepping, but not plantar stepping (Basso, 2006). 
 
 
 
Figure 4.5. PM-NPCs Improve Recovery of Hind-Limb Function. 
The open field locomotion was the test employed for the determination of motor function recovery, the score is determined 
according to the Basso Mouse Scale (Basso, 2006). The experimental animals, tested the day prior to the injury, scored 9 
points in the BMS scale (see in Materials and Methods), then the score fell to 0 following SCI and gradually recovered 
thereafter. The recovery ofhind limb function oflesioned mice showed a remarkable and long lasting improvement when 
animals treated with PM-NPCs. The groups were randomized, the analysis was performed in double blind fashion, and 15 
animals composed each group.  Values represent average ± SEM. We determined the statistical differences by means of 
ANOVA test followed by Tukey’s post-test. ***P< 0.001; **P< 0.01 vs Saline; °°°P< 0.001; °°P< 0.01 vs CTRL 
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After transplant of PM-NPCs in the injured mice the recovery was earlier and  reached  a higher 
recovery extent up to 5.14 ± 0.06 at d 28, corresponding to frequent or consistent plantar 
stepping without coordination, or frequent or consistent plantar stepping with some 
coordination(see Materials and Methods). The behavioral improvement was particularly evident 
between days 7 and 14 after SCI, and then it kept steadily improving up to 90 days (Fig. 4.5). 
Throughout the observational period no signs of allodynia-like forelimb hypersensibility 
(Hoffstetter, 2005) were recorded in any experimental group. 
 
4.4.2 PM-NPCs-mediated tissue sparing 
 
 Thirty days after lesioning tissue sparing at lesion site was analyzed by means of quantitative 
analysis (see Materials and Methods) following thionin staining. The post-traumatic tissue loss is 
far more evident in the cord of PBS-treated lesioned mice (Fig. 4.6A), than in the cord of the 
animals treated with PM-NPCs (Fig. 4.6B).  This result is confirmed by the quantitative analysis 
(Fig. 4.6C). 
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Figure 4.6. PM-NPCs-Mediated Reduction of Post-Traumatic Injury. 
Morphology preservation was qualitatively and quantitatively analyzed by means of thionin staining. For qualitative analyses 
serial cross (T9 level) and longitudinal-sections of spinal cord injury after 30 days from injury were acquired from animals 
treated with PM-NPCs or PBS. The quantitative analyses of tissue preservation after traumatic injury was performed considering 
cross sections for at least seven animals for each group and calculating the length of lesion extension. PM-NPCs determine a 
significant reduction of lesion length through the lesion site compared with PBS treated group. Values represent average ± SEM; 
**P < 0.01 vs PBS. 
 
 
Ten months after lesioning, in vivo NMR analysis was performed in saline and cell-treated 
animals. In Figure 4.7 is shown that spinal tissue in the animals treated with PM-NPCs was 
preserved. The T2-weighted RARE images show that the spinal cord matter become very thin at 
the injury site surrounded by a very high hyperintense signal in saline treated mice. This effect is 
probably due to spinal liquor filling the empty space left by the reduced size of the surviving 
cord. Spinal cord shrinkage at lesion site and liquor accumulation is a constant finding in all 
chronically-lesioned untreated animals (Fig. 4.7). 
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Differently, the spinal cord matter of the PM-NPCs transplanted animals, is rather well preserved 
at site of injury even 10 months later and the hyperintensive signal is far less intense than in 
saline-treated animals (Fig. 4.7), it can be observed that the protective effect of the cells is 
maintained chronically. The reduced tissue loss is likely due to tissue sparing.  
 
 
 
Figure 4.7. In Vivo MRI 10 Months  After Spinal Cord Injury.  
RARE sequences obtained at 10 months after injury and cells transplantation by means of a 7 tesla NMR (Bruker). It is shown 
a significantly better parenchymal preservation in PM-NPCs treated animals, while there is only a thin  residual tract in saline-
treated mice that is accompanied by a   major liquor accumulation. The images are representative for 2 mice, but similar images 
were obtained for at least 4 animals per group. 
 
 
The reticulospinal tract is an important pathway in eliciting locomotion, by electrophysiological 
studies it was shown its function in the coordination of rhythmic stepping movements 
(Bellerman, 2006; Mori, 1998). The preservation ofmyelin inthe reticulospinal tractthat 
descends throught theipsilateraldorso-andventro- lateral funiculi was studied by means of 
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FluoroMyelin™ staining followed by confocal quantitative analysis as detailed in Material and 
Methods (Vitellaro-Zuccarello, 2007; Vitellaro-Zuccarello, 2008). Myelin preservation was 
quantified 30 days after lesioning, sections were taken at the center of lesion and 2 mm 
caudally to the lesion site. Only intact myelin was assessed, and the rubble of degenerated 
myelin was obviously not considered. Inproximityof the lesion, the trauma caused almost 50% 
loss of myelin and about 70% more caudally. The application of PM-NPCs reduced themyelin 
loss inremarkable and highly significant manner inbothevaluationpoint, lesion site and 
caudally. (Figure 4.8). 
 
 
 
Figure 4.8. Sparing of Myelin in the Injured Cord 
The images and the relative quantification show the protective action of PM-NPCs on the myelin tracts in the injured cord. 
Myelin was quantified by means of Fluoromyelin™ staining (green) performed in sections at the lesion epicenter and 2  mm 
caudally to the lesion site through quantitative confocal analysis of ventral and lateral white matter as indicated in the graphs. 
The confocal microscope images for the laminectomy, saline and PM-NPCs-treated mice were obtained using the same 
intensity, pinhole, wavelength and thickness of the acquisition. As reference we used sections close to the ones analyzed and 
not treated with fluoromyelin. For the quantification we considered sections from at least six animal per group. Values 
represent average ± SEM. We determined the statistical differences by means of ANOVA test followed by Tukey’s  post-test. 
°°°, ***P< 0.001; °°,** P<0.05; °, *P< 0.01. 
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Figure 4.9 show that near the PM-NPCs cluster the post injury reaction of GFAP cellular profiles 
was markedly reduced. The quantification confirmed that GFAP positive cells were reduced in 
the site where PM-NPCs are located (Fig. 4.9A) respect the other part of the lesioned cord (Fig. 
4.9B). None of the transplanted cells PM-NPCs differentiated into GFAP positive cells different 
to the in vitro results where about 40-50% of the cells differentiate in oligodendrocytes. 
 
 
 
Figure 4.9. GFAP Immunoreactive-Positive Profiles 30 Days after Lesioning  
PM-NPCs reduce the extent of gliosis in their microenvironment in the injured cord. Sections were taken at 1 mm caudally to 
the lesion site from cords of PBS (A) and PM-NPCs-treated (B) mice. Quantification of GFAP-positive profiles (green) in a 
100 µm radius around PKH26-labeled PM-NPCs clusters (C).  GFAP staining is showed in green and PKH26 labeled PM-
NPCs are showed in red. Values represent average ± SEM. ***P < 0.001 vs Saline. 
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4.4.3 PM-NPCs Homing to Site of Injury, Survival, and Differentiation   
 
PKH26- labeled PM-NPCs transplanted mice were killed after 48 h and CCD camera analysis 
was performed to isolated following organs: spinal cord, kidney, bowel, spleen, lungs and liver. 
PM-NPCs were distributed mainly at the center of the lesion site; Figure 4.10 shows a highest 
detected fluorescence peak in this region, only a smaller positivity was observed in the spleen 
(Fig. 4.10A). Figure 4.10B shown the comparison of spinal cords from PM-NPCs- and saline-
treated where it is can possible to observe a higher and specific signal of fluorescence 
correlated with the presence of transplanted cells in the former, and the absence of specific 
signal in the latter. Four weeks after injury, we have also serially sectioned seven cords of 
treated mice, and detected PKH26- or GFP-positive PM-NPCs by means of confocal 
microscopy at the edge of the lesion.  Total number of positive cells was 260.000 ± 45.000 per 
cord, that is 100 fold higher than surviving ES cells as reported previously and 10 fold higher 
than adult NSCs (Bottai et al, 2010;  Bottai et al, 2008). 
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Figure 4.10. Organ distribution of i.v. administered PM-NPCs 
PKH26 labeled PM-NPCs distribution 48 hours after injection was investigated by means of CCD camera. Animals were killed 
and spinal cords and organs extracted and acquired to investigate organ distribution of PM-NPCs.  (A) The picture shows the 
high accumulation of the labeled cells at the lesion site and a lower signal in the spleen. (B) Comparison of spinal cord 
fluorescence of PM-NPC injected mice and saline-treated animals showed a high fluorescent signal relative to the presence of 
labeled transplanted cells only in the animals treated with PM-NPCs. Pictures are referred to one PM-NPCs treated mouse, we 
observed very similar results in at least other six animals.  
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Most engrafted PM-NPCs accumulated at the edges of the lesion (Fig. 4.11, 4.12, 4.13), where 
formed clusters since the early days of their administration, then the clusters dispersed along 
the lesion edges and transplanted cells differentiate assuming gradually the asymmetric cellular 
conformation of neurons.  At one week after lesioning and transplantation small PM-NPCs are 
grouped along the irregular margins of the lesion and almost 50% of the cells are already 
positive for MAP-2 and ChAT (Figures 4.11, 4.13). 
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Figure 4.11. PM-NPCs MAP2 tlrans-differentiation in lesioned cords 
GFP-labeled PM-NPCs (A) are clustered at the edges of lesion site at 7 days after their i.v. supplementation to the injured mice, 
some of them have differentiated in MAP2 positive cells (Bar = 100 µm). A magnified detail is represented on the right site of 
the figure (Bar = 50 µm). (B) PKH-labelled PM-NPCs (red) are present throughout the edges of lesion site at 60 days after their 
i.v. supplementation to spinal cord injured mice. Most of them have differentiated in MAP2 positive cells (green; Bar = 100 
µm). A magnified detail is represented on the right site of the figure (Bar = 50 µm). Most PKH-labeled PM-NPCS have 
acquired a neuronal-like shape with dendritic-like processes that intermingle with those of local spinal neurons that survived 
the lesion. Together they form a rich neuropil. All labeled cells have one nucleus. Nuclei are stained in blue (DAPI). 
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Analayzing the section of spinal cord transplanted animals at days 30 and 60 after lesioning we 
can observe that the cell body of PM-NPCS increases in size and most cells extend dendritic 
like processes that are fully immunostained by the specific antibodies to MAP-2 and β-tubulin 
III (Figures 4.11, 4.12). 
 
 
 
 
 
Figure 4.12.  β-Tubulin III Expression by PM-NPCs at the Edges of the Lesion 
 
Pictures representing the edges of the lesion at 60 days after i.v. supplementation of PKH26–labeled PM-NPCs. The 
preparation was immunostained for β tubulin III. Several PM-NPCs are present among the surviving neural profiles, practically 
all PKH26-labeled cells are positive for β-tubulin III. We show two fields at different magnification ( bar =  75 or 20 µm), and 
a detailed enlargement that shows clearly how each labeled cell has one nucleus and bears profiles positive for β-tubulin III. 
Toniella Giallongo Matr. R10212 
105 
 
Immunohistochemical staining for Choline-AcetylTransferase (ChAT) revealed that most 
transplanted PM-NPCs are positive for this enzyme (ChAT), and that the positivity with time is 
present also in the cellular dendritic-like processes (Fig. 4.13). Such a differentiation into 
cholinergic neural cells in vivo confirms the earlier in vitro observations (Marfia, 2011).  
 
 
 
Figure 4.13. PM-NPCs transplanted cells differentiate into cholinergic neurons 
 
(A). Some GFP-labeled PM-NPCs clustered at the edges of the lesion at 7 days after their i.v. administration. Several PM-
NPCs are positively immunostained for Choline Acetyl Transferase (ChAT; red).  The pictures  (bar = 100 µm) are enlarged in 
the right part of the panel (bar = 20 µm). (B) Several PKH26-labelled PM-NPCs (red) are accumulated at the edges of the 
lesion 30 days after their i.v. administration. Most PM-NPCs are positive for ChAT immunostaining (green) as shown clearly  
in the enlargement on the right side. ChAT stain is dotted and in most cases perinuclear, although some positive processes are 
evident (bar =  75 and 20 µm),  (C) PKH26-labeled PM-NPCs clustered at the edge of the lesion 60 days after their 
administration. All PM-NPCs are positive for ChAT immunostaining as clearly shown by the two consecutive enlargements 
(bar = 50 µm). The labeling is now diffused throughout the neuron-like cell bodies and in the cellular processes. 
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The achievement of morphological complexity and the positivity to ChAT, MAP2, and β-
tubulin III by transplanted PM-NPCs is not likely due to fusion with surviving host spinal cord 
neurons (Figs. 4.11, 4.12, 4.13), this is evident by their  clear different morphology and the 
absence of two nuclei in any single labeled cell. The quantification of such differentiation is 
shown in Table I, performed on spinal cords 60 days after lesioning and PM-NPCs 
transplantation. 
 
 
Table 1.  Percentage of transplanted PM-NPCs positive for neuronal markers 60 days after intravenous administration. 
 
4.4.4 PM-NPCs-Mediated chemokine and growth factor expression in the injured cord 
 
Some additional effects of PM-NPCs was suggested by the action of these cells  in promoting 
the recovery of function, therefore, we have assayed the production of  neurotrophic factors and 
inflammatory cytokines that represent the major targets of pharmacological agents aimed at 
repair in neurodegenerative disorders. The mRNA levels of six different factors was 
quantitatively evaluated (Fig. 4.14), these factor are  nerve growth factor (NGF); tumor 
necrosis factor α (TNFα); interleukin-6 (IL-6); MIP-2; and leukemia inhibitory factor (LIF).  
The animals treated with Saline or PM-NPCs was compared. As controls, we assayed the 
chemokines in the T9 region of the spinal cord of both uninjured and laminectomized animals. 
As expected in the lesioned animals cord all the assayed chemokines were increased. We 
observed that MIP 2 expression is diminished by PM-NPCs at 48 hours and 1 week after 
lesioning; differently IL-6, TNFα, NGF and LIF are reduced at the earlier time, but 
significantly increased at 1 week compared to saline treated mice. BDNF was increased by PM-
NPCs in lesioned mice only at 48 hours (Fig. 4.14). 
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Figure 4.14. PM-NPCs transplanted cells affect local expression of cytokines.  
Expression of cytokines mRNA was evaluated by real time RT-PCR. Each group was composed of six mice, and we performed 
three quantitative (Q)–RT-PCRs in each experiment, we run a duplicate per each sample and a parallel PCR for the gene of 
interest and the reference gene Glyceraldehyde-3-Phosphate Dehydrogenase. Values represent average ± SEM. ***, °°°, ###P< 
0.001; °°,**, ## P<0.01; °,*. # P<0.05; * vs Control (CTRL); ° vs LAM; # vs Saline 
 
4.4.5 Inflammatory Cell Migration to the Lesion Site 
The invasion of the lesioned spinal cord by neutrophils and macrophages was counteracts by 
the administration of PM-NPCs. Two days after lesioning, neutrophils infiltration was 
investigated at the site of injury by means of Leder stain throughout the lesion site. As reported 
previously neutrophils decreases with time (Bottai, 2008). In the better preserved tissue the number 
of neutrophils is reduced, and the preventive effect PM-NPC is quantitatively very significant 
(Fig. 4.15).  
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Figure 4.15. Tissue infiltration by neutrophils.  
Neutrophil infiltration was quantitatively assessed at lesion epicenter 48 h after lesioning by means of the naphtol AS-D 
chloroacetate (Sigma-Aldrich) technique for esterase. Results are expressed as number of neutrophils per HPF. The presence of 
transplanted PM-NPCs greatly reduced the invasion by neutrophils. For the quantification, we considered sections from at least 
six animals per group. Values represent average ± SEM. ***p < 0.001 versus saline. 
 
Figure 4.16 shown the effect of the transplanted cells monitoring the number of ED-1-positive 
cells (macrophages) in the site of lesion and rostrally one week after injury. Both qualitatively 
and quantitatively the counteracting action of PM-NPCs is evident and significant. 
 
 
 
Figure 4.16. Tissue infiltration by macrophages. 
Coronal cryostat section of cord lesion epicenter and cord 0.4 mm rostral to the lesion were stained for ED-1, and the number 
of positive cells was quantitatively evaluated as described in Materials and Methods. Results are expressed as the number of 
ED-1-positive cells per HPF.  For the quantification, we considered sections from at least six animals per group. Values 
represent average ± SEM. ***p < 0.001 versus saline 
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4.4.6 PM-NPCs promote neural markers expression in recipient injured spinal cord 
Previously was reported that PM-NPCS have a specific distribution reaching at high prevalence 
the lesion site in the spinal cord. At 30 days after lesion and transplantation, PM-NPCs were 
still alive and are localized at the lesion site. At this observation time, PM-NPCs cell bodies 
resulted with a more structured morphology characterized by the presence of dendritic-like 
processes (Fig. 4.18). This is particularly evident with the immunohistochemical staining for 
Choline-AcetylTransferase (ChAT) (Fig. 4.17) and MAP-2 and β-tubulin III (Fig. 4.18). Figure 
1 reveals that at 30 days after transplantation 75± 9.35 percent of transplanted PM-NPCs were 
positive for ChAT. ChAT immunoreactivity is dotted and in most cases perinuclear, although 
some positive processes are evident 
 
 
Figure 4.17. PM-NPCs transplanted cells differentiate into cholinergic neurons.  
 
At 30 days after i.v. injection, several PKH26-labeled PM-NPCs (red) were accumulated at the edges of the lesion. Most PM-
NPCs were positive for ChAT immunostaining (green) (Scale bar = 50 µm). 
 
Moreover, transplanted PM-NPCs accumulate at the irregular margins of the lesion and almost 
50% of the cells were already positive for MAP-2 and β-tubulin III (Fig. 4.18).  This suggests  
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that transplanted neural precursors attempt to form contacts with the near microenvironment of 
the host tissue. The quantification of MAP-2 and β-tubulin III staining performed both at distal 
end (Rostral and caudal) and at the lesion site shows that higher expression of neuronal markers 
are determined in PM-NPCs treated animals (Fig. 4.18). 
 
Figure 4.18. PM-NPCs transplantation improves neural markers expression in injured spinal cord.  
Pictures represent the edges of the lesion at 30 days after i.v. administration of PKH26 – labeled PM-NPCs. Coronal sections of 
the tissue were immune stained for β tubulin III and MAP-2 (showed in green).  PKH26-labeled cells were positive for β-tubulin 
III and MAP-2 (white stars) (Scale bar=75 and 100 µm). Immunoreactivity was quantified in sections taken at the lesion 
epicenter, 1 mm rostral and caudal to the lesion site through quantitative confocal analysis. The confocal microscope images for 
Laminectomy (LAM), PBS, and PM-NPCs-treated mice were obtained using the same intensity, pinhole, wavelength and 
thickness of the acquisition. As reference, we used sections close to the ones analyzed. In negative controlsthe primary antibodies 
were omitted and replaced with equivalent concentrations of unrelated IgG of the same subclass. Values represent average ± SD. 
We determined the statistical differences by means of ANOVA test followed by Tukey’s post-test. ***p < 0.001 vs LAM; $$ 
p<0.01 vs PBS. 
 
4.4.7 Monoaminergic fibers in the injured cord 
 
Both the above findings and our prior ones (Carelli, 2014 and 2015) suggest that injection of 
PM-NPCs promotes axonal regeneration after SCI. We therefore searched for the identification 
of mechanisms that could contribute to the functional improvements. Since serotonin (5-HT) can 
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regulate the CPG and facilitate locomotion (Liu, 2009), we examined the 5-HT 
immunoreactivity rostral, within, and caudal to the lesion in CD-1 mice comparing the PM-
NPCs, PBS and control groups. 
Figure 4.19 shows the 5-HT immunoreactivity both in the lesion epicenter (Fig. 4.19A) and 
distally (2 mm rostral or caudal from the lesion site; Figure 4.19B). Serotonin (5-HT)-positive 
fibers (green) are present also caudally to the lesion. The quantification, performed 4 weeks after 
lesioning, shows that labeling is only about 20 % of LAM values in intermediate-lateral gray 
matter and ventral horns of PBS injected animals. Differently, the extent of 5-HT innervation is 
more than doubled when lesioned animals were treated with PM-NPCs (Fig. 4.19). 
 
 
 
 
Figure 4.19.PM-NPCs promote serotoninergic fibers sprouting through the lesion site 
Serotoninergic (5-HT) fibers were investigated at the lesion site (panel A) and 2 mm away from the lesion (panel B) 4 weeks 
after PM-NPCs infusion in lesioned mice. In panel A, PM-NPCs are showed in red and 5-HT is showed in green. Nuclei were 
counterstained with DAPI (blue). In panel B, 5-HT staining is showed in red and neuronal fibers were identified with beta-tubulin  
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A comparable analysis was conducted also for Tyrosine Hydroxilase (TH)-positive fibers (red) 
of the intermediate-lateral gray matter and ventral horn areas caudally to the lesion (Fig. 4.20 and 
Fig. 4.21).  
 
 
 
Figure 4.20. PM-NPCs promote Tyrosine Hydroxilase (TH)-positive fibers sprouting through the lesion site 
Tyrosine Hydroxilase (TH)-positive fibers were investigated at the lesion site (panel A) and 2 mm caudal from the lesion (panel 
B) 4 weeks after PM-NPCs infusion in lesioned mice. In panel A, PM-NPCs are showed in red and TH is showed in green. 
Nuclei were counterstained with DAPI (blue). In panel B, TH terminals are showed in red and neuronal fibers were identified 
with beta-tubulin III (green).  Nuclei were counterstained with DAPI (blue). Scale bars = 25 µm. 
 
In saline treated animals, the loss of TH-positive fibers was significant but quantitatively not as 
large as we observed for 5-HT. TH-positive innervation of these areas was quantitatively similar to 
healthy animals when lesioned animals were treated with PM-NPCs (Fig. 4.21). Thus 
transplantation of PM-NPCs promotes sparing and perhaps regrowth of monoaminergic fibers in the 
distal portions of the traumatically injured cord. 
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Figure 4.21. Quantification of serotoninergic and Tyrosine Hydroxilase (TH) immunoreactivity. 
Serotoninergic (5-HT) and Tyrosine Hydroxilase (TH) fibers quantification was performed at 4 weeks after PM-NPC 
transplantation in lesioned animals. The quantification was performed in spinal cord coronal sections (n=3 for each animal; at 
least 3 animal per group) as described in detail in M&M section in intermedio-lateral and ventral horns (please see the 
representation).   Values represent average ± SD. We determined the statistical differences by means of an ANOVA test followed 
by Bonferroni’s post-test. ***p< 0.001 vs PBS; °°°p<0.001, °°p<0.01, °p<0.05 vs LAM.  
 
 
4.4.8 PM-NPCs treatment results in increased expression of GAP-43  
 
Growth-associated protein 43 (GAP43) it is expressed at high levels in neuronal growth cones 
during development, during axonal regeneration and it is considered a well-known marker of 
neurite outgrowth (Skene, 1986).  To corroborate the above evidences on PM-NPCs stimulation 
of neurons regeneration, cryostat sections of spinal cord of cells injected animals, taken at 2 mm 
from the lesion epicenter, were examined for the GAP-43 expression at 30 days after cells 
injection (Fig. 4.22). The immunoreactivity of GAP-43 was especially noticeable in bundles 
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positive to staining with beta-tubulin III and GAP-43 staining resulted near the PM-NPCs 
localization (Hoechst). 
 
 
 
 
 
Figure 4.22. GAP43 expression in PM-NPCS transplanted cord. 
Qualitative picture ofGAP43 expression investigated 2 mm away (rostral and caudal) from the cord lesion site of lesioned 
animals transplanted with PM-NPCs. GAP 43 is showed in red and neuronal fibres were detected with beta-tubulin III staining 
(green). In order to perform double staining in these experiments PM-NPCs were labelled with Hoechst (blue). Scale bars = 75 
µm. Pictures are representative of at least three different immunostaining experiments.  
 
4.4.9 Enhanced axonal sparing/regeneration by PM-NPCs 
 
To evaluate anterograde axonal sparing/regeneration twenty days after injury fluororuby was 
injected rostrally at T6/T7 level (Fig. 4.23, 4.24 and 4.25) and animals were sacrificed 5 day later 
(25 days after PM-NPCs infusion). Fluororubywas picked up by intact axons and transported 
caudally (Fig. 4.24). The extent of dorsal tract labeling is high at the point of injection then it 
gradually decreases. Axonal fluororuby labeling is practically absent at the lesion site (Fig. 4.25 
and 4.24) in saline-treated mice, while a significant fluorescence can be detected across and 
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caudally to the lesion in PM-NPCs treated lesioned mice (Fig. 4.23, 4.25  and 4.24). The detail of 
lesion epicenter is reported in Figure 4.23.  The labeling is also higher rostral to the lesion 
suggesting a powerful axonal sparing by PM-NPCs (Fig. 4.23 and 4.24). The quantification 
fluorescence labeling at the lesion site (Fig. 4.25) shows that PM-NPCs-treated animals show 10 
fold more labeled axonal profiles than in saline-treated. In addition, it can be noted that the 
number of labeled profiles decreases moving from injection site to the lesion in saline-treated 
animals, while it remains almost resistant in PM-NPCs treated mice.  
 
 
Figure 4.23. In vivo axonal transport recovery in spinal cord of animal transplanted with PM-NPCs.  
Anterograde axonal transport was studied, by fluororuby injection at T6/T7, 30 days after PM-NPCs transplantation. 
Reconstruction of longitudinal sections of  lesion site epicenter (T9) and 1 µm away from the lesion from animals transplanted 
with PM-NPCs. Scale bars = 100 µm. 
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Figure 4.24.  In vivo reconstruction of axonal tracer transport in spinal cord of animal transplanted with PM-NPCs. 
Qualitative image of anterograde axonal transport was 30 days after lesion.As described in material and methods section 
fluororubywas injection at T6/T7 at day 25 after lesioning and animal sacrificed five days later. Schematic reconstruction of 
spinal cord longitudinal sections of lesioned (below) and lesioned+PM-NPCs (above) treated animals.  PM-NPCs were stained 
with Hoechst (blue). 
 
 
Figure 4.25.Quantification of Fluororuby immunoreactivityin spinal cord of animal transplanted with PM-NPCs.  
Quantification of fluorescent areas 2 cm, 1 cm and 1 mm away from the lesion from animals transplanted with PM-NPCs was 
performed in three animals per group. We determined the statistical differences by means of an ANOVA test followed by 
Bonferroni’s post-test. **p< 0.01, ***p< 0.001 vs saline treatment; °°p <0.01 vs 2cm transplanted mice; ### p< 0.001 vs 1 cm 
transplanted mice. 
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4.5 PM-NPCs transplanted in Parkinson’s disease 
4.5.1Loss of function correlate with loss of striatal dopamine  
The effect of MPTP administration on TH-positive neurons and axons in the nigrostriatal system 
was evaluated at 10 days after MPTP administration. Panel A of figure 4.6 TH immunoreactivity 
in striatum and in SN pars compacta (SNpc) of controls and MPTP-treated mice. As is well 
known, MPTP causes a highly significant loss in TH-positive cell bodies and axons. The 
quantification shows that the reduction is higher than 50% (Fig 4.6A). Ventral tegmental area 
(VTA) provided the internal control zone, since VTA dopaminergic neurons were affected by 
MPTP to a much lesser extent than SNpc neurons (Liang, 2004). In addition to the 
neuropathological changes, we observed that striatal DA and related DOPAC and HVA 
metabolites (Phani, 2010) were reduced by MPTP exposure (Fig. 4.26B). Three behavioral tests 
were performed in support of the histological and biochemical data (Fig 4.26C). The horizontal 
grid test allowed assessment of the forepaw faults in healthy and MPTP-treated mice. The 
behavioral impairment was already marked as early as 1 day after MPTP administration with 73 
percent of forepaw faults (p < 0.001 vs control mice, CTRL). This behavioral impairment 
remained significantly high throughout the experimental period (Fig 4.26C). Through the vertical 
grid test, we assessed the time required by the mouse to turn around and descend the grid once 
positioned on the top. Following MPTP treatment, mice hesitated and remained on the top of the 
grid much longer, therefore the time required to turn and descend from the top to the bottom of 
the grid was much longer from day 1 (Fig 4.26C). The time was exactly 112.8 ± 19.4 sec for 
MPTP-treated mice and 14.1 ± 7.76 sec for controls (p < 0.001). At later times, after the second 
injection of MPTP, mice required even more time to perform the test (126.33 ± 14.2), while in 
controls it was only slightly higher (20,5 ± 4,5 sec). The olfactory impairment is a classic 
symptom in Parkinson disease. In our experimental protocol, olfactory capabilities were 
evaluated at day 10 after the second MPTP administration (Fig 4.26C). MPTP-treated mice did 
not find and bite the buried chip as quickly as controls (MPTP= 350.0 ± 10.58 sec; CTRL= 100.8 
± 19.44 sec; p < 0.001). 
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Figure 4.26. The applied paradigm of MPTP impairs nigrostriatal dopamine neurons and causes functional impairment 
in mice. 
 (A) TH immunoreactivity performed on brain coronal sections of mice intoxicated or not with MPTP (bars =100 μm). TH-ir was 
evaluated at day 10. Quantification was made by ImageJ picture analysis. *** p<0.001 vs CTRL. (B) DA, DOPAC, HVA, and 3-
MT striatum levels in control and MPTP intoxicated mice (day 10). Values are expressed as mean ± SD of three independent 
experiments (n =5 mice in each group). (C) Evaluation of functional impairment was performed by means of three different 
behavioral tests (inverted grid, vertical grid and olfactory tests). Data are expressed as mean ± SD of 3 independent experiments. 
 
 
 
4.5.2 PM-NPCs transplantation and recovery of function  
In order to evaluate the effects of intrastriatal injection of PM-NPCs (2.5 x 105 cells/5 µl; see 
Materials and Methods for details) on functional recovery of MPTP treated mice, the behavioral 
tests described above were performed (Fig 4.27). Three days after cell injection, the percentage 
of forepaw faults of PM-NPCs-transplanted mice was 42.6 ± 9.6 % (horizontal grid test) 
compared to69.8 ± 5 % of saline-treated (p < 0.001 vs CTRL; p< 0.001 vs MPTP saline-treated). 
The early improvement observed in PM-NPCs-transplanted mice was then maintained 
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throughout the period of observation, while saline-treated MPTP mice gradually worsened, 
reaching the maximum deficit 8 days after treatment with values similar to untreated MPTP-
mice. The difference between cell-treated and saline-treated groups was even more conspicuous, 
when their motor coordination ability was tested by means of the vertical grid test. At 3 days 
after transplantation, animals showed a significant improvement in the time required for turning 
and descending the grid (62.7 ± 8.4 sec), while the time employed by MPTP-treated mice was 
almost twice as long (112.7 ± 2.7 sec), even worse than MPTP alone. The deficit was 
comparable between these two latter groups at day 8. The functional improvement promoted by 
PM-NPCs treatment steadily increased reaching values similar to controls (healthy mice) within 
two weeks after cell injection (Figure 1A). The loss of olfactory capabilities caused by MPTP 
was also evaluated after the PM-NPCs infusion. The improvement was observed as soon as 3 
days after transplantation and was maintained throughout the observational period (Fig 4.27A). 
The histology performed at two weeks after transplantation shows that TH-positive cell bodies of 
the SN were less detectable after MPTP intoxication, and the total TH-immunoreactivity was 
reduced to about 30%. In contrast, it was as high as 60% after PM-NPCs infusion (Fig 4.27B). 
The neuroprotective effects of exogenous PM-NPCs were also present in SNpc contralateral to 
the injection site (Fig 4.27C). Histological evaluation showed that the reduced number of TH 
profiles after MPTP in the not treated group was not due to neural loss (Fig 4.28). 
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Figure 4.27. PM-NPCs injection promotes recovery of function and protects SN from degeneration.  
(A) Vertical grid test.PM-NPCs treated animals recover the motor deficit and climb down quickly from the grid. Horizontal grid 
test. PM-NPCs treated mice reduces the percentage of forepaw faults per step. Olfactory test. PM-NPCs treated animals recover 
the olphactory capabilities. Two observers in blind rated each trial for vertical grid, forepaw faults per step and bite of the buried 
chip. Data are expressed as mean ± SD (n= sixty mice for CTRL, MPTP and MPTP + PM-NPCs groups; n= six  mice 
MPTP+PBS group). We determined the statistical differences by means of one-way ANOVA test followed by Bonferroni post-
test. *** p< 0.001 vs CTRL; ### p< 0.001; # #p< 0.01; # p< 0.05 vs MPTP. (B) SN coronal slices of CTRL mice, MPTP mice 
treated or not with PM-NPCs were immune-decorated with anti-TH antibody (bars = 500 μm; and 100 μm). Quantification was 
made by ImageJ picture analysis. *** p<0.001 vs CTRL, §§§ p< 0.001 vs MPTP. (C) Reconstruction image of whole mid-brain 
coronal section relative to MPTP mouse treated with PM-NPCs. Section was immune-decorated with anti-TH antibody (bars = 
100 μm).  
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Figure 4.28. Cresyl violet staining of SNpc neurons. 
Cresyl violet staining was performed on brain coronal sections of healthy mice (CTRL) or mice intoxicated with MPTP (MPTP) 
at the end of observational period (day 14 post transplantation) (bars =100 μm). Cresyl violet staining was performed by 
following the procedure described by Goldberg and co-workers (Goldberg, 2011). 
 
 
4.5.3 Reduced striatal levels of dopamine  
Tissue levels of dopamine and its metabolites were determined by HPLC (see Materials and 
Methods). MPTP exposure caused a 50% reduction of dopamine in both the left and right 
striatum that was maintained up to the end of experimentation period (24 days after 1st MPTP 
administration). Such a loss was not modified by PM-NPCs transplantation (Fig 4.29A). 
Therefore, the behavioral recovery promoted by PM-NPCs occurs in absence of any restoration 
of DA. DOPAC, HVA and 3-MT were also reduced bilaterally, and remained as such unaffected 
by treatment. 5-hydrossitriptamine, 5-HIAA, and norepinephrine did not change after MPTP 
exposure and cell transplantation (Fig 4.29B). However, with the loss of striatal DA and DA 
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synapses there is a dramatic decrease in the expression of both dopamine and norepinephrine 
transporters, as assessed by real time RT-PCR (Table 4.1). Such reduced levels of mRNA were 
increased ten and six fold respectively by PM-NPCs (Table 4.1). In addition, TH expression was 
augmented by 18 fold (Table 4.1). This may suggest that transplantation could have improved 
synaptic efficacy in the striatum. 
 
 
 
Figure 4.29. Striatal levels of neurotransmitters after PM-NPCs transplantation. 
The determination was performed 2 weeks after cells transplantation (day 14 post-injection). (A) Levels of DA, DOPAC, HVA, 
and 3-MT were determined separately in the left (ipsilateral to the injection) and right (contralateral to the injection site) striatum. 
(B) Levels of 5-hydrossitriptamine (5-HT), norepinephrine (NE) and 5-Hydroxyindoleacetic acid (5-HIAA) were determined 
separately in the left and right striatum. Data are expressed as mean of three experiments ± SD (n = nine mice in each group); *** 
p< 0.001; ** p< 0.01; * p< 0.05 vs CTRL. 
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Left 
striatum 
 
CTR
L 
 
MPTP+PBS 
 
MPTP+PM-NPCs  
7 days 
NET 1± 0 0,78 E-02 ± 0,29E-03   
(p<0.001 vs CTRL) 
 
5,9E-02 ± 0,14E-02 
(p<0.001 vs MPTP+PBS; 
p<0.001 vs CTRL) 
DAT 1± 0 0,93 E-02 ± 0,08E-01  
(p<0.001 vs CTRL) 
9,99E-02 ±0,12E-02 
(p<0.001 vs MPTP+PBS; 
p<0.001 vs CTRL) 
TH 1± 0 0,94E-01 ± 0,47 E-02 
(p<0.001 vs CTRL) 
31,8 E-02 ± 0,79E-02 
(p<0.001vs MPTP+PBS;p<0.001 
vs CTRL ) 
 
Table 4.1.  DAT, TH, and NET mRNA expression levels 7 days after treatment with PM-NPCs or PBS.  
mRNA levels was evaluated by real time RT-PCR. Each group was composed of three mice; three quantitative (Q)–RT-PCRs in 
each experiment was performed, each sample was run in triplicate. 18S ribosomal RNA was used as reference gene. Values 
represent the number of fold increase versus control and is reported as mean ± SD. 
 
 
4.5.4 Localization of transplanted PM-NPCs 
Healthy and lesioned animal brains with or without PM-NPCs injection were sectioned. A large 
portion (78.50 ±7.5 %) of the 2.5 x 105cells injected into the left striatum of each animal were 
still present 2 weeks after transplantation. The vast majority (69.56±4.5 %) of GFP-positive 
transplanted PM-NPCs were within the striatum (Fig 4.30A).Grafted PM-NPCs appeared rather 
differentiated with an oval soma and abundant neuritic processes, even 30 µm long (Fig 4.30B). 
As expected, the axonal TH immunoreactivity resulted significantly decreased into the striatum 
of MPTP-treated animals (Fig 4.30A), and such a loss was slightly affected by cell 
transplantation (Fig 4.30A). However, a high number of PM-NPCs resulted strongly labelled by 
anti-TH antibodies (see arrows in Fig 4.30C). The quantitative evaluation of total TH 
immunoreactivity in the striatum resulted slightly higher in transplanted animals, probably 
because of the presence of transplanted cells.  
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Figure 4.30. Intrastriatal localization of PM-NPCs.  
(A) Confocal images of tyrosine hydroxylase-labeled (TH; Red) coronal striatum sections of control animals (CTRL), MPTP 
injected mice and MPTP injected mice treated with PM-NPCs (Green). Pictures refer to animals sacrificed 2 weeks after cells 
transplantation. Nuclei are stained in blue (DAPI) (bars= 100 μm). Coronal cryostat sections of CTRL, MPTP and MPTP+PM-
NPCs were quantitatively evaluated and the number of TH positive cells was determined as described in materials and methods. 
Results are expressed as percentage of TH positive cells per HPF. For the quantification we considered sections from at least 
three animals per group. Values represent average ± SD. **p<0.01, *p<0.05. (B) and (C) Magnified details (bars = 50 µm) of 
MPTP+ PM-NPCs injected mice striatum coronal sections stained with TH(red). GFP is showed in green and nuclei are stained 
in blue (DAPI). Co-expression of the cytoplasmic protein TH (red) and GFP (green) within a cell suggests dopaminergic 
differentiation of the transplanted PM-NPCs within the injured mouse brain. 
 
 
 
4.5.5 Astrogliosis and cytokines changes  
Inflammation is part of the physiological response to MPTP as also indicated by astroglia 
activation. Figure 4 shows that the density reactive GFAP-positive cellular profiles was 
markedly increased in striatum of MPTP mice (Fig 4.31A); such an augmentation was 
significantly reduced in the striatum ipsilateral to the cell injection site. Differently, the 
astrogliosis was unaffected in the contralateral striatum (Fig 4.31A). The quantification 
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confirmed the visual impression that GFAP-positive cells were reduced in the striatum ipsilateral 
to PM-NPCs injection site (Fig 4.31A). We also evaluated the extent of macrophages infiltration 
in the striatum, which resulted, increased after MPTP (Fig 4.31B). As for astrogliosis, the 
staining for MOMA (MOuseMAcrophages) was normalized in the striatum were PM-NPCs were 
infused. While in the contralateral the counteractive effect of PM-NPCs was attenuated (Fig 
4.31B).Several reports had shown that exogenous applied stem cells have anti-inflammatory 
properties (Carelli 2014 and 2015; Aggarwal, 2005; Ortiz, 2007; Martino, 2006). It is possible 
that the PM-NPCs restorative action could be mediated by anti-inflammatory activity. Here we 
observed that MPTP caused a marked cytokines mRNAs increase in both left and right striatum 
that was attenuated by the application of PM-NPCs (Table 4.2). The effect was quite remarkable 
for TNF-alpha, and IL-6. The reduction of IL-15 expression was modest and did not reach 
statistical significance. In addition, also, NGF increased in the striatum of MPTP mice and its 
expression was significantly reduced by cell transplantation, while BDNF was unaffected. In 
contrast, in the right striatum (contralateral to the transplant), the anti-inflammatory action of 
PM-NPCs was less marked, with changes not statistically significant for IL-1-alpha, TNF-alpha, 
IL-6, and IL-15. Only NGF mRNA expression was also clearly reduced in the right striatum 
(Table 4.2). 
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Figure 4.31. Striatal GFAP Immunoreactive-Positive Profiles after PM-NPCs transplantation PM-NPCs reduce the extent 
of astrogliosis in the MPTP damaged striatum. 
Confocal images of (A) GFAP-labeled (Red) and (B) MOMA-labeled (Red) coronal striatum sections of control animals 
(CTRL), MPTP injected mice and MPTP injected mice treated with  PM-NPCs. Pictures refer to animals sacrificed 2 weeks after 
cells transplantation. Nuclei are stained in blue (DAPI) (bars= 100 µm). Quantification of GFAP (A) and MOMA (B) positive 
cells. The percentage of cells positive to GFAP and MOMA are reported in the graph. Data are expressed as mean of six different 
fields for each condition ± SD (n= two mice each group; three fields/mouse). °°p<0.01 vs MPTP+PM-NPCs ipsilateral; **p<0.01 
vs CTRL. 
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Left striatum CTRL MPTP+PBS MPTP+PM-NPCs 
IL-1 alpha 1 ± 0 1.063± 0.09 
(ns vs CTRL) 
1.764 ± 0.486 
(ns vs MPTP+PBS; 
ns vs CTRL) 
TNF-alpha 1± 0 9,89± 2,38 
(p<0.01 vs CTRL) 
3,22 ± 0.67 
(p<0.05 vs 
MPTP+PBS; 
P<0.05 vs CTRL) 
IL-6 1 ± 0 5.655 ± 0.92 
(p<0.01 vs CTRL) 
3.7361± 0.39 
(p<0.05 MPTP+PBS; 
p<0.05 vs CTRL) 
IL-15 1 ± 0 4.6202 ± 0.83 
(p<0.01 vs CTRL) 
3.481 ± 0.693 
(ns vs MPTP+PBS; 
p<0.05 vs CTRL) 
NGF 1 ± 0 4.866 ± 0.4844 
(p<0.001 vs CTRL) 
2.2256 ± 0.643 
(p<0.001 vs 
MPTP+PBS; 
p<0.05 vs CTRL) 
BDNF 1 ± 0 5.8256 ± 0.831 
(p<0.01 vs CTRL) 
4.1657 ± 0.787 
(ns vs MPTP+PBS; 
p<0.05 vs CTRL) 
 
Table 4.2 Cytokines mRNA expression levels 7 days after treatment with PM-NPCs or PBS. 
Expression of cytokines mRNA levels was evaluated by real time RT-PCR. Each group was composed of three mice; three 
quantitative (Q)–RT-PCRs in each experiment was performed, each sample was run in duplicate per and a parallel PCR for the 
gene of interest and the reference gene 18S. Values represent the number of fold increase versus control and is reported as mean 
± SD. 
 
 
 
4.5.6 PM-NPCs migratory processes  
Previous reports had shown that that transplanted stem cells can migrate into the host striatum (7, 
26), here we observed that grafted PM-NPCs migrate from the injection site across the striatum 
(Fig 4.32). In 2 weeks PM-NPCs had migrated up to 3125.72 μm from the site of injection 
following a ventral direction (Fig 4.32A). In addition, the re-assembly of serial pictures from 
longitudinal sections, obtained by confocal acquisitions, demonstrates that PM-NPCs moved 
away from the site of injection following rostra-caudal and rostra-ventral pathways, which 
appeared to be specific (Fig 4.32B) for distances longer than 1 mm. These directions of 
migrations were monitored and quantified in three animals, and the migration pathways were 
highly comparable. It therefore appears that some specific signals capable of directing the 
cellular migratory process must exist. Furthermore, when transversal brain sections were used, 
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we observed that the PM-NPCs migrated beyond the borders of the striatum and SN pars 
compacta, and that ipsilateral and contralateral to the injection site was reached (Fig 4.32C). 
Here, the transplanted cells are intermingled with endogenous TH-positive neurons (Fig 4.32D 
and 4.32E). 
 
 
 
Figure 4.32. Injected PM-NPCs migrate throughout the striatum and reach the Substantia Nigra.  
Confocal images of intrastrial distribution  PM-NPCs (green) 2 weeks after transplantation in coronal (A), longitudinal (B), and 
transeversal sections(C) of PM-NPCs injected parkinsonian mouse brains. Transplanted neural precursors (green) migrate for 
many microns in the striatum following both ventral and caudal directions. (D) and (E) Magnification of brain coronal sections 
obtained from  PM-NPCs injected parkinsonian mice stained with anti-NeuN or anti-TH (red), GFP is showed in green and 
N). 
 
 
4.5.7 Expression of typical markers by transplanted PM-NPCs  
Close to the injection site a higher number of cells were positive to Nestin (precursor cell 
marker), while most migrated PM-NPCs resulted positively marked by anti-NeuN and anti-
MAP2 antibodies (markers of neuronal differentiation) (Fig 4.33). Here only a lower percentage 
of cells was positive to NG2 (marker of oligodendrocytes precursors) and Nestin. The 
quantification shows that migrated grafted cells differentiated in this proportion: 81.88 % ± 2.3 
% of GFP positive cells resulted positive for NeuN and 62% for MAP-2, while 38.77% ± 3.8 % 
of GFP positive cells were positive for NG2 and 36% for Nestin (Fig 4.33). Therefore, PM-
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NPCs migration is correlated with a higher differentiation (Fig 4.33A). We also found that a 
large amount of transplanted cells expressed a marker related to dopamine synthesis, such as TH 
(47.88% ± 11%, in 511 analyzed cells). The cholinergic marker ChAT, which is expressed by 
striatal excitatory interneurons, was found in 58.33%± 8% of the 489 analyzed cells, and a 
relative lower amount of cells expressed GABA (35% ± 4%, in354 analyzed cells) (Fig 4.33). 
 
 
 
 
Figure 4.33. Most PM-NPCs adopted a neuronal fate when transplanted into Striatum of MPTP mice and express neuron 
specific markers. (A) Confocal images of striatal coronal sections stained with neural differentiation specific markers (MAP-2, 
NeuN, NG2 and nestin). The immunostaining is showed in red. PM-NPCs are showed in green (GFP). Nuclei are stained in blue 
(DAPI). Images were taken two weeks after PM-NPCs injection. Quantification of neural fate markers expression 2 weeks after 
transplantation. The percentage of cells co-expressing specific investigated marker and GFP is reported in the graph. Data are 
expressed as mean of six different fields for each condition ± SD (n= two mice each group; 3 fields/mouse). Scale bar represents 
100 and 500 μm. (B) Confocal images of coronal striatum sections of MPTP mice treated with PM-NPCs (Green) stained with 
Tyrosine Hydroxylase (TH; red), Choline Acetyl Transferase (ChAT; Red) and gamma-aminobutyric acid (GABA; red). Co-
expression of ChAT (red), GABA (red) and GFP (green) within a cell suggests that transplanted neural precursors differentiate 
also into cholinergic- and GABAergic neurons within the injured mouse brain. Nuclei are stained in blue (DAPI), scale bar 
represent 500μm. For the quantification, we considered sections from two animals per group (3 fields/animal). The percentage of 
cells co-expressing specific investigated marker and GFP is reported in the graph. Values represent mean ± SD. 
Toniella Giallongo Matr. R10212 
130 
 
4.5.8 Is PM-NPCs action mediated by EPO? 
 
We had previously reported that PM-NPCs differentiation was dependent on the autocrine 
release of EPO (Carelli, 2014), so we then determined whether the striatal functional recovery 
promoted by PM-NPCs was also mediated by EPO. PM-NPCs inoculation was  performed with 
or without co-administration of anti- EPO or anti-EPOR specific antibodies at comparable 
concentration previously used in vitro (3μg/ml, respectively). The data show that the addition of 
either antibodies obliterated the positive effect of PM-NPCs administration above described (Fig 
4.34). Such a counteractive effect was observed with both behavioral motor tests. As a further 
control, we administered EPO alone through the same route. The administration of recombinant 
human-EPO (rh-EPO; 1U/gr) in MPTP parkinsonian mice significantly improved the behavioral 
impairment as early as 3 days after injection, as cells did in both tests (Fig 4.34). The intrastriatal 
injection of anti-EPO and anti-EPOR antibodies alone did not modify the animal behavioral 
impairment caused by MPTP. These data suggest that the positive action of PM-NPCs in MPTP 
mice was likely due to EPO release by transplanted PM-NPCs (Fig 4.34). 
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Figure 4.34. Erythropoietin released by transplanted PM-NPCs promotes functional recovery. 
(A) Vertical grid test and (B) Horizontal grid test showed an increase in activity for MPTP animals transplanted with PM-NPCs 
and Erythropoietin (EPO) in comparison with MPTP animals that received specific antibodies against Erythropoietin (anti-EPO) 
and EPO receptor (Anti-EPO R). Data are expressed as mean of three different experiments ± SD (n= five animals for each 
group). We determined the statistical differences by means of one-way ANOVA test followed by Bonferroni post-test. ***p < 
0.001; **p < 0.01 vs CTRL; ###p < 0.001; ##p < 0.01 vs MPTP. (C) Confocal images of coronal striatum sections of MPTP + 
PM-NPCs (Green) mice stained with Erythropoietin (EPO; red). Nuclei are stained in blue (DAPI), scale bar represents 20 μm. 
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5. Discussion 
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The development of neuroprotective and restorative therapies remains a major unfulfilled medical 
need. In this regard to prevent further neuronal damage through the attenuation of secondary 
degeneration and promote repair and recovery of function in SCI, a stem cell-based therapy 
provides a promising therapeutic approach. Their characteristic abilities to self-renew and 
differentiate into any cell type in the body, justify the intense efforts on investigating application in 
cell therapy of stem cells [Furlan, 2011; Gorio, 2002; Sahni, 2010; Marfia, 2011; Thuret, 2006). 
Cell-based therapeutics for spinal cord injury could affect tissue and/or functional outcomes in 
different manners: (i) differentiation and functional integration of new cells into spared spinal cord 
circuitry,(ii) increased sparing of host neurons, myelin, and axons, and/ordecreased host glial 
scaring, and (iii) increased host-mediatedaxonal regeneration or remyelination. 
In this study we evaluated the potential therapeutic of the Post Mortem Neural Precursor Cells (PM-
NPCs) (Marfia, 2011) in the treatment of the acute traumatic spinal cord lesion. In cell therapy of 
spinal cord injury have been used different types of cells such as embryonic (Bottai, 2010), 
mesenchymal (Cizkova, 2006), hematopoietic (Koshizuka, 2004), Neural (Bottai, 2008; Abematsu, 
2010), Schwann (Schaal, 2007) and oligodendrocyte ensheating cells (OECs) (Richter and 
Roskams, 2008). Neural stem cells / precursor are the most used, probably because it already 
directed towards a neural phenotype, and then already programmed to differentiate in a appropriate 
manner to regenerate nerve cells damaged by the trauma. Following intravenous administration, the 
PM-NPC reach the injury site through the bloodstream, the ematospinalbarrier exceed, which has 
been deeply affected by the injury and subsequent inflammatory response (Maikos and Shreiber, 
2007). Unlike neural cell / classic precursors (Bottai, 2008), the PM-NPCs are not phagocytized by 
macrophages during the first weeks in the damaged bone and integrate the parenchyma injured 
edge; then they differentiate into neuronal sense and create a neural tissue inside the spinal cord 
damaged (Carelli, 2015). The morphological examination of the injured cord showed that PM-NPCs 
are developed into newly formed neurons, which largely have differentiated in a cholinergic 
phenotype. The transplanted cells formed in the injured bone a sort of circular section with a one-
millimeter diameter, this is mainly made up of differentiated PM-NPCs, and there is a real tissue 
reorganization within the lesioned area, with a structure highly suitable for supporting regenerative 
events. 
The morphological differentiate framework of injured tissue is associated with a major functional 
recovery of hind limbs.This recovery was quantified through the Basso Mouse Scale (Basso, 2006) 
and was observed that the ability to use the hindlimbs increases rapidly from the seventh day, 
reaching the biggest value after three weeks post lesion and remaining constant. The mice treated 
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with saline solution, instead, show a markedly lower recovery. An imported recovery of motor 
function is a common factor that is found in most of the studies on spinal cord injury using a cell-
mediated therapy (Barakat, 2005; Firouzi, 2006; Ramon-Cueto, 2000; Moreno-Flores, 2006; 
Setoguchi, 2004; Ziv, 2006; Bottai, 2008; Bambakidis and Miller. 2004; Carelli, 2014; Carelli, 
2015). The cytoarchitecture of bone marrow in the injury site improves by PM-NPCs 
transplantation, the extension of necrotic tissue is significantly reduced in the treated mice and in 
the areas of scarring is inserted the new nerve tissue formed by stem cells. The PM-NPCs 
cytoprotection extends to the white matter, in particular 0.5 mm caudal from the lesion this structure 
is similar to the control mice, while animals treated with PBS show a myelin density significantly 
reduced. The preservation of the white matter can explain the increased recovery of motor function 
after treatment with PM-NPCs. Although in this type of injury the corticospinal tract (CST) is 
seriously compromised, there are sections of the same pathways which run to the spine: the 
dorsolateral corticospinal tract (LCST) (Steward, 2004) and the ventral corticospinal tract (VCST) 
(Brosamle and Schwab, 1997), though, normally they have a less importance function than the CST 
can replace the functions after spinal cord injury (Brosamle and Schwab, 2000). Since these 
"secondary" ways shall commence in areas of white matter that we have demonstrated be better 
preserved by PM-NPCs treatment, it could be probably related to better recovery of motor activity 
observed in the treated mice. A better motor recovery correlated to a greater preservation of the 
white matter has also been shown in a spinal contusive model that used rats in which was 
administered recombinant human erythropoietin rhEPO (Vitellaro-Zuccarello, 2007; Vitellaro-
Zuccarello, 2008; Gorio, 2002).  
Immunohistochemical analysis revealed that the neuroprotective effect of PMNPCs is also effective 
at the level of the gray substance. In fact, the presence of surviving axonal damage fibers such as: 
the serotonergic, positive for serotonin (5-HT), and adrenergic processes, positive for tyrosine 
hydroxylase (TH),as significantly increased in transplanted animals. Gray matter reinnervation in 
the caudal portions of the spinal cord is indicative of the PM-NPCs ability to transform the injured 
area in a site appointed to support the regeneration of injured axons, which probably contributes to 
the functional recovery improvement. Is known that if the neurons are not stimulated by a proper 
innervation undergo some morphological and physiological changes such as reducing the number of 
dendrites and the reduction of their ramifications (Bose, 2005). This events can lead cells to 
atrophy, a mechanism defined transinaptic degeneration (Eidelberg, 1989; Van De Meent, 2010). 
This process bring to the loss of synaptic signals and a non-activation of neurons, which become 
functionally inactive (McComas, 1973 Benecke, 1983). 
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For this reason is important to preserve not only the motor neurons, but also the greater number of 
fibers. The treatment with PM-NPCs that preserves a part of fibers catecholaminergic, adrenergic 
and serotonergic helps to keep the active neurons, and therefore maintain a neural network that 
contributes to the recovery of motor activity.  
In addition to preserve the descending fibers from the encephalon, PM-NPCs have a 
neuroprotective effect on the gray matter, and in particular, we have shown that they exert their 
action on the cell neuron bodies that are in the ventral horns where motor neurons reside. Therefore 
these cells have a three different therapeutic effect on the spinal cord damaged: preserves cell 
bodies present in the ventral horns where there are motor neurons; preserves the monoaminergic 
fibers descendants correlated with locomotion control and finally also preserves the white matter in 
areas where there are  important motor pathway that can partially support corticospinal pathway 
functions damaged. We have also observed that at 4 weeks after the lesion, many PM-NPCs 
differentiate into neuronal sense and therefore have the ability to integrate in a functional manner in 
the neural network that re-arranges post trauma (Abematsu, 2010, Xu, 2011) and also contributing 
in this case to the functionality motor recovery. 
The injection of Fluororuby (Lu, 2001) in CST rostral to the lesion showed that in animals treated 
with the PM-NPCs the fluorescent tracer is transported in an anterograde manner through survival 
axons of CST that go around the lesion and in part in the caudal level to the injured spinal cord 
tissue. In transplanted animals, the fluororuby is significantly higher than that observed in mice 
treated with saline. This shows that the treatment with PM-NPCs provides a favorable environment 
to nerve regeneration in the injured cord. 
Treatment with PM-NPCs also shows a marked reduction of infiltration of neutrophils that is 
accompanied by a better preservation of bone marrow cytoarchitecture. Neutrophils usually invade 
the bone marrow damaged 12-24 hours after injury (Popovich, 1997) and release them pro-
inflammatory cytokines and reactive oxygen species (Popovich, 1999; Taoka and Nakajima 1998). 
Similarly, the infiltration of macrophages at the damage site, which usually has its peak 5-7 days 
after injury (Taoka, 1997) is reduced following administration of PM-NPCs. It was also 
demonstrated that anti-inflammatory treatments have a high efficacy in reducing selectively early 
injury mediated by leukocytes in spinal cord injury, leaving the opportunity to attend later with 
targeted interventions repair and regeneration of damaged tissue (Gorio, 2007; Gris, 2004). 
Treatment with this type of neural precursors therefore seems to have also a powerful anti-
inflammatory effect probably due to factors / cytokines that the cells themselves release in the 
lesion site. 
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We have studied the anti-inflammatory effect of PM-NPCs in glial reaction, an event that ever 
occurs in spinal cord injury (Silver and Miller, 2004; Fitch and Silver, 2008). The glial scar is 
important to create a barrier that protects the CNS area already damaged from the other damage 
(Myer, 2006), but on the other hand it was shown that it acts as a real barrier to axonal regeneration 
(Fitch andSilver, 1997; Fitch and Silver 2008).  
The reduction in glial reaction following administration of PM-NPCs, and then the resulting 
reduction the scar entity, allows to maintain a microenvironment with a reduced quantity of 
molecules / stimuli for axonal growth inhibitors; which can lead to a greater regeneration of nerve 
fibers in the long time. The treatment with the PM-NPCs has also influenced the expression of 
numerous proinflammatory and anti-inflammatory cytokines analyzed, which are not normally 
produced by the bone marrow (Pineau, 2007) and may therefore play a very important role in 
response to the spinal cord trauma. It is known that the exogenous administration of different types 
of cytokines is able to improve the functional recovery after the spinal trauma (Giehl and Tetzlaff, 
1,996; Ruitenberg, 2004; Sayer, 2002) and in fact the increase in the motor recovery promoted by 
adult NSCs is accompanied by a significant increase the cytokines expression (Bottai, 2008). The 
increase of the expression of trophic factors into the lesion site cannot be derived directly from 
NSCs, because in vitro cultured tests revealed that there is only a low production of these trophic 
molecules (Pluchino, 2003). It is possible that the interaction of the cells with the lesion 
environment will have increased their production of trophic factors (Sroga, 2003). 
IL-6 is a major pro-inflammatory cytokines whose expression increases significantly after SCI, this 
increase was associated with an increase of infiltration of neutrophils, and at an expansion of the 
neural damaged due to injury (Lacroix, 2002); PM-NPCs reduce significantly the expression in the 
acute phase of lesion decreasing the damage tissue, however, 7 days after injury, animals treated 
with cells show an expression of this cytokine that is significantly increased compared to animals 
treated with PBS. This data is in agree with some results reported in literature which show that in 
addition to the involvement of IL-6 in the initial phase of the inflammatory response, it can also 
affect directly and / or indirectly neuronal survival (Marz, 1999). In addition, IL-6 has also been 
demonstrated to have neuroprotective effects (Loddick, 1998; Allan and Rothwell, 2001) and 
promote regeneration and axonal sprouting (Hakkoum, 2007). This cytokine has a neurotoxic effect 
in the acute phase of injury where his activity is antagonized by the PM-NPCs, while in the chronic 
phase has a positive effect on the neural tissue and the treatment with the cells contributes to 
increase the expression.  
Toniella Giallongo Matr. R10212 
137 
 
The production of TNF-α to the site of injury increases in a short time from the lesion and its 
activity is implicated in the damage of secondary type at multiple levels (Wang, 1996; Liefner, 
2000; Paterniti, 2009). The expression levels of this cytokine are increased in animals treated with 
PBS, while treatment with the PM-NPCs maintains significantly low the expression levels in acute 
phase of damage this activity helps to reduce the effects of secondary damage. A week after the 
injury, however, the mice treated with the cells show values of TNF-α higher respect to the animals 
treated with PBS. This effect  may explain the improvements observed with the PM-NPCs as is 
been demonstrated that TNF-α  has also a neuroprotective effect (Shohami, 1999) and is indirectly 
involved in neuronal survival through stimulus for the production of neuorotrofic factors such as 
NGF (Hattori, 1993) and the BDNF (Saha, 2006). The TNF-α was also known to be implicated in 
the processes of myelinization and demyelination, then the improvement in the motor recovery 
could also be in part due to the effect that TNF-α promotes remyelination axons survived in the 
lesion (Arnett et al, 2001; Huang, 2002). This hypothesis is supported by the reduction of the motor 
recovery degree observed following the trauma of the CNS in KO mice for the expression of TNF-α 
or its receptor (Sullivan, 1999). 
LIF is a cytokine that has been shown to have pro-inflammatory effects. It is considered one of the 
most potent mediators of the initial phase of the inflammatory response following CNS injury. It 
has been demonstrated to be essential for the initial recruitment of macrophages and neutrophils 
(Sugiura, 2000) and is one of the main molecules that regulates the glia response following cortical 
damage (Sugiura, 2000). In addition, in this case the treatment with the PM-NPCs reduces the 
expression of this cytokine in the first hour after SCI so antagonize a damaged effect spinal cord.  
As it happens, however, with IL-6 and TNF-α, also with LIF at the end of acute phase of the 
damage we can observe hight level of this cytokine in the animals treated with 
cells compared to the mice treated with PBS. The literature support our data, it has been 
demonstrated that the administration of exogenous LIF at the end of acute injury leads  to a 
shutdown of the oligodendrocytes death through upregulation of anti-apoptotic molecules and to a 
downregulation of those pro-apoptotic, with a consequent reduction of demyelination, and then 
reduction of molecules inhibiting axonal growth (Azari, 2006). We then observed that three major 
pro-inflammatory molecules such as IL-6, TNF-α and LIF have a negative effect in the acute phase 
post injury, but are instead very important for the next phase in which they can participate in 
neuroprotective and regenerative processes. The treatment with the PM-NPCs rule perfectly the 
activity of these cytokines, reduce the expression when they have a damage effect on neural tissue 
and promoting it when they can make a positive contribution.  
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MIP 2 is a major chemotactic factors and activation of neutrophils. Her overproduction in the 
injured spinal cord is associated to the infiltration of neutrophils suggesting that this mediator plays 
a key role in the recruitment of inflammatory cells after SCI (Bethea, 2000;  
Gris, 2004). In the acute phase after injury the MIP 2 expression increases compared to the controls, 
as is already known from the literature. The treatment with PM-NPCs antagonizes this increase, 
maintaining the expression levels of the cytokine to values similar to control animals. BDNF is a 
neurotrophin that has neuroprotective effects in vivo (Novikova, 2000) and stimulates axonal 
regrowth (Oudega and Hagg, 1999; Zhou and Shine,2003). It was shown that the local 
administration of BDNF may revertatrophy of neuronal cell bodies in the red nucleus induced by 
SCI (Ruitenberg, 2004) and that it may also prevent the degeneration of the ascending sensory 
fibers(Sayer et al, 2002). The treatment with PM-NPCs leads to a significant increase in the 
expression ofBDNF in the acute phase of injury, while later there are no differences in the two types 
of treatments. 
Although NGF is an important neurotrophin which is very important for the processes ofneuronal 
survival (Cao, 2002) and regeneration (Oudega and Hagg, 1996) that are established following CNS 
traumaand (Grilll,1997). Its expression is always increased in response to the spinal cord injury 
(Brown, 2004), and, we have not found in the acute phasesignificant differences in the animals 
treated with PBS compared to those treated withPM-NPCs. In later stage, we observed that 
treatment with thePM-NPCs maintains the expression of NGF to higher values, whichprobably 
contributes regenerative effect that we found. 
In this study the effect of PM-NPCs transplantation has been also investigated on experimental 
models of another neurodegenerative disease due to the loss of the specific population of neurons 
such as in Parkinson’s disease.  After intra-striatal infusion, more than 75% of PM-NPCs survive in 
the striatum, and differentiate mostly in neuronal-like cells. Such differentiation is higher for those 
cells that have migrated to more distal sites from the injection point: 60% MAP-2 positive and 
above than 80% NeuN-positive. Most of PM-NPCs transdifferentiated in TH positive cells, and a 
large percentage of these were positive for GABA and ChAT. Some had migrated throughout the 
striatum reaching the SN. At 10 days after MPTP administration mice made several errors in 
forepaw placement on the horizontal grid test, were practically unable to descend properly from the 
top of the vertical grid, and showed a severe impairment in the olfactory test. Such stable deficits 
were promptly reversed when PM-NPCs were administered. Within 3- 4 days the recovery was 
highly significant and with another 4 days, the behavioral parameters were practically identical to 
the control animals without any lesions. Such a recovery was likely independent from any 
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improvement in striatal dopamine content, since the loss, caused by MPTP intoxication, was 
unaltered after transplantation. HPLC analysis had unequivocally shown that MPTP administration 
caused about 50% loss of dopamine content in the striatum, and such a decrease was not modified 
by PM-NPCs. It is therefore clear that the protective or reparative action of PM-NPCs may not be 
mediated by the simple recovery of dopamine levels in the striatum, but rather by different 
mechanisms that may lead to an enhanced efficacy of the synaptic dopaminergic transmission from 
the surviving striatal axon terminals. Cell treatment had slightly increased striatal TH 
immunoreactivity that correlates with the higher expression of DAT and NET in the transplanted 
lesioned mice. Our observations are in line with observations made in MPTP lesioned monkeys, 
where the amount of DAT activity, investigated with PET neuroimaging, was related to the number 
of surviving dopaminergic fibers (Hallett, 2015). Moreover, very recent investigations on DAT 
expression, performed in post-mortem brain sections of PD patients treated with fetal 
mesencephalic grafts, highlighted that the expression of DAT decreases with time after 
transplantation (Hallett, 2014). This decrease had been related to the loss of efficacy in long-term 
fetal mesencephalic grafts (Barker, 2013;Hallett, 2015; Hantraye, 1992). The improved 
functionality of the surviving DA axons as a PM-NPCs mechanism of action is also supported by 
the fact that, after transplantation, the SN cell bodies do not die and re-acquire the expression of 
TH, which was strongly reduced 10 days after MPTP treatment. It should be noted that PM-NPCs 
migrate to SN ipsilateral and contralateral to the injection site.  
PM-NPCs have the peculiar properties of releasing erythropoietin (EPO), which is critical factor for 
their own differentiation (Marfia, 2011). So it is conceivable that the release of such a neuro-
protective factor may also have a favorable impact on the striatum dopaminergic functions and, 
consequently, on behavioral recovery. The EPO neuroprotective effects are very well known and 
supported by a large body of literature showing that in vivo administration of EPO promotes 
recovery of function after CNS lesions (Gorio, 2002; Brines, 2008). Moreover, it has been shown 
that the rh-EPO or EPO analogs administration in the rodent model of PD had neuroprotective and 
neuro-rescue effects (Jia, 2014; Tayra, 2013; Erbas, 2015). Since PM-NPCs-mediated behavioral 
recovery was prevented by the blockade of EPO or EPOR, we believe that EPO may be the effector 
of PM-NPCs transplants. This may have a dual effect on the striatum microenvironment. One 
related to both a local neuroprotective action on neurons and neural processes affected by MPTP, 
and the stimulation of a migratory response of endogenous stem cells towards the area of PM-NPCs 
accumulation. EPO has been shown to direct the migration of endogenous stem cells towards EPO 
reach source (Erbas, 2015; Shingo, 2000). The other local action of EPO maybe anti-inflammatory, 
mitigating the inflammatory reaction to MPTP as indicated by there-expression of TH by MPTP-
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lesioned SN neurons. A similar effect was observed after a septo-ippocampal lesion, where septal 
neurons recovered ChAT positivity following NGF or BDNF infusion (Morse, 1993). We have 
observed that PM-NPCs reduce both inflammatory cytokines and reactive GFAP-positive gliosis 
and macrophages infiltration caused by MPTP ipsilateral to the injection site. A similar result was 
obtained in experimental traumatic spinal cord injury after treatment with PM-NPCs (21) or EPO 
(Gorio, 2002). These counteractive effects on astrogliosis are quite relevant, since these cells are 
positively activated in PD and produce an elevated level of inflammatory cytokines and reactive 
oxygen species (Block, 2007); such an activation is correlated with increased neural death (McGeer, 
1988; Sofroniew, 2005). 
In conclusion, we found that treatment with PM-NPCs could limit the effects of secondary 
degeneration of the traumatic injury in the spinal cord through a significant reduction in the area 
affected by neurodegenerative process and with the preservation of the white matter rostral and 
caudal to the lesion. The PM-NPCs also have an important anti-inflammatory effect that is 
expressed with a strong reduction of reactive gliosis and a decrease infiltration of neutrophils and 
macrophages in the lesion. The PM-NPCs modulate the expression of cytokines reducing the effect 
pf those pro-inflammatory and increasing the function of those neurotrophic / anti-inflammatory. 
The treatment of the injured cord with these cells promotes the formation of a favorable 
environment that leads to neuronal differentiation of the cells themselves and to a vigorous axon 
regeneration that passes the site of injury as demonstrated by the injection of fluororuby at the 
cervical level of the corticospinal tract. In fact, animals treated with the cells show a greater number 
of axons with tracer caudal to the lesion, indicating a significant axonal regrowth through the site of 
injury. The multiple effects that have the PM-NPCs on the damaged spinal cord will lead to a good 
therapeutic result which is expressed in a significant improvement in therecovery of motor function. 
Morover PM-NPCs markedly improve morphological, biochemical and behavioral dysfunctions 
caused by MPTP intoxication. This effect may be mediated by local EPO release, which mitigates 
neuro-inflammatory events leading to recovery of function. Therefore, transplantable natural 
unmodified cells capable of releasing anti-inflammatory factors may represent a promising path for 
the treatment of neurodegenerative disorders. 
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